Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof

ABSTRACT

The present disclosure relates to RNA interference (RNAi) reagents, such as short hairpin microRNA (shmiR) and short hairpin RNA (shRNA), for treatment of oculopharyngeal muscular dystrophy (OPMD), compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto. The present disclosure also relates to the use of the RNAi reagents in combination with PABPN1 replacement reagents, such as constructs which encode functional PABPN1 protein, for treatment of OPMD, compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a U.S. National Phase Application of internationalapplication number PCT/AU2017/051385, filed on Dec. 14, 2017, whichclaims the right of priority to U.S. Provisional No. 62/434,312, filed14 Dec. 2016, the complete contents of which is incorporated byreference herein in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted via EFS-Web and is hereby incorporated by reference in itsentirety. Said ASCII copy, created on Jun. 13, 2019, is namedFBB-030_CRF_sequencelisting.txt, and is 39,903 bytes in size.

TECHNICAL FIELD

The present disclosure relates to RNA interference (RNAi) reagents fortreatment of oculopharyngeal muscular dystrophy (OPMD), compositionscomprising same, and use thereof to treat individuals suffering fromOPMD or which are predisposed thereto.

BACKGROUND

OPMD is an autosomal dominant inherited, slow progressing, late-onsetdegenerative muscle disorder. The disease is mainly characterised byprogressive eyelid drooping (ptosis) and swallowing difficulties(dysphagia). The pharyngeal and cricopharyngeal muscles are specifictargets in OPMD. Proximal limb weakness tends to follow at a later stageof disease progression. The mutation that causes the disease is anabnormal expansion of a (GCN)n trinucleotide repeat in the coding regionof the poly(A) binding protein nuclear 1 (PABPN1) gene. This expansionleads to an expanded polyalanine tract at the N-terminal of the PABPN1protein: 10 alanines are present in the normal protein, expanded to 11to 18 alanines in the mutant form (expPABPN1). The main pathologicalhallmark of the disease is nuclear aggregates of expPABPN1. A misfoldingof expanded PABPN1 results in the accumulation of insoluble polymericfibrillar aggregates inside nuclei of affected cells. PABPN1 is anaggregation prone protein and mutant alanine-expanded PABPN1 in OPMD hasa higher aggregation rate than that of the wild type normal protein.However, it is still unclear whether the nuclear aggregates in OPMD havea pathological function or a protective role as a consequence of acellular defence mechanism.

No treatment, pharmacological or otherwise, is presently available forOPMD, Symptomatic surgical interventions can partly correct ptosis andimprove swallowing in moderate to severely affected individuals. Forexample, the cricopharyngeal myotomy is at present the only possibletreatment available to improve swallowing in these patients. However,this does not correct the progressive degradation of the pharyngealmusculature, which often leads to death following swallowingdifficulties and choking.

Accordingly, there remains a need for therapeutic agents to treat OPMDin patients suffering therefrom and/or who are predisposed thereto.

Any discussion of documents, acts, materials, devices, articles or thelike which has been included in the present specification is not to betaken as an admission that any or all of these matters form part of theprior art base or were common general knowledge in the field relevant tothe present disclosure as it existed before the priority date of each ofthe appended claims.

SUMMARY

The present disclosure is based, in part, on the recognition by theinventors that no therapeutic agents currently exist for the treatmentof OPMD. The present disclosure therefore provides RNAi reagentstargeting regions of the PABPN1 mRNA transcript which is causative ofOPMD. The inventors have shown that these RNAi reagents are effectivefor post-transcriptional suppression of PABPN1 mRNA transcripts,including transcript variants which would otherwise be translated intothe mutant PABPN1 protein causative of OPMD i.e., those PABPN1 proteinscomprising an expanded polyalanine tract. For example, it has been shownthat exemplary RNAi reagents of the disclosure inhibit or reduceexpression of PABPN1 protein in vitro. Furthermore, the presentdisclosure provides reagents for expression of wild-type human PABPN1protein having a mRNA transcript which is not targeted by the RNAireagents of the disclosure (hereinafter “PABPN1 replacement reagents”).The inventors have shown that when expressed in conjunction with theRNAi reagents of the disclosure, the PABPN1 replacement reagents arecapable of producing a PABPN1 transcript which is resistant to the RNAireagents and which is capable of being translated into functional PABPN1protein. These findings by the inventors provide reagents which may havetherapeutic applications in the treatment of OPMD.

Accordingly, the present disclosure provides a nucleic acid comprising aDNA sequence which encodes a short hairpin micro-RNA (shmiR), said shmiRcomprising:

an effector sequence of at least 17 nucleotides in length;

an effector complement sequence;

a stemloop sequence; and

a primary micro RNA (pri-miRNA) backbone;

wherein the effector sequence is substantially complementary to a regionof corresponding length in an RNA transcript set forth in any one of SEQID NOs: 1-13. Preferably, the effector sequence will be less than 30nucleotides in length. For example, a suitable effector sequence may bein the range of 17-29 nucleotides in length. Preferably, the effectorsequence will be 20 nucleotides in length. More preferably, the effectorsequence will be 21 nucleotides in length and the effector complementsequence will be 20 nucleotides in length.

The effector sequence may comprise 4 base pair mismatches relative to aregion of corresponding length in an RNA transcript set forth in any oneof SEQ ID NOs: 1-13 to which the effector sequence is substantiallycomplementary. In another example, the effector sequence comprises 3base pair mismatches relative to a region of corresponding length in anRNA transcript set forth in any one of SEQ ID NOs: 1-13 to which theeffector sequence is substantially complementary. In another example,the effector sequence comprises 2 base pair mismatches relative to aregion of corresponding length in an RNA transcript set forth in any oneof SEQ ID NOs: 1-13 to which the effector sequence is substantiallycomplementary. In another example, the effector sequence comprises 1base pair mismatch relative to a region of corresponding length in anRNA transcript set forth in any one of SEQ ID NOs: 1-13 to which theeffector sequence is substantially complementary. In yet anotherexample, the effector sequence is 100% complementary to a region ofcorresponding length in an RNA transcript set forth in any one of SEQ IDNOs: 1-13. Where mismatches are present, it is preferred that they arenot located within the region corresponding to the seed region of theshmiR i.e., nucleotides 2-8 of the effector sequence.

Exemplary shmiRs comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 1 are described herein (hereinafter referred toas “shmiR2”).

Exemplary shmiRs comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 2 are described herein (hereinafter referred toas “shmiR3”).

Exemplary shmiRs comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 3 are described herein (hereinafter referred toas “shmiR4”).

Exemplary shmiRs comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 4 are described herein (hereinafter referred toas “shmiR5”).

Exemplary shmiRs comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 5 are described herein (hereinafter referred toas “shmiR6”).

Exemplary shmiRs comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 6 are described herein (hereinafter referred toas “shmiR7”).

Exemplary shmiRs comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 7 are described herein (hereinafter referred toas “shmiR9”).

Exemplary shmiRs comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 8 are described herein (hereinafter referred toas “shmiR11”).

Exemplary shmiRs comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 9 are described herein (hereinafter referred toas “shmiR13”).

Exemplary shmiRs comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 10 are described herein (hereinafter referred toas “shmiR14”).

Exemplary shmiRs comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 11 are described herein (hereinafter referred toas “shmiR15”).

Exemplary shmiRs comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 12 are described herein (hereinafter referred toas “shmiR16”).

Exemplary shmiRs comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 13 are described herein (hereinafter referred toas “shmiR17”).

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR selected from the group consisting of:

a shmiR comprising: (i) an effector sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:14 with theexception of 1, 2, 3 or 4 base mismatches, provided that the effectorsequence is capable of forming a duplex with a sequence set forth in SEQID NO: 14; and (ii) an effector complement sequence comprising asequence which is substantially complementary to the effector sequence(shmiR2);

a shmiR comprising: (i) an effector sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:16 with theexception of 1, 2, 3 or 4 base mismatches, provided that the effectorsequence is capable of forming a duplex with a sequence set forth in SEQID NO: 16; and (ii) an effector complement sequence comprising asequence which is substantially complementary to the effector sequence(shmiR3);

a shmiR comprising: (i) an effector sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:18 with theexception of 1, 2, 3 or 4 base mismatches, provided that the effectorsequence is capable of forming a duplex with a sequence set forth in SEQID NO:18; and (ii) an effector complement sequence comprising a sequencewhich is substantially complementary to the effector sequence (shmiR4);

a shmiR comprising: (i) an effector sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:20 with theexception of 1, 2, 3 or 4 base mismatches, provided that the effectorsequence is capable of forming a duplex with a sequence set forth in SEQID NO:20; and (ii) an effector complement sequence comprising a sequencewhich is substantially complementary to the effector sequence (shmiR5);

a shmiR comprising: (i) an effector sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:22 with theexception of 1, 2, 3 or 4 base mismatches, provided that the effectorsequence is capable of forming a duplex with a sequence set forth in SEQID NO:22; and (ii) an effector complement sequence comprising a sequencewhich is substantially complementary to the effector sequence (shmiR6);

a shmiR comprising: (i) an effector sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:24 with theexception of 1, 2, 3 or 4 base mismatches, provided that the effectorsequence is capable of forming a duplex with a sequence set forth in SEQID NO:24; and (ii) an effector complement sequence comprising a sequencewhich is substantially complementary to the effector sequence (shmiR7);

a shmiR comprising: (i) an effector sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:26 with theexception of 1, 2, 3 or 4 base mismatches, provided that the effectorsequence is capable of forming a duplex with a sequence set forth in SEQID NO:26; and (ii) an effector complement sequence comprising a sequencewhich is substantially complementary to the effector sequence (shmiR9);

a shmiR comprising: (i) an effector sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:28 with theexception of 1, 2, 3 or 4 base mismatches, provided that the effectorsequence is capable of forming a duplex with a sequence set forth in SEQID NO:28; and (ii) an effector complement sequence comprising a sequencewhich is substantially complementary to the effector sequence (shmiR11);

a shmiR comprising: (i) an effector sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:30 with theexception of 1, 2, 3 or 4 base mismatches, provided that the effectorsequence is capable of forming a duplex with a sequence set forth in SEQID NO:30; and (ii) an effector complement sequence comprising a sequencewhich is substantially complementary to the effector sequence (shmiR13);

a shmiR comprising: (i) an effector sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:32 with theexception of 1, 2, 3 or 4 base mismatches, provided that the effectorsequence is capable of forming a duplex with a sequence set forth in SEQID NO:32; and (ii) an effector complement sequence comprising a sequencewhich is substantially complementary to the effector sequence (shmiR14);

a shmiR comprising: (i) an effector sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:34 with theexception of 1, 2, 3 or 4 base mismatches, provided that the effectorsequence is capable of forming a duplex with a sequence set forth in SEQID NO:34; and (ii) an effector complement sequence comprising a sequencewhich is substantially complementary to the effector sequence (shmiR15);

a shmiR comprising: (i) an effector sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:36 with theexception of 1, 2, 3 or 4 base mismatches, provided that the effectorsequence is capable of forming a duplex with a sequence set forth in SEQID NO:36; and (ii) an effector complement sequence comprising a sequencewhich is substantially complementary to the effector sequence (shmiR16);and

a shmiR comprising: (i) an effector sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:38 with theexception of 1, 2, 3 or 4 base mismatches, provided that the effectorsequence is capable of forming a duplex with a sequence set forth in SEQID NO:38; and (ii) an effector complement sequence comprising a sequencewhich is substantially complementary to the effector sequence (shmiR17).

In another example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR selected from the group consisting of:

a shmiR comprising an effector sequence set forth in SEQ ID NO:15 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO: 15 and capable of forming a duplextherewith (shmiR2);

a shmiR comprising an effector sequence set forth in SEQ ID NO:17 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:17 and capable of forming a duplextherewith (shmiR3);

a shmiR comprising an effector sequence set forth in SEQ ID NO:19 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO: 19 and capable of forming a duplextherewith (shmiR4);

a shmiR comprising an effector sequence set forth in SEQ ID NO:21 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:21 and capable of forming a duplextherewith (shmiR5);

a shmiR comprising an effector sequence set forth in SEQ ID NO:23 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:23 and capable of forming a duplextherewith (shmiR6);

a shmiR comprising an effector sequence set forth in SEQ ID NO:25 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:25 and capable of forming a duplextherewith (shmiR7);

a shmiR comprising an effector sequence set forth in SEQ ID NO:27 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:27 and capable of forming a duplextherewith (shmiR9);

a shmiR comprising an effector sequence set forth in SEQ ID NO:29 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:29 and capable of forming a duplextherewith (shmiR11);

a shmiR comprising an effector sequence set forth in SEQ ID NO:31 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:31 and capable of forming a duplextherewith (shmiR13);

a shmiR comprising an effector sequence set forth in SEQ ID NO:33 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:33 and capable of forming a duplextherewith (shmiR14);

a shmiR comprising an effector sequence set forth in SEQ ID NO:35 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:35 and capable of forming a duplextherewith (shmiR15);

a shmiR comprising an effector sequence set forth in SEQ ID NO:37 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:37 and capable of forming a duplextherewith (shmiR16); and

a shmiR comprising an effector sequence set forth in SEQ ID NO:39 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:39 and capable of forming a duplextherewith (shmiR17).

For example, the shmiR encoded by the nucleic acid described herein maycomprise an effector complement sequence comprising 1, 2, 3 or 4mismatches relative to the corresponding effector sequence, providedthat the cognate effector and effector complement sequences are capableof forming a duplex region.

In another example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR selected from the group consisting of:

a shmiR comprising an effector sequence set forth in SEQ ID NO: 15 andan effector complement sequence set forth in SEQ ID NO: 14 (shmiR2);

a shmiR comprising an effector sequence set forth in SEQ ID NO: 17 andan effector complement sequence set forth in SEQ ID NO: 16 (shmiR3);

a shmiR comprising an effector sequence set forth in SEQ ID NO: 19 andan effector complement sequence set forth in SEQ ID NO: 18 (shmiR4);

a shmiR comprising an effector sequence set forth in SEQ ID NO: 21 andan effector complement sequence set forth in SEQ ID NO: 20 (shmiR5);

a shmiR comprising an effector sequence set forth in SEQ ID NO: 23 andan effector complement sequence set forth in SEQ ID NO: 22 (shmiR6);

a shmiR comprising an effector sequence set forth in SEQ ID NO: 25 andan effector complement sequence set forth in SEQ ID NO: 24 (shmiR7);

a shmiR comprising an effector sequence set forth in SEQ ID NO: 27 andan effector complement sequence set forth in SEQ ID NO: 26 (shmiR9);

a shmiR comprising an effector sequence set forth in SEQ ID NO: 29 andan effector complement sequence set forth in SEQ ID NO: 28 (shmiR11);

a shmiR comprising an effector sequence set forth in SEQ ID NO: 31 andan effector complement sequence set forth in SEQ ID NO: 30 (shmiR13);

a shmiR comprising an effector sequence set forth in SEQ ID NO: 33 andan effector complement sequence set forth in SEQ ID NO: 32 (shmiR14);

a shmiR comprising an effector sequence set forth in SEQ ID NO: 35 andan effector complement sequence set forth in SEQ ID NO: 34 (shmiR15);

a shmiR comprising an effector sequence set forth in SEQ ID NO: 37 andan effector complement sequence set forth in SEQ ID NO: 36 (shmiR16);and

a shmiR comprising an effector sequence set forth in SEQ ID NO: 39 andan effector complement sequence set forth in SEQ ID NO: 38 (shmiR17).

The shmiR encoded by the nucleic acid of the disclosure may comprise, ina 5′ to 3′ direction:

a 5′ flanking sequence of the pri-miRNA backbone;

the effector complement sequence;

the stemloop sequence;

the effector sequence; and

a 3′ flanking sequence of the pri-miRNA backbone.

The shmiR encoded by the nucleic acid of the disclosure may comprise, ina 5′ to 3′ direction:

a 5′ flanking sequence of the pri-miRNA backbone;

the effector sequence;

the stemloop sequence;

the effector complement sequence; and

a 3′ flanking sequence of the pri-miRNA backbone.

Suitable loop sequences may be selected from those known in the art.However, an exemplary stemloop sequence is set forth in SEQ ID NO: 40.

Suitable primary micro RNA (pri-miRNA or pri-R) backbones for use in anucleic acid of the disclosure may be selected from those known in theart. For example, the pri-miRNA backbone may be selected from apri-miR-30a backbone, a pri-miR-155 backbone, a pri-miR-21 backbone anda pri-miR-136 backbone. Preferably, however, the pri-miRNA backbone is apri-miR-30a backbone. In accordance with an example in which thepri-miRNA backbone is a pri-miR-30a backbone, the 5′ flanking sequenceof the pri-miRNA backbone is set forth in SEQ ID NO: 41 and the 3′flanking sequence of the pri-miRNA backbone is set forth in SEQ ID NO:42.

In one example, the nucleic acid described herein comprises a DNAsequence selected from the sequence set forth in any one of SEQ ID NOs:56-68. In accordance with this example, a shmiR encoded by the nucleicacid of the disclosure may comprise a sequence set forth in any one ofSEQ ID NOs: 43-55.

It will be understood by a person of skill in the art that a nucleicacid in accordance with the present disclosure may be combined or usedin conjunction with other therapeutic agents for treating OPMD e.g.,such as other RNAi agents targeting RNA transcripts corresponding to aPABPN1 protein which is causative of OPMD. Accordingly, the presentdisclosure provides a nucleic acid comprising a DNA sequence encoding ashmiR as described herein in combination with one or more other RNAiagents for treating OPMD. In one example, a plurality of nucleic acidsare provided comprising:

(a) at least one nucleic acid as described herein; and

(b) at least one further nucleic acid selected from:

-   -   (i) a nucleic acid in accordance with the nucleic acids        described herein; or    -   (ii) a nucleic acid comprising a DNA sequence encoding a shmiR        or short hairpin RNA (shRNA) comprising an effector sequence of        at least 17 nucleotides in length and a effector complement        sequence, wherein the effector sequence is substantially        complementary to a RNA transcript corresponding to a PABPN1        protein which is causative of oculopharyngeal muscular dystrophy        (OPMD);

wherein the shmiR encoded by the nucleic acid at (a) and the shmiR orshRNA encoded by the nucleic acid at (b) comprise different effectorsequences.

In one example, the effector sequence of the shmiR or shRNA at (b)(ii)is substantially complementary to a region of corresponding length in anRNA transcript set forth in any one of SEQ ID NOs: 1-13. Preferably, theeffector sequence of the shmiR or shRNA at (b)(ii) which issubstantially complementary to a region of corresponding length in anRNA transcript set forth in any one of SEQ ID NOs: 1-13 will be lessthan 30 nucleotides in length. For example, a suitable effector sequenceof the shmiR or shRNA may be in the range of 17-29 nucleotides inlength.

In one example, at least one of the nucleic acids in the pluralitycomprises a DNA sequence encoding shmiR2 as described herein.

In one example, at least one of the nucleic acids in the pluralitycomprises a DNA sequence encoding shmiR3 as described herein.

In one example, at least one of the nucleic acids in the pluralitycomprises a DNA sequence encoding shmiR4 as described herein.

In one example, at least one of the nucleic acids in the pluralitycomprises a DNA sequence encoding shmiR5 as described herein.

In one example, at least one of the nucleic acids in the pluralitycomprises a DNA sequence encoding shmiR6 as described herein.

In one example, at least one of the nucleic acids in the pluralitycomprises a DNA sequence encoding shmiR7 as described herein.

In one example, at least one of the nucleic acids in the pluralitycomprises a DNA sequence encoding shmiR9 as described herein.

In one example, at least one of the nucleic acids in the pluralitycomprises a DNA sequence encoding shmiR11 as described herein.

In one example, at least one of the nucleic acids in the pluralitycomprises a DNA sequence encoding shmiR13 as described herein.

In one example, at least one of the nucleic acids in the pluralitycomprises a DNA sequence encoding shmiR14 as described herein.

In one example, at least one of the nucleic acids in the pluralitycomprises a DNA sequence encoding shmiR15 as described herein.

In one example, at least one of the nucleic acids in the pluralitycomprises a DNA sequence encoding shmiR16 as described herein.

In one example, at least one of the nucleic acids in the pluralitycomprises a DNA sequence encoding shmiR17 as described herein.

A plurality of nucleic acids in accordance with the present disclosuremay comprise up to 10 nucleic acids, each encoding a shmiR as describedherein i.e., shmiR2-7, shmiR9, shmiR11, and shmiR13-17, such as twonucleic acids or three nucleic acids or four nucleic acids or fivenucleic acids or six nucleic acids or seven nucleic acids or eightnucleic acids or nine nucleic acids or ten nucleic acids. In oneexample, the plurality of nucleic acids comprises two nucleic acids ofthe disclosure, each encoding a shmiR as described herein. In anotherexample, the plurality of nucleic acids comprises three nucleic acids ofthe disclosure, each encoding a shmiR as described herein. In oneexample, the plurality of nucleic acids comprises four nucleic acids ofthe disclosure, each encoding a shmiR as described herein. In oneexample, the plurality of nucleic acids comprises five nucleic acids ofthe disclosure, each encoding a shmiR as described herein. In oneexample, the plurality of nucleic acids comprises six nucleic acids ofthe disclosure, each encoding a shmiR as described herein. In oneexample, the plurality of nucleic acids comprises seven nucleic acids ofthe disclosure, each encoding a shmiR as described herein. In oneexample, the plurality of nucleic acids comprises eight nucleic acids ofthe disclosure, each encoding a shmiR as described herein. In oneexample, the plurality of nucleic acids comprises nine nucleic acids ofthe disclosure, each encoding a shmiR as described herein. In oneexample, the plurality of RNAs comprises ten nucleic acids of thedisclosure, each encoding a shmiR as described herein. In accordancewith any of the examples described herein, one or more of the nucleicacids in the plurality may encode a shRNA as described herein.

In one example, the plurality of nucleic acids of the disclosurecomprises at least two nucleic acids, each comprising a DNA sequenceencoding a shmiR selected from the group consisting of shmiR2, shmiR3,shmiR5, shmiR9, shmiR13, shmiR14 and shmiR17 as described herein.

One exemplary plurality of nucleic acids of the disclosure comprises onenucleic acid comprising a DNA sequence encoding shmiR13 as describedherein and another nucleic acid comprising a DNA sequence encodingshmiR17 as described herein.

Another exemplary plurality of nucleic acids of the disclosure comprisesone nucleic acid comprising a DNA sequence encoding shmiR3 as describedherein and another nucleic acid comprising a DNA sequence encodingshmiR14 as described herein.

In accordance with an example in which a plurality of nucleic acids isprovided, two or more of the nucleic acids may form separate parts ofthe same polynucleotide. In another example, two or more of the nucleicacids in the plurality form parts of different polynucleotides,respectively.

The or each nucleic acid in accordance with the present disclosure maycomprise, or be in operable linkage with, one or more transcriptionalterminator sequences. For example, the or each nucleic acid may comprisea transcriptional terminator sequence at the 3′ terminus of the sequenceencoding the shmiR. Such sequences will depend on the choice of promoterand will be known to a person of skill in the art. However, suitablechoices of promoter and transcriptional terminator sequences for use inaccordance with a nucleic acid of the disclosure or plurality thereofare described herein.

Alternatively, or in addition, the or each nucleic acid in accordancewith the present disclosure may comprise, or be in operable linkagewith, a transcription initiator sequence. For example, the or eachnucleic acid may comprise a transcription initiator sequence at the 5′terminus of the sequence encoding the shmiR. Such sequences will beknown to a person of skill in the art.

Alternatively, or in addition, the or each nucleic acid in accordancewith the present disclosure may comprise one or more restriction sitese.g., to facilitate cloning of the nucleic acid(s) into cloning orexpression vectors. For example, the nucleic acids described herein mayinclude a restriction site upstream and/or downstream of the sequenceencoding a shmiR of the disclosure. Suitable restriction enzymerecognition sequences will be known to a person of skill in the art.

A nucleic acid in accordance with the present disclosure, or a pluralityof nucleic acids as described herein, may also be provided in the formof, or be comprised in, a DNA-directed RNA interference (ddRNAi)construct which is capable of expressing one or more shmiRs which is/areencoded by the nucleic acid(s) of the present disclosure.

In one example, the ddRNAi construct comprises at least two nucleicacids of the disclosure, such that the ddRNAi construct encodes at leasttwo shmiRs targeting a RNA transcript corresponding to a PABPN1 proteinwhich is causative of OPMD, each of which is different to one another.

In one example, each of the at least two nucleic acids in the ddRNAiconstruct encode a shmiR comprising an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript set forth in one of SEQ ID NOs: 1, 2, 4, 7, 9, 10 and 13.Thus, a ddRNAi construct in accordance with this example encodes twoshmiRs selected from shmiR2, shmiR3, shmiR5, shmiR9, shmiR13, shmiR14and shmiR17 as described herein.

One example of a ddRNAi construct of the disclosure comprises at leasttwo nucleic acids selected from the group consisting of:

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 15 and aneffector complement sequence which is substantially complementary to SEQID NO: 15 and capable of forming a duplex therewith e.g., an effectorcomplement sequence set forth in SEQ ID NO: 14 (shmiR2);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 17 and aneffector complement sequence which is substantially complementary to SEQID NO: 17 and capable of forming a duplex therewith e.g., an effectorcomplement sequence set forth in SEQ ID NO: 16 (shmiR3);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 21 and aneffector complement sequence which is substantially complementary to SEQID NO: 21 and capable of forming a duplex therewith e.g., an effectorcomplement sequence set forth in SEQ ID NO: 20 (shmiR5);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 27 and aneffector complement sequence which is substantially complementary to SEQID NO: 27 and capable of forming a duplex therewith e.g., an effectorcomplement sequence set forth in SEQ ID NO: 26 (shmiR9);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 31 and aneffector complement sequence which is substantially complementary to SEQID NO: 31 and capable of forming a duplex therewith e.g., an effectorcomplement sequence set forth in SEQ ID NO: 30 (shmiR13);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 33 and aneffector complement sequence which is substantially complementary to SEQID NO: 33 and capable of forming a duplex therewith e.g., an effectorcomplement sequence set forth in SEQ ID NO: 32 (shmiR14); and

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 39 and aneffector complement sequence which is substantially complementary to SEQID NO: 39 and capable of forming a duplex therewith e.g., an effectorcomplement sequence set forth in SEQ ID NO: 38 (shmiR17).

In one example, the ddRNAi construct comprises at least two nucleicacids selected from the group consisting of:

a nucleic acid comprising or consisting of a DNA sequence set forth inSEQ ID NO: 56 (shmiR2);

a nucleic acid comprising or consisting of a DNA sequence set forth inSEQ ID NO: 57 (shmiR3);

a nucleic acid comprising or consisting of a DNA sequence set forth inSEQ ID NO: 59 (shmiR5);

a nucleic acid comprising or consisting of a DNA sequence set forth inSEQ ID NO: 62 (shmiR9);

a nucleic acid comprising or consisting of a DNA sequence set forth inSEQ ID NO: 64 (shmiR13);

a nucleic acid comprising or consisting of a DNA sequence set forth inSEQ ID NO: 65 (shmiR14); and

a nucleic acid comprising or consisting of a DNA sequence set forth inSEQ ID NO: 68 (shmiR17).

In one example, each of the at least two nucleic acids in the ddRNAiconstruct encode a shmiR comprising an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript set forth in one of SEQ ID NOs: 2, 9, 10 and 13. Thus, addRNAi construct in accordance with this example encodes two shmiRsselected from shmiR3, shmiR13, shmiR14 and shmiR17 as described herein.

One example of a ddRNAi construct of the disclosure comprises at leasttwo nucleic acids selected from the group consisting of:

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 17 and aneffector complement sequence which is substantially complementary to SEQID NO: 17 and capable of forming a duplex therewith e.g., an effectorcomplement sequence set forth in SEQ ID NO: 16 (shmiR3);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 31 and aneffector complement sequence which is substantially complementary to SEQID NO: 31 and capable of forming a duplex therewith e.g., an effectorcomplement sequence set forth in SEQ ID NO: 30 (shmiR13);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 33 and aneffector complement sequence which is substantially complementary to SEQID NO: 33 and capable of forming a duplex therewith e.g., an effectorcomplement sequence set forth in SEQ ID NO: 32 (shmiR14); and

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 39 and aneffector complement sequence which is substantially complementary to SEQID NO: 39 and capable of forming a duplex therewith e.g., an effectorcomplement sequence set forth in SEQ ID NO: 38 (shmiR17).

In one example, the ddRNAi construct comprises at least two nucleicacids selected from the group consisting of:

a nucleic acid comprising or consisting of a DNA sequence set forth inSEQ ID NO: 57 (shmiR3);

a nucleic acid comprising or consisting of a DNA sequence set forth inSEQ ID NO: 64 (shmiR13);

a nucleic acid comprising or consisting of a DNA sequence set forth inSEQ ID NO: 65 (shmiR14); and

a nucleic acid comprising or consisting of a DNA sequence set forth inSEQ ID NO: 68 (shmiR17).

One exemplary ddRNAi construct of the disclosure comprises:

(a) a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 31 and aneffector complement sequence set forth in SEQ ID NO: 30 (shmiR13); and

(b) a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 39 and aneffector complement sequence set forth in SEQ ID NO: 38 (shmiR17).

A ddRNAi construct in accordance with this example may comprise:

(a) a nucleic acid comprising or consisting of the DNA sequence setforth in SEQ ID NO: 64 (shmiR13); and

(b) a nucleic acid comprising or consisting of the DNA sequence setforth in SEQ ID NO: 68 (shmiR17).

Another exemplary ddRNAi construct of the disclosure comprises:

(a) a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 17 and aneffector complement sequence set forth in SEQ ID NO: 16 (shmiR3); and

(b) a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 33 and aneffector complement sequence set forth in SEQ ID NO: 32 (shmiR14).

A ddRNAi construct in accordance with this example may comprise:

(a) a nucleic acid comprising or consisting of the sequence set forth inSEQ ID NO:57 (shmiR3); and

(b) a nucleic acid comprising or consisting of the sequence set forth inSEQ ID NO:65 (shmiR14).

In one example, a ddRNAi construct as described herein comprises asingle promoter which is operably-linked to the or each nucleic acidencoding a shmiR of the disclosure. In another example, each nucleicacid encoding a shmiR of the disclosure is operably-linked to a separatepromoter. For example, the promoter(s) is (are) positioned upstream ofthe respective nucleic acid(s) encoding the shmiR(s).

In accordance with an example in which the ddRNAi construct comprisesmultiple promoters, the promoters may be the same or different.Exemplary promoters which may be employed are muscle-specific promoters,such as for example, Spc512 and CK8. Other promoters which may beemployed are RNA pol III promoters, such as for example, the U6 and H1promoters. Exemplary U6 promoters are U6-1, U6-8 and U6-9 promoters.

A plurality of nucleic acids as described herein may also be provided inthe form of, or be comprised in, a plurality of ddRNAi constructs, eachcapable of expressing one or more shmiRs which is/are encoded by thenucleic acid(s) of the present disclosure. For example, each nucleicacid in the plurality of nucleic acids may be provided in the form of,or be comprised in, a separate ddRNAi construct.

In one example, the plurality of ddRNAi constructs comprises at leasttwo ddRNAi constructs, each comprising a nucleic acid of the pluralityof nucleic acids described herein, such that collectively, the ddRNAiconstructs encode at least two shmiRs targeting a RNA transcriptcorresponding to a PABPN1 protein which is causative of OPMD, each ofwhich is different to one another.

In one example, each of the at least two ddRNAi constructs encodes ashmiR comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in one of SEQ ID NOs: 1, 2, 4, 7, 9, 10 and 13. Thus, aplurality of ddRNAi constructs in accordance with this examplecollectively encode two shmiRs selected from shmiR2, shmiR3, shmiR5,shmiR9, shmiR13, shmiR14 and shmiR17 as described herein.

One example of a plurality of ddRNAi constructs of the disclosurecomprises at least two ddRNAi constructs selected from the groupconsisting of:

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence encoding a shmiR comprising an effector sequence setforth in SEQ ID NO: 15 and an effector complement sequence which issubstantially complementary to SEQ ID NO: 15 and capable of forming aduplex therewith e.g., an effector complement sequence set forth in SEQID NO: 14 (shmiR2);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence encoding a shmiR comprising an effector sequence setforth in SEQ ID NO: 17 and an effector complement sequence which issubstantially complementary to SEQ ID NO: 17 and capable of forming aduplex therewith e.g., an effector complement sequence set forth in SEQID NO: 16 (shmiR3);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence encoding a shmiR comprising an effector sequence setforth in SEQ ID NO: 21 and an effector complement sequence which issubstantially complementary to SEQ ID NO: 21 and capable of forming aduplex therewith e.g., an effector complement sequence set forth in SEQID NO: 20 (shmiR5);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence encoding a shmiR comprising an effector sequence setforth in SEQ ID NO: 27 and an effector complement sequence which issubstantially complementary to SEQ ID NO: 27 and capable of forming aduplex therewith e.g., an effector complement sequence set forth in SEQID NO: 26 (shmiR9);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence encoding a shmiR comprising an effector sequence setforth in SEQ ID NO: 31 and an effector complement sequence which issubstantially complementary to SEQ ID NO: 31 and capable of forming aduplex therewith e.g., an effector complement sequence set forth in SEQID NO: 30 (shmiR13);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence encoding a shmiR comprising an effector sequence setforth in SEQ ID NO: 33 and an effector complement sequence which issubstantially complementary to SEQ ID NO: 33 and capable of forming aduplex therewith e.g., an effector complement sequence set forth in SEQID NO: 32 (shmiR14); and

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence encoding a shmiR comprising an effector sequence setforth in SEQ ID NO: 39 and an effector complement sequence which issubstantially complementary to SEQ ID NO: 39 and capable of forming aduplex therewith e.g., an effector complement sequence set forth in SEQID NO: 38 (shmiR17).

In one example, the plurality of ddRNAi constructs comprises at leastddRNAi constructs selected from the group consisting of:

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence set forth in SEQ ID NO: 56 (shmiR2);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence set forth in SEQ ID NO: 57 (shmiR3);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence set forth in SEQ ID NO: 59 (shmiR5);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence set forth in SEQ ID NO: 62 (shmiR9);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence set forth in SEQ ID NO: 64 (shmiR13);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence set forth in SEQ ID NO: 65 (shmiR14); and

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence set forth in SEQ ID NO: 68 (shmiR17).

In one example, each of the at least two ddRNAi constructs encodes ashmiR comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in one of SEQ ID NOs: 2, 9, 10 and 13. Thus, a plurality ofddRNAi constructs in accordance with this example collectively encodestwo shmiRs selected from shmiR3, shmiR13, shmiR14 and shmiR17 asdescribed herein.

One example of a plurality of ddRNAi constructs of the disclosurecomprises at least two ddRNAi constructs selected from the groupconsisting of:

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence encoding a shmiR comprising an effector sequence setforth in SEQ ID NO: 17 and an effector complement sequence which issubstantially complementary to SEQ ID NO: 17 and capable of forming aduplex therewith e.g., an effector complement sequence set forth in SEQID NO: 16 (shmiR3);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence encoding a shmiR comprising an effector sequence setforth in SEQ ID NO: 31 and an effector complement sequence which issubstantially complementary to SEQ ID NO: 31 and capable of forming aduplex therewith e.g., an effector complement sequence set forth in SEQID NO: 30 (shmiR13);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence encoding a shmiR comprising an effector sequence setforth in SEQ ID NO: 33 and an effector complement sequence which issubstantially complementary to SEQ ID NO: 33 and capable of forming aduplex therewith e.g., an effector complement sequence set forth in SEQID NO: 32 (shmiR14); and

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence encoding a shmiR comprising an effector sequence setforth in SEQ ID NO: 39 and an effector complement sequence which issubstantially complementary to SEQ ID NO: 39 and capable of forming aduplex therewith e.g., an effector complement sequence set forth in SEQID NO: 38 (shmiR17).

In one example, the at least two ddRNAi constructs is selected from thegroup consisting of:

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence set forth in SEQ ID NO: 57 (shmiR3);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence set forth in SEQ ID NO: 64 (shmiR13);

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence set forth in SEQ ID NO: 65 (shmiR14); and

a ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence set forth in SEQ ID NO: 68 (shmiR17).

One exemplary plurality of ddRNAi constructs of the disclosurecomprises:

(a) a ddRNAi construct comprising a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR comprising an effectorsequence set forth in SEQ ID NO: 31 and an effector complement sequenceset forth in SEQ ID NO: 30 (shmiR13); and

(b) a ddRNAi construct comprising a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR comprising an effectorsequence set forth in SEQ ID NO: 39 and an effector complement sequenceset forth in SEQ ID NO: 38 (shmiR17).

A plurality of ddRNAi constructs in accordance with this example maycomprise:

(a) a ddRNAi construct comprising a nucleic acid comprising orconsisting of the DNA sequence set forth in SEQ ID NO: 64 (shmiR13); and

(b) a ddRNAi construct comprising a nucleic acid comprising orconsisting of the DNA sequence set forth in SEQ ID NO: 68 (shmiR17).

Another exemplary plurality of ddRNAi constructs of the disclosurecomprises:

(a) a ddRNAi construct comprising a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR comprising an effectorsequence set forth in SEQ ID NO: 17 and an effector complement sequenceset forth in SEQ ID NO: 16 (shmiR3); and

(b) a ddRNAi construct comprising a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR comprising an effectorsequence set forth in SEQ ID NO: 33 and an effector complement sequenceset forth in SEQ ID NO: 32 (shmiR14).

A plurality of ddRNAi constructs in accordance with this example maycomprise:

(a) a ddRNAi construct comprising a nucleic acid comprising orconsisting of the sequence set forth in SEQ ID NO:57 (shmiR3); and

(b) a ddRNAi construct comprising a nucleic acid comprising orconsisting of the sequence set forth in SEQ ID NO:65 (shmiR14).

Each ddRNAi construct in the plurality of ddRNAi constructs as describedherein comprises a single promoter which is operably-linked to the oreach nucleic acid encoding a shmiR comprised therein. Where a ddRNAiconstruct in the plurality of ddRNAi constructs comprises more than onenucleic acid encoding a shmiR, each nucleic acid may be operably linkedto the same promoter or be operably-linked to a separate promoter. Ineach of the foregoing examples describing a plurality of ddRNAiconstructs, the promoter(s) is(are) positioned upstream of therespective nucleic acid(s) encoding the shmiR(s).

Exemplary promoters which may be employed are muscle-specific promoters,such as for example, Spc512 and CK8. Other promoters which may beemployed are RNA pol III promoters, such as for example, the U6 and H1promoters. Exemplary U6 promoters are U6-1, U6-8 and U6-9 promoters. Thepromoters comprised in the respective ddRNAi constructs of the pluralityof ddRNAi constructs may be the same or different.

The present disclosure also provides a DNA construct comprising:

(a) a ddRNAi construct as described herein; and

(b) a PABPN1 construct comprising a DNA sequence encoding a functionalPABPN1 protein having a mRNA transcript which is not targeted by theshmiR(s) encoded by the ddRNAi construct. Preferably, the DNA sequenceencoding the functional PABPN1 protein is codon optimised such that itsmRNA transcript is not targeted by the shmiRs of the ddRNAi construct.In one example, functional PABPN1 protein is a wild-type human PABPN1protein e.g., having a sequence set forth in SEQ ID NO: 74. In oneexample a codon optimised DNA sequence encoding the functional PABPN1protein is set forth in SEQ ID NO: 73.

The DNA construct may comprise one or more promoters. Exemplarypromoters for use in the DNA constructs of the disclosure aremuscle-specific promoter, such as for example, Spc512 and CK8.

According to one example, the DNA construct comprises a promoter whichis operably-linked to the PABPN1 construct and the ddRNAi construct,wherein the promoter is positioned upstream of the PABPN1 construct andthe ddRNAi construct.

In one example, the DNA construct comprises, in a 5′ to 3′ direction:

(a) a muscle-specific promoter e.g., Spc512;

(b) a PABPN1 construct as described herein comprising a DNA sequenceencoding a functional PABPN1 protein having a mRNA transcript which isnot targeted by the shmiRs encoded by the ddRNAi construct; and

(c) a ddRNAi construct of the disclosure comprising a nucleic acidcomprising a DNA sequence encoding shmiR13 as described herein and anucleic acid comprising a DNA sequence encoding shmiR17 as describedherein.

In another example, the DNA construct comprises:

(a) a muscle-specific promoter e.g., Spc512;

(b) a PABPN1 construct as described herein comprising a DNA sequenceencoding a functional PABPN1 protein having a mRNA transcript which isnot targeted by the shmiRs encoded by the ddRNAi construct; and

(c) a ddRNAi construct of the disclosure comprising a nucleic acidcomprising a DNA sequence encoding shmiR3 as described herein and anucleic acid comprising a DNA sequence encoding shmiR14 as describedherein.

In another example, the PABPN1 construct and the ddRNAi construct areeach operably-linked to separate promoters within the DNA construct. Forexample, the promoter which is in operable linkage with the PABPN1construct will be operably linked to the DNA sequence encoding afunctional PABPN1 protein comprised therein. The or each promoter whichis in operable linkage with the ddRNAi construct will be operably-linkedwith one or more nucleic acids encoding a shmiR of the disclosurecomprised in the ddRNAi construct. Exemplary promoters for use in theDNA constructs of the disclosure are muscle-specific promoter, such asfor example, Spc512 and CK8.

One DNA construct in accordance with this example comprises, in a 5′ to3′ direction:

(a) a muscle-specific promoter e.g., CK8 promoter, positioned upstreamof a ddRNAi construct of the disclosure comprising a nucleic acidcomprising a DNA sequence encoding shmiR13 as described herein and anucleic acid comprising a DNA sequence encoding shmiR17 as describedherein; and(b) a muscle-specific promoter e.g., Spc512 promoter, positionedupstream of a PABPN1 construct as described herein comprising a DNAsequence encoding a functional PABPN1 protein having a mRNA transcriptwhich is not targeted by the shmiRs encoded by the ddRNAi construct.

Another DNA construct in accordance with this example comprises, in a 5′to 3′ direction:

(a) a muscle-specific promoter e.g., CK8 promoter, positioned upstreamof a ddRNAi construct of the disclosure comprising a nucleic acidcomprising a DNA sequence encoding shmiR3 as described herein and anucleic acid comprising a DNA sequence encoding shmiR14 as describedherein; and(b) a muscle-specific promoter e.g., Spc512 promoter, positionedupstream of a PABPN1 construct as described herein comprising a DNAsequence encoding a functional PABPN1 protein having a mRNA transcriptwhich is not targeted by the shmiRs encoded by the ddRNAi construct.

An exemplary ddRNAi construct encoding shmiR13 and shmiR17 for inclusionin a DNA construct of the disclosure may comprise a nucleic acidcomprising or consisting of a DNA sequence encoding a shmiR comprisingan effector sequence set forth in SEQ ID NO: 31 and an effectorcomplement sequence which is substantially complementary to the sequenceset forth in SEQ ID NO: 31 e.g., an effector complement sequence setforth in SEQ ID NO: 30 (shmiR13), and a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR comprising an effectorsequence set forth in SEQ ID NO: 39 and an effector complement sequencewhich is substantially complementary to the sequence set forth in SEQ IDNO: 39 e.g., an effector complement sequence set forth in SEQ ID NO: 38(shmiR17). For example, the ddRNAi construct in accordance with thisexample of the DNA construct may comprise a nucleic acid comprising orconsisting of the DNA sequence set forth in SEQ ID NO: 64 (shmiR13), anda nucleic acid comprising or consisting of the DNA sequence set forth inSEQ ID NO: 68 (shmiR17).

An exemplary ddRNAi construct encoding shmiR3 and shmiR14 for inclusionin a DNA construct of the disclosure may comprise a nucleic acidcomprising or consisting of a DNA sequence encoding a shmiR comprisingan effector sequence set forth in SEQ ID NO: 17 and an effectorcomplement sequence which is substantially complementary to the sequenceset forth in SEQ ID NO: 17 e.g., an effector complement sequence setforth in SEQ ID NO: 16 (shmiR3), and a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR comprising an effectorsequence set forth in SEQ ID NO: 33 and an effector complement sequencewhich is substantially complementary to the sequence set forth in SEQ IDNO: 33 e.g., an effector complement sequence set forth in SEQ ID NO: 34(shmiR14). For example, the ddRNAi construct in accordance with thisexample of the DNA construct may comprise a nucleic acid comprising orconsisting of the DNA sequence set forth in SEQ ID NO: 57 (shmiR3), anda nucleic acid comprising or consisting of the DNA sequence set forth inSEQ ID NO: 65 (shmiR14).

The present disclosure also provides an expression vector, comprising addRNAi construct of the disclosure, or a plurality of ddRNAi constructsof the disclosure or a DNA construct of the disclosure.

The present disclosure also provides plurality of expression vectorseach of which comprises a ddRNAi construct of the disclosure. Forexample, one or more of the plurality of expression vectors comprises aplurality of ddRNAi constructs as disclosed herein. In another example,each expression vector in the plurality of expression vectors comprisesa plurality of ddRNAi constructs as disclosed herein. In a furtherexample, each expression vector in the plurality of expression vectorscomprises a single ddRNAi construct as described herein. In any of theforegoing ways in this paragraph, the plurality of expression vectorsmay collectively express a plurality of shmiRs in accordance with thepresent disclosure.

The present disclosure also provides plurality of expression vectorscomprising:

(a) an expression vector comprising one or more ddRNAi constructs of thedisclosure; and

(b) an expression vector comprising a PABPN1 construct comprising a DNAsequence encoding a functional PABPN1 protein having a mRNA transcriptwhich is not targeted by the shmiR(s) encoded by the ddRNAi construct.

Preferably, the DNA sequence encoding the functional PABPN1 protein iscodon optimised such that its mRNA transcript is not targeted by theshmiRs of the ddRNAi construct. In one example, functional PABPN1protein is a wild-type human PABPN1 protein e.g., having a sequence setforth in SEQ ID NO: 74. In one example, a codon optimised DNA sequenceencoding the functional PABPN1 protein is set forth in SEQ ID NO: 73.

In one example, the DNA sequence encoding the functional PABPN1 proteinmay be operably-linked to a promoter comprised within the PABPN1construct and positioned upstream of the DNA sequence encoding thefunctional PABPN1 protein. In another example, the expression vectorcomprising the PABPN1 construct comprises a promoter upstream of thePABPN1 construct and in operable-linkage with the DNA sequence encodingthe functional PABPN1 protein. Exemplary promoters for use in theexpression vector(s) of the disclosure are muscle-specific promoter,such as for example, Spc512 and CK8.

In one example, the or each expression vector is a plasmid or aminicircle.

In one example, the plasmid or minicircle or expression vector or ddRNAiconstruct is complexed with a cationic DNA binding polymer e.g.,polyethylenimine.

In another example, the or each expression vector is a viral vector. Forexample, the viral vector is selected from the group consisting of anadeno-associated viral (AAV) vector, a retroviral vector, an adenoviralvector (AdV) and a lentiviral (LV) vector.

The present disclosure also provides a composition comprising a ddRNAiconstruct and/or a plurality of ddRNAi constructs and/or expressionvector and/or a plurality of expression vectors as described herein. Inone example, the composition may also comprise one or morepharmaceutically acceptable carriers and/or diluents.

The present disclosure also provides a method of inhibiting expressionof a PABPN1 protein which is causative of OPMD in a subject, said methodcomprising administering to the subject a nucleic acid, a plurality ofnucleic acids, a ddRNAi construct, a plurality of ddRNAi constructs, aDNA construct, an expression vector, a plurality of expression vector,or a composition described herein.

The present disclosure also provides a method of treating OPMD in asubject suffering therefrom, the method comprising administering to thesubject a nucleic acid, a plurality of nucleic acids, a ddRNAiconstruct, a plurality of ddRNAi constructs, a DNA construct, anexpression vector, a plurality of expression vectors, or a compositiondescribed herein. The method may comprise administering the plurality ofexpression vectors to the subject together, simultaneously orconsecutively.

The present disclosure also provides a kit comprising:

-   (a) one or more agents for inhibiting expression of a PABPN1 protein    which is causative of OPMD, said agent(s) being selected from a    nucleic acid, a plurality of nucleic acids, a ddRNAi construct, a    plurality of ddRNAi constructs, a DNA construct, an expression    vector, a plurality of expression vectors, or a composition    described herein; and-   (b) an expression vector comprising a DNA sequence encoding a    functional PABPN1 protein having a mRNA transcript which is not    targeted by shmiRs expressed by the agent at (a).

Preferably, the DNA sequence encoding the functional PABPN1 protein iscodon optimised such that its mRNA transcript is not targeted by theshmiRs encoded by the agent at (a). In one example, functional PABPN1protein is a wild-type human PABPN1 protein e.g., having a sequence setforth in SEQ ID NO: 74. In one example, the codon optimised DNA sequenceencoding the functional PABPN1 protein is set forth in SEQ ID NO: 73.

The DNA sequence encoding the functional PABPN1 protein may beoperably-linked to a promoter comprised within the expression vector at(b) and positioned upstream of the DNA sequence encoding the functionalPABPN1 protein. An exemplary promoter for use in the expression vectorat (b) is a muscle-specific promoter, such as for example, a Spc512 orCK8 promoter.

The present disclosure also provides a kit comprising the plurality ofexpression vectors described herein packaged as separate components.

The present disclosure also provides a kit comprising a nucleic acid, aplurality of nucleic acids, a ddRNAi construct, a plurality of ddRNAiconstructs, a DNA construct, an expression vector, a plurality ofexpression vectors, or a composition described herein, packaged withinstruction for use in a method of the disclosure.

In one example, the kit as described herein is for use in treating OPMDaccording to a method described herein.

The present disclosure also provides use of a nucleic acid, a pluralityof nucleic acids, a ddRNAi construct, a plurality of ddRNAi constructs,a DNA construct, an expression vector, a plurality of expressionvectors, and/or a composition described herein in the preparation of amedicament, e.g., for treating OPMD in a subject and/or in a methoddisclosed herein.

The present disclosure also provides nucleic acid, a plurality ofnucleic acids, a ddRNAi construct, a plurality of ddRNAi constructs, aDNA construct, an expression vector, a plurality of expression vectors,and/or a composition described herein for use in therapy. For example,the nucleic acid, the plurality of nucleic acids, the ddRNAi construct,the plurality of ddRNAi constructs, the DNA construct, the expressionvector, the plurality of expression vectors and/or the composition maybe for use in treating OPMD in a subject suffering therefrom orpredisposed thereto and/or in a method disclosed herein.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 illustrates the predicted secondary structure of a representativeshmiR construct comprising a 5′ flanking region, a siRNA sense strand; astem/loop junction sequence, an siRNA anti-sense strand, and a 3′flanking region.

FIG. 2 illustrates the wtPABPN1 inhibitory activity of shmiRs havingantisense and sense sequences of shmiRs designated shmiR2-17 relative tothe psilencer control in HEK293 cells. This graph illustrates that allshmiRs except shmiR11 downregulated the level of luciferase expressionfrom the wtPABPN1 Luciferase reporter.

FIG. 3 illustrates the optPABPN1 inhibitory activity of shmiRs havingantisense and sense sequences of shmiRs designated shmiR 2-17 relativeto the psilencer control in HEK293 cells. This graph illustrates thatthere was no downregulation of expression from the optPABPN1 Luciferasereporter.

FIG. 4(A) is a western blot showing levels of FLAG-tagged wtPABPN1protein relative to Hsp90 protein expressed in HEK293T cells transfectedwith plasmids encoding shmiR2, shmiR3, shmiR5, shmiR9, shmiR13, shmiR14,shmiR16 or shmiR17. This shows that all of the selected shmiRs knockeddown the expression of wtPABPN1.

FIG. 4(B) illustrates the percent inhibition of FLAG-tagged wtPABPN1protein in HEK293 cells relative to the psilencer control. This graphillustrates that all of the selected shmiRs knocked down the expressionof wtPABPN1 with percent inhibition >90%, as determined by densiometricanalysis of the western blot at FIG. 4(A).

FIG. 5(A) is a western blot showing levels of FLAG-taggedcodon-optimised PABPN1 protein relative to Hsp90 protein expressed inHEK293T cells transfected with shmiRs plasmids encoding shmiR2, shmiR3,shmiR5, shmiR9, shmiR13, shmiR14, shmiR16 or shmiR17. This shows thatnone of the shmiRs resulted in inhibition of the expression product ofthe codon-optimised PABPN1 construct.

FIG. 5(B) illustrates the percent inhibition of FLAG-taggedcodon-optimised PABPN1 protein in HEK293 cells relative to the psilencercontrol. This graph illustrates that none of the shmiRs resulted ininhibition of the expression product of the codon-optimised PABPN1construct, as determined by densiometric analysis of the western blot atFIG. 5(A).

FIG. 6 illustrates the percent inhibition of endogenous wtPABPN1expression in HEK293T cells by shmiR2, shmiR3, shmiR5, shmiR9, shmiR13,shmiR14, shmiR16 or shmiR17, as determined by qPCR analysis. This graphillustrates that the shmiRs downregulated the expression of wtPABPN1with percent inhibition ranging between 16.4% to 49.1% (mean 35.5%).

FIG. 7 illustrates the percent inhibition of endogenous PABPN1expression in C2C12 cells in response to inhibition by shmiR2, shmiR3,shmiR5, shmiR9, shmiR13, shmiR14, shmiR16 or shmiR17, as determined byqPCR analysis. The graph illustrates that all of the individual shmiRs,with the exception of shmiR 16 (percentage inhibition of ˜43%),downregulated the expression of PABPN1 in C2C12 cells with a meanpercentage inhibition of approximately 80% relative to the pSilencercontrol.

FIG. 8 illustrates the percent inhibition of PABPN1 expression in C2C12cells by shmiRs shmiR13, shmiR17, shmiR3 and shmiR14 individually;shmiR13 in combination with shmiR17 (shmiR13/17); and shmiR3 incombination with shmiR14 (shmiR3/14), as determined by qPCR analysis.This graph illustrates that shmiR13/17 co-transfection resulted in apercent inhibition of PABPN1 expression of 84.4%, compared to 92.5% and76.7% for individual shmiR13 and shmiR17 respectively, and shmiR3/14co-transfection resulted in 79.0% percent inhibition, compared to 76.2%and 80.4% for individual shmiR3 and shmiR14 respectively.

FIG. 9 illustrates the percent inhibition of PABPN1 expression inARPE-19 cells by shmiR13, shmiR17, shmiR3 and shmiR14 individually;shmiR13 in combination with shmiR17 (shmiR13/17); and shmiR3 incombination with shmiR14 (shmiR3/14), as determined by qPCR analysis.The graph illustrates that the percent inhibition of PABPN1 expressionincreased 1.14 fold between 48 and 72 hours in ARPE-19 cells.

FIG. 10(A) shows standard curves obtained by qPCR determining the totalnumber of shmiRs expressed in C2C12 cells transfected with shmiR13,shmiR14 and shmiR17.

FIG. 10(B) shows a non-linear standard curve obtained by qPCRdetermining the total number of shmiRs expressed in C2C12 cellstransfected with shmiR3.

FIG. 11 illustrates the levels of expression of shmiR3, shmiR13, shmiR14and shmiR17 in C2C12 cells transduced with the shmiR vectors expressingsaid shmiRs.

FIG. 12(A) is a schematic illustrating a construct for simultaneous genesilencing of endogenous PABPN1 and replacement with codon optimisedPABPN1 generated by subcloning two shmiRs targeting wtPABPN1 into the 3′untranslated region of the codon optimized PABPN1 transcript in thepAAV2 vector backbone.

FIG. 12(B) is a schematic illustrating a construct for simultaneous genesilencing of endogenous PABPN1 and replacement with codon optimisedPABPN1 generated by subcloning two shmiRs targeting wtPABPN1 into thesequence upstream of the optPABPN1.

FIG. 13 shows in vivo fluorescence in mouse limb following injectionwith AAV9-eGFP.

FIG. 14 is a schematic illustrating the SR-construct designed forsimultaneous gene silencing of endogenous PABPN1 and replacement withcodon optimised PABPN1 generated by subcloning two shmiRs targetingwtPABPN1 (shmiR17 and shmiR13) into the 3′ untranslated region of thecodon optimized PABPN1 transcript in the pAAV2 vector backbone.

FIG. 15 illustrates percent inhibition of PABPN1 in A17 mice treatedwith the silence and replace construct (hereinafter the “SR-construct”),and shows that robust inhibition of PABPN1 is achieved at both high andlow doses.

FIG. 16 illustrates the level of expression of codon-optimised PABPN1relative to wildtype PABPN1 (including mutant form) in A17 mice treatedwith the SR-construct at high and low doses.

FIG. 17 shows immunofluorescence histochemistry for PABPN1 and laminindetection in sections of Tibialis anterior (TA) muscles from (i) A17mice treated with saline, (ii) FvB mice treated with saline, (iii) A17mice treated with the SR-construct at high and low doses. The number ofPABPN1 positive intranuclear inclusions (INIs) is significantly reducedin muscles from mice treated with the SR-construct at both high and lowdoses.

FIG. 18 illustrates the level of nuclei containing INIs (expressed as apercentage) in sections of Tibialis anterior (TA) muscles from (i) A17mice treated with saline, (ii) FvB mice treated with saline, (iii) A17mice treated with the SR-construct at high and low doses. This graphillustrates that treatment with the SR-construct at both high and lowdoses reduces the amount of INIs to about 10% compared to salineinjected A17 muscles.

FIG. 19 shows weight of Tibialis anterior (TA) muscles excised from (i)A17 mice treated with saline, (ii) FvB mice treated with saline, (iii)A17 mice treated with the SR-construct at high and low doses. This graphshows that treatment with the SR-construct at both high and low dosesrestored muscle weight to near wildtype levels of the FvB animals. Allmuscle measurement were taken on the day of sacrifice, at 14 or 20 weekspost-injection.

FIG. 20 shows isometric maximal force of Tibialis anterior (TA) musclesexcised from (i) A17 mice treated with saline, (ii) FvB mice treatedwith saline, (iii) A17 mice treated with the SR-construct at high andlow doses. This graph shows that treatment with the SR-construct at bothhigh and low doses restored roughly 66% of the reduced strengthdifference noted in the A17 mice relative to FvB wildtype animals. Allmuscle measurement were taken on the day of sacrifice, at 14 or 20 weekspost-injection. Statistics shown as unpaired t-test relative to A17Saline mice. *p<0.05, **p<0.01.

KEY TO THE SEQUENCE LISTING

-   SEQ ID NO: 1: RNA sequence for region within mRNA transcript    corresponding to PABPN1 protein designated PABPN1 mRNA Region 2.-   SEQ ID NO: 2: RNA sequence for region within mRNA transcript    corresponding to PABPN1 protein designated PABPN1 mRNA Region 3.-   SEQ ID NO: 3: RNA sequence for region within mRNA transcript    corresponding to PABPN1 protein designated PABPN1 mRNA Region 4.-   SEQ ID NO: 4: RNA sequence for region within mRNA transcript    corresponding to PABPN1 protein designated PABPN1 mRNA Region 5.-   SEQ ID NO: 5: RNA sequence for region within mRNA transcript    corresponding to PABPN1 protein designated PABPN1 mRNA Region 6.-   SEQ ID NO: 6: RNA sequence for region within mRNA transcript    corresponding to PABPN1 protein designated PABPN1 mRNA Region 7.-   SEQ ID NO: 7: RNA sequence for region within mRNA transcript    corresponding to PABPN1 protein designated PABPN1 mRNA Region 9.-   SEQ ID NO: 8: RNA sequence for region within mRNA transcript    corresponding to PABPN1 protein designated PABPN1 mRNA Region 11.-   SEQ ID NO: 9: RNA sequence for region within mRNA transcript    corresponding to PABPN1 protein designated PABPN1 mRNA Region 13.-   SEQ ID NO: 10: RNA sequence for region within mRNA transcript    corresponding to PABPN1 protein designated PABPN1 mRNA Region 14.-   SEQ ID NO: 11: RNA sequence for region within mRNA transcript    corresponding to PABPN1 protein designated PABPN1 mRNA Region 15.-   SEQ ID NO: 12: RNA sequence for region within mRNA transcript    corresponding to PABPN1 protein designated PABPN1 mRNA Region 16.-   SEQ ID NO: 13: RNA sequence for region within mRNA transcript    corresponding to PABPN1 protein designated PABPN1 mRNA Region 17.-   SEQ ID NO: 14: RNA effector complement sequence for shmiR designated    shmiR2.-   SEQ ID NO: 15: RNA effector sequence for shmiR designated shmiR2.-   SEQ ID NO: 16: RNA effector complement sequence for shmiR designated    shmiR3.-   SEQ ID NO: 17: RNA effector sequence for shmiR designated shmiR3.-   SEQ ID NO: 18: RNA effector complement sequence for shmiR designated    shmiR4.-   SEQ ID NO: 19: RNA effector sequence for shmiR designated shmiR4.-   SEQ ID NO: 20: RNA effector complement sequence for shmiR designated    shmiR5.-   SEQ ID NO: 21: RNA effector sequence for shmiR designated shmiR5.-   SEQ ID NO: 22: RNA effector complement sequence for shmiR designated    shmiR6.-   SEQ ID NO: 23: RNA effector sequence for shmiR designated shmiR6.-   SEQ ID NO: 24: RNA effector complement sequence for shmiR designated    shmiR7.-   SEQ ID NO: 25: RNA effector sequence for shmiR designated shmiR7.-   SEQ ID NO: 26: RNA effector complement sequence for shmiR designated    shmiR9.-   SEQ ID NO: 27: RNA effector sequence for shmiR designated shmiR9.-   SEQ ID NO: 28: RNA effector complement sequence for shmiR designated    shmiR11.-   SEQ ID NO: 29: RNA effector sequence for shmiR designated shmiR11.-   SEQ ID NO: 30: RNA effector complement sequence for shmiR designated    shmiR13.-   SEQ ID NO: 31: RNA effector sequence for shmiR designated shmiR13.-   SEQ ID NO: 32: RNA effector complement sequence for shmiR designated    shmiR14.-   SEQ ID NO: 33: RNA effector sequence for shmiR designated shmiR14.-   SEQ ID NO: 34: RNA effector complement sequence for shmiR designated    shmiR15.-   SEQ ID NO: 35: RNA effector sequence for shmiR designated shmiR15.-   SEQ ID NO: 36: RNA effector complement sequence for shmiR designated    shmiR16.-   SEQ ID NO: 37: RNA effector sequence for shmiR designated shmiR16.-   SEQ ID NO: 38: RNA effector complement sequence for shmiR designated    shmiR17.-   SEQ ID NO: 39: RNA effector sequence for shmiR designated shmiR17.-   SEQ ID NO: 40: RNA stem loop sequence for shmiRs-   SEQ ID NO: 41: 5′ flanking sequence of the pri-miRNA backbone.-   SEQ ID NO: 42: 3′ flanking sequence of the pri-miRNA backbone-   SEQ ID NO: 43: RNA sequence for shmiR designated shmiR2.-   SEQ ID NO: 44: RNA sequence for shmiR designated shmiR3.-   SEQ ID NO: 45: RNA sequence for shmiR designated shmiR4.-   SEQ ID NO: 46: RNA sequence for shmiR designated shmiR5.-   SEQ ID NO: 47: RNA sequence for shmiR designated shmiR6.-   SEQ ID NO: 48: RNA sequence for shmiR designated shmiR7.-   SEQ ID NO: 49: RNA sequence for shmiR designated shmiR9.-   SEQ ID NO: 50: RNA sequence for shmiR designated shmiR11.-   SEQ ID NO: 51: RNA sequence for shmiR designated shmiR13.-   SEQ ID NO: 52: RNA sequence for shmiR designated shmiR14.-   SEQ ID NO: 53: RNA sequence for shmiR designated shmiR15.-   SEQ ID NO: 54: RNA sequence for shmiR designated shmiR16.-   SEQ ID NO: 55: RNA sequence for shmiR designated shmiR17.-   SEQ ID NO: 56: DNA sequence coding for shmiR designated shmiR2.-   SEQ ID NO: 57: DNA sequence coding for shmiR designated shmiR3.-   SEQ ID NO: 58: DNA sequence coding for shmiR designated shmiR4.-   SEQ ID NO: 59: DNA sequence coding for shmiR designated shmiR5.-   SEQ ID NO: 60: DNA sequence coding for shmiR designated shmiR6.-   SEQ ID NO: 61: DNA sequence coding for shmiR designated shmiR7.-   SEQ ID NO: 62: DNA sequence coding for shmiR designated shmiR9.-   SEQ ID NO: 63: DNA sequence coding for shmiR designated shmiR11.-   SEQ ID NO: 64: DNA sequence coding for shmiR designated shmiR13.-   SEQ ID NO: 65: DNA sequence coding for shmiR designated shmiR14.-   SEQ ID NO: 66: DNA sequence coding for shmiR designated shmiR15.-   SEQ ID NO: 67: DNA sequence coding for shmiR designated shmiR16.-   SEQ ID NO: 68: DNA sequence coding for shmiR designated shmiR17.-   SEQ ID NO: 69: DNA sequence for double construct version 1 coding    for shmiR3 and shmiR14 under control of the muscle specific CK8    promoter and codon optimized PABPN1 under control of Spc512-   SEQ ID NO: 70: DNA sequence for double construct version 1 coding    for shmiR17 and shmiR13 under control of the muscle specific CK8    promoter and codon optimized PABPN1 under control of Spc512-   SEQ ID NO: 71: DNA sequence for double construct version 2 coding    for coPABPN1 and shmiRs designated shmiR3 and shmiR14, under control    of Spc512.-   SEQ ID NO: 72: DNA sequence for double construct version 2 coding    for coPABPN1 and shmiRs designated shmiR17 and shmiR13 under control    of Spc512.-   SEQ ID NO: 73 DNA sequence for Human codon-optimized PABPN1 cDNA    sequence.-   SEQ ID NO: 74 Amino acid sequence for codon-optimised human PABPN1    protein.-   SEQ ID NO: 75 Amino acid sequence for wildtype human PABPN1 protein    with FLAG-tag.-   SEQ ID NO: 76 Amino acid sequence for codon-optimised human PABPN1    protein with FLAG-tag.-   SEQ ID NO: 77 DNA sequence for primer designated wtPABPN1-Fwd.-   SEQ ID NO: 78 DNA sequence for primer designated wtPABPN1-Rev-   SEQ ID NO: 79 DNA sequence for probe designated wtPABPN1-Probe-   SEQ ID NO: 80 DNA sequence for primer designated optPABPN1-Fwd-   SEQ ID NO: 81 DNA sequence for primer designated optPABPN1-Rev-   SEQ ID NO: 82 DNA sequence for probe designated optPABPN1-Probe-   SEQ ID NO: 83 DNA sequence for primer designated shmiR3-FWD-   SEQ ID NO: 84 DNA sequence for primer designated shmiR13-FWD-   SEQ ID NO: 85 DNA sequence for primer designated shmiR14-FWD-   SEQ ID NO: 86 DNA sequence for primer designated shmiR17-FWD

DETAILED DESCRIPTION

General

Throughout this specification, unless specifically stated otherwise orthe context requires otherwise, reference to a single step, feature,composition of matter, group of steps or group of features orcompositions of matter shall be taken to encompass one and a plurality(i.e. one or more) of those steps, features, compositions of matter,groups of steps or groups of features or compositions of matter.

Those skilled in the art will appreciate that the present disclosure issusceptible to variations and modifications other than thosespecifically described. It is to be understood that the disclosureincludes all such variations and modifications. The disclosure alsoincludes all of the steps, features, compositions and compounds referredto or indicated in this specification, individually or collectively, andany and all combinations or any two or more of said steps or features.

The present disclosure is not to be limited in scope by the specificexamples described herein, which are intended for the purpose ofexemplification only. Functionally-equivalent products, compositions andmethods are clearly within the scope of the present disclosure.

Any example of the present disclosure herein shall be taken to applymutatis mutandis to any other example of the disclosure unlessspecifically stated otherwise.

Unless specifically defined otherwise, all technical and scientificterms used herein shall be taken to have the same meaning as commonlyunderstood by one of ordinary skill in the art (for example, in cellculture, molecular genetics, immunology, immunohistochemistry, proteinchemistry, and biochemistry).

Unless otherwise indicated, the recombinant DNA, recombinant protein,cell culture, and immunological techniques utilized in the presentdisclosure are standard procedures, well known to those skilled in theart. Such techniques are described and explained throughout theliterature in sources such as, J. Perbal, A Practical Guide to MolecularCloning, John Wiley and Sons (1984), J. Sambrook et al. MolecularCloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press(1989), T. A. Brown (editor), Essential Molecular Biology: A PracticalApproach, Volumes 1 and 2, IRL Press (1991), D. M. Glover and B. D.Hames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRLPress (1995 and 1996), and F. M. Ausubel et al. (editors), CurrentProtocols in Molecular Biology, Greene Pub. Associates andWiley-Interscience (1988, including all updates until present), EdHarlow and David Lane (editors) Antibodies: A Laboratory Manual, ColdSpring Harbor Laboratory, (1988), and J. E. Coligan et al. (editors)Current Protocols in Immunology, John Wiley & Sons (including allupdates until present).

Throughout this specification, unless the context requires otherwise,the word “comprise”, or variations such as “comprises” or “comprising”,is understood to imply the inclusion of a stated step or element orinteger or group of steps or elements or integers but not the exclusionof any other step or element or integer or group of elements orintegers.

The term “and/or”, e.g., “X and/or Y” shall be understood to mean either“X and Y” or “X or Y” and shall be taken to provide explicit support forboth meanings or for either meaning.

Selected Definitions

By “RNA” is meant a molecule comprising at least one ribonucleotideresidue. By “ribonucleotide” is meant a nucleotide with a hydroxyl groupat the 2′ position of a β-D-ribo-furanose moiety. The terms includedouble-stranded RNA, single-stranded RNA, isolated RNA such as partiallypurified RNA, essentially pure RNA, synthetic RNA, recombinantlyproduced RNA, as well as altered RNA that differs from naturallyoccurring RNA by the addition, deletion, substitution and/or alterationof one or more nucleotides. Such alterations can include addition ofnon-nucleotide material, such as to the end(s) of the siNA orinternally, for example at one or more nucleotides of the RNA.Nucleotides in the RNA molecules of the instant disclosure can alsocomprise non-standard nucleotides, such as non-naturally occurringnucleotides or chemically synthesized nucleotides or deoxynucleotides.These altered RNAs can be referred to as analogs or analogs ofnaturally-occurring RNA.

The term “RNA interference” or “RNAi” refers generally to RNA-dependentsilencing of gene expression initiated by double stranded RNA (dsRNA)molecules in a cell's cytoplasm. The dsRNA molecule reduces or inhibitstranscription products of a target nucleic acid sequence, therebysilencing the gene or reducing expression of that gene.

As used herein, the term “double stranded RNA” or “dsRNA” refers to aRNA molecule having a duplex structure and comprising an effectorsequence and an effector complement sequence which are of similar lengthto one another. The effector sequence and the effector complementsequence can be in a single RNA strand or in separate RNA strands. The“effector sequence” (often referred to as a “guide strand”) issubstantially complementary to a target sequence, which in the presentcase, is a region of a PABPN1 mRNA transcript. The “effector sequence”can also be referred to as the “antisense sequence”. The “effectorcomplement sequence” will be of sufficient complementary to the effectorsequence such that it can anneal to the effector sequence to form aduplex. In this regard, the effector complement sequence will besubstantially homologous to a region of target sequence. As will beapparent to the skilled person, the term “effector complement sequence”can also be referred to as the “complement of the effector sequence” orthe sense sequence.

As used herein, the term “duplex” refers to regions in two complementaryor substantially complementary nucleic acids (e.g., RNAs), or in twocomplementary or substantially complementary regions of asingle-stranded nucleic acid (e.g., RNA), that form base pairs with oneanother, either by Watson-Crick base pairing or any other manner thatallows for a stabilized duplex between the nucleotide sequences that arecomplementary or substantially complementary. It will be understood bythe skilled person that within a duplex region, 100% complementarity isnot required; substantial complementarity is allowable. Substantialcomplementarity includes may include 79% or greater complementarity. Forexample, a single mismatch in a duplex region consisting of 19 basepairs (i.e., 18 base pairs and one mismatch) results in 94.7%complementarity, rendering the duplex region substantiallycomplementary. In another example, two mismatches in a duplex regionconsisting of 19 base pairs (i.e., 17 base pairs and two mismatches)results in 89.5% complementarity, rendering the duplex regionsubstantially complementary. In yet another example, three mismatches ina duplex region consisting of 19 base pairs (i.e., 16 base pairs andthree mismatches) results in 84.2% complementarity, rendering the duplexregion substantially complementary, and so on.

The dsRNA may be provided as a hairpin or stem loop structure, with aduplex region comprised of an effector sequence and effector complementsequence linked by at least 2 nucleotide sequence which is termed a stemloop. When a dsRNA is provided as a hairpin or stem loop structure itcan be referred to as a “hairpin RNA” or “short hairpin RNAi agent” or“shRNA”. Other dsRNA molecules provided in, or which give rise to, ahairpin or stem loop structure include primary miRNA transcripts(pri-miRNA) and precursor microRNA (pre-miRNA). Pre-miRNA shRNAs can benaturally produced from pri-miRNA by the action of the enzymes Droshaand Pasha which recognize and release regions of the primary miRNAtranscript which form a stem-loop structure. Alternatively, thepri-miRNA transcript can be engineered to replace the natural stem-loopstructure with an artificial/recombinant stem-loop structure. That is,an artificial/recombinant stem-loop structure may be inserted or clonedinto a pri-miRNA backbone sequence which lacks its natural stem-loopstructure. In the case of stemloop sequences engineered to be expressedas part of a pri-miRNA molecule, Drosha and Pasha recognize and releasethe artificial shRNA. dsRNA molecules produced using this approach areknown as “shmiRNAs”, “shmiRs” or “microRNA framework shRNAs”.

As used herein, the term “complementary” with regard to a sequencerefers to a complement of the sequence by Watson-Crick base pairing,whereby guanine (G) pairs with cytosine (C), and adenine (A) pairs witheither uracil (U) or thymine (T). A sequence may be complementary to theentire length of another sequence, or it may be complementary to aspecified portion or length of another sequence. One of skill in the artwill recognize that U may be present in RNA, and that T may be presentin DNA. Therefore, an A within either of a RNA or DNA sequence may pairwith a U in a RNA sequence or T in a DNA sequence.

As used herein, the term “substantially complementary” is used toindicate a sufficient degree of complementarity or precise pairing suchthat stable and specific binding occurs between nucleic acid sequencese.g., between the effector sequence and the effector complement sequenceor between the effector sequence and the target sequence. It isunderstood that the sequence of a nucleic acid need not be 100%complementary to that of its target or complement. The term encompassesa sequence complementary to another sequence with the exception of anoverhang. In some cases, the sequence is complementary to the othersequence with the exception of 1-2 mismatches. In some cases, thesequences are complementary except for 1 mismatch. In some cases, thesequences are complementary except for 2 mismatches. In other cases, thesequences are complementary except for 3 mismatches. In yet other cases,the sequences are complementary except for 4 mismatches.

The term “encoded”, as used in the context of a shRNA or shmiR of thedisclosure, shall be understood to mean a shRNA or shmiR which iscapable of being transcribed from a DNA template. Accordingly, a nucleicacid that encodes, or codes for, a shRNA or shmiR of the disclosure willcomprise a DNA sequence which serves as a template for transcription ofthe respective shRNA or shmiR.

The term “DNA-directed RNAi construct” or “ddRNAi construct” refers to anucleic acid comprising DNA sequence which, when transcribed produces ashRNA or shmiR molecule (preferably a shmiR) which elicits RNAi. TheddRNAi construct may comprise a nucleic acid which is transcribed as asingle RNA that is capable of self-annealing into a hairpin structurewith a duplex region linked by a stem loop of at least 2 nucleotidesi.e., shRNA or shmiR, or as a single RNA with multiple shRNAs or shmiRs,or as multiple RNA transcripts each capable of folding as a single shRNAor shmiR respectively. The ddRNAi construct may be provided within alarger “DNA construct” comprising one or more additional DNA sequences.For example, the ddRNAi construct may be provided in a DNA constructcomprising a further DNA sequence coding for functional PABPN1 proteinwhich has been codon optimised such that its mRNA transcript is nottargeted by shmiRs of the ddRNAi construct. The ddRNAi construct and/orthe DNA construct comprising same may be within an expression vectore.g., operably linked to a promoter.

As used herein, the term “operably-linked” or “operable linkage” (orsimilar) means that a coding nucleic acid sequence is linked to, or inassociation with, a regulatory sequence, e.g., a promoter, in a mannerwhich facilitates expression of the coding sequence. Regulatorysequences include promoters, enhancers, and other expression controlelements that are art-recognized and are selected to direct expressionof the coding sequence.

A “vector” will be understood to mean a vehicle for introducing anucleic acid into a cell. Vectors include, but are not limited to,plasmids, phagemids, viruses, bacteria, and vehicles derived from viralor bacterial sources. A “plasmid” is a circular, double-stranded DNAmolecule. A useful type of vector for use in accordance with the presentdisclosure is a viral vector, wherein heterologous DNA sequences areinserted into a viral genome that can be modified to delete one or moreviral genes or parts thereof. Certain vectors are capable of autonomousreplication in a host cell (e.g., vectors having an origin ofreplication that functions in the host cell). Other vectors can bestably integrated into the genome of a host cell, and are therebyreplicated along with the host genome. As used herein, the term“expression vector” will be understood to mean a vector capable ofexpressing a RNA molecule of the disclosure.

A “functional PABPN1 protein” shall be understood to mean a PABPN1protein having the functional properties of a wild-type PABPN1 proteine.g., an ability to control site of mRNA polyadenylation and/or intronsplicing in a mammalian cell. Accordingly, a “functional PABPN1 protein”will be understood to be a PABPN1 protein which is not causative of OPMDwhen expressed or present in a subject. In one example, a referenceherein to “functional PABPN1 protein” is a reference to human wild-typePABPN1 protein. The sequence of human wild-type PABPN1 protein is setforth in NCBI RefSeq NP_004634. Accordingly, a functional human PABPN1protein may have the functional properties in vivo of the human PABPN1protein set forth in NCBI RefSeq NP_004634.

As used herein, the terms “treating”, “treat” or “treatment” andvariations thereof, refer to clinical intervention designed to alter thenatural course of the individual or cell being treated during the courseof clinical pathology. Desirable effects of treatment include decreasingthe rate of disease progression, ameliorating or palliating the diseasestate, and remission or improved prognosis. It follows that treatment ofOPMD includes reducing or inhibiting expression of a PABPN1 proteinwhich is causative of OPMD in the subject and/or expressing in thesubject a PABPN1 protein having the normal length of polyalanineresidues. Preferably, treatment of OPMD includes reducing or inhibitingexpression of the PABPN1 protein which is causative of OPMD in thesubject and expressing in the subject a PABPN1 protein having the normallength of polyalanine residues. An individual is successfully “treated”,for example, if one or more of the above treatment outcomes is achieved.

A “therapeutically effective amount” is at least the minimumconcentration or amount required to effect a measurable improvement inthe OPMD condition, such as a measurable improvement in one or moresymptoms of OPMD e.g., including but not limited to ptosis, dysphagiaand muscle weakness in the subject. A therapeutically effective amountherein may vary according to factors such as the disease state, age,sex, and weight of the patient, and the ability of the shmiR, nucleicacid encoding same, ddRNAi construct, DNA construct, expression vector,or composition comprising same, to elicit a desired response in theindividual and/or the ability of the expression vector to expressfunctional PABPN1 protein in the subject. A therapeutically effectiveamount is also one in which any toxic or detrimental effects of theshmiR, nucleic acid encoding same, ddRNAi construct, DNA construct,expression vector, or composition comprising same, are outweighed by thetherapeutically beneficial effects of the shmiR, nucleic acid encodingsame, ddRNAi construct, DNA construct, expression vector, or compositioncomprising same, to inhibit, suppress or reduce expression of PABPN1protein causative of OPMD considered alone or in combination with thetherapeutically beneficial effects of the expression of functionalPABPN1 protein in the subject.

As used herein, the “subject” or “patient” can be a human or non-humananimal suffering from or genetically predisposed to OPMD i.e., possess aPABPN1 gene variant which is causative of OPMD. The “non-human animal”may be a primate, livestock (e.g. sheep, horses, cattle, pigs, donkeys),companion animal (e.g. pets such as dogs and cats), laboratory testanimal (e.g. mice, rabbits, rats, guinea pigs, drosophila, C. elegans,zebrafish), performance animal (e.g. racehorses, camels, greyhounds) orcaptive wild animal. In one example, the subject or patient is a mammal.In one example, the subject or patient is a human.

The terms “reduced expression”, “reduction in expression” or similar,refer to the absence or an observable decrease in the level of proteinand/or mRNA product from the target gene e.g., the PABPN1 gene. Thedecrease does not have to be absolute, but may be a partial decreasesufficient for there to a detectable or observable change as a result ofthe RNAi effected by the shmiR, nucleic acid encoding same, ddRNAiconstruct, DNA construct, expression vector, or composition comprisingsame of the disclosure. The decrease can be measured by determining adecrease in the level of mRNA and/or protein product from a targetnucleic acid relative to a cell lacking the shmiR, nucleic acid encodingsame, ddRNAi construct, DNA construct, expression vector, or compositioncomprising same, and may be as little as 1%, 5% or 10%, or may beabsolute i.e., 100% inhibition. The effects of the decrease may bedetermined by examination of the outward properties i.e., quantitativeand/or qualitative phenotype of the cell or organism, and may alsoinclude detection of the presence or a change in the amount of nuclearaggregates of expPABPN1 in the cell or organism following administrationof a shmiR, nucleic acid encoding same, ddRNAi construct, DNA construct,expression vector, or composition comprising same, of the disclosure.

Agents for RNAi

In one example, the present disclosure provides a nucleic acidcomprising a DNA sequence which encodes a short hairpin micro-RNA(shmiR), said shmiR comprising:

an effector sequence of at least 17 nucleotides in length;

an effector complement sequence;

a stemloop sequence; and

primary micro RNA (pri-miRNA) backbone;

wherein the effector sequence is substantially complementary to a regionof corresponding length in an RNA transcript set forth in any one of SEQID NOs: 1-13. Preferably, the effector sequence will be less than 30nucleotides in length. For example, a suitable effector sequence may bein the range of 17-29 nucleotides in length. In a particularly preferredexample, the effector sequence will be 21 nucleotides in length. Morepreferably, the effector sequence will be 21 nucleotides in length andthe effector complement sequence will be 20 nucleotides in length.

In one example, the shmiR comprises an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 1. For example, the effector sequence may be substantiallycomplementary to a region of corresponding length in an RNA transcriptcomprising or consisting of the sequence set forth in SEQ ID NO: 1 andcontain 4 mismatch bases relative thereto. For example, the effectorsequence may be substantially complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 1 and contain 3 mismatch bases relative thereto. Forexample, the effector sequence may be substantially complementary to aregion of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 1 and contain 2mismatch bases relative thereto. For example, the effector sequence maybe substantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 1 and contain 1 mismatch base relative thereto. For example, theeffector sequence may be 100% complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 1.

In one example, the shmiR comprises an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 2. For example, the effector sequence may be substantiallycomplementary to a region of corresponding length in an RNA transcriptcomprising or consisting of the sequence set forth in SEQ ID NO: 2 andcontain 4 mismatch bases relative thereto. For example, the effectorsequence may be substantially complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 2 and contain 3 mismatch bases relative thereto. Forexample, the effector sequence may be substantially complementary to aregion of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 2 and contain 2mismatch bases relative thereto. For example, the effector sequence maybe substantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 2 and contain 1 mismatch base relative thereto. For example, theeffector sequence may be 100% complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 2.

In one example, the shmiR comprises an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 3. For example, the effector sequence may be substantiallycomplementary to a region of corresponding length in an RNA transcriptcomprising or consisting of the sequence set forth in SEQ ID NO: 3 andcontain 4 mismatch bases relative thereto. For example, the effectorsequence may be substantially complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 3 and contain 3 mismatch bases relative thereto. Forexample, the effector sequence may be substantially complementary to aregion of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 3 and contain 2mismatch bases relative thereto. For example, the effector sequence maybe substantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 3 and contain 1 mismatch base relative thereto. For example, theeffector sequence may be 100% complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 3.

In one example, the shmiR comprises an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 4. For example, the effector sequence may be substantiallycomplementary to a region of corresponding length in an RNA transcriptcomprising or consisting of the sequence set forth in SEQ ID NO: 4 andcontain 4 mismatch bases relative thereto. For example, the effectorsequence may be substantially complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 4 and contain 3 mismatch bases relative thereto. Forexample, the effector sequence may be substantially complementary to aregion of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 4 and contain 2mismatch bases relative thereto. For example, the effector sequence maybe substantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 4 and contain 1 mismatch base relative thereto. For example, theeffector sequence may be 100% complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 4.

In one example, the shmiR comprises an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 5. For example, the effector sequence may be substantiallycomplementary to a region of corresponding length in an RNA transcriptcomprising or consisting of the sequence set forth in SEQ ID NO: 5 andcontain 4 mismatch bases relative thereto. For example, the effectorsequence may be substantially complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 5 and contain 3 mismatch bases relative thereto. Forexample, the effector sequence may be substantially complementary to aregion of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 5 and contain 2mismatch bases relative thereto. For example, the effector sequence maybe substantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 5 and contain 1 mismatch base relative thereto. For example, theeffector sequence may be 100% complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 5.

In one example, the shmiR comprises an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 6. For example, the effector sequence may be substantiallycomplementary to a region of corresponding length in an RNA transcriptcomprising or consisting of the sequence set forth in SEQ ID NO: 6 andcontain 4 mismatch bases relative thereto. For example, the effectorsequence may be substantially complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 6 and contain 3 mismatch bases relative thereto. Forexample, the effector sequence may be substantially complementary to aregion of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 6 and contain 2mismatch bases relative thereto. For example, the effector sequence maybe substantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 6 and contain 1 mismatch base relative thereto. For example, theeffector sequence may be 100% complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 6.

In one example, the shmiR comprises an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 7. For example, the effector sequence may be substantiallycomplementary to a region of corresponding length in an RNA transcriptcomprising or consisting of the sequence set forth in SEQ ID NO: 7 andcontain 4 mismatch bases relative thereto. For example, the effectorsequence may be substantially complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 7 and contain 3 mismatch bases relative thereto. Forexample, the effector sequence may be substantially complementary to aregion of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 7 and contain 2mismatch bases relative thereto. For example, the effector sequence maybe substantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 7 and contain 1 mismatch base relative thereto. For example, theeffector sequence may be 100% complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 7.

In one example, the shmiR comprises an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 8. For example, the effector sequence may be substantiallycomplementary to a region of corresponding length in an RNA transcriptcomprising or consisting of the sequence set forth in SEQ ID NO: 8 andcontain 4 mismatch bases relative thereto. For example, the effectorsequence may be substantially complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 8 and contain 3 mismatch bases relative thereto. Forexample, the effector sequence may be substantially complementary to aregion of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 8 and contain 2mismatch bases relative thereto. For example, the effector sequence maybe substantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 8 and contain 1 mismatch base relative thereto. For example, theeffector sequence may be 100% complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 8.

In one example, the shmiR comprises an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 9. For example, the effector sequence may be substantiallycomplementary to a region of corresponding length in an RNA transcriptcomprising or consisting of the sequence set forth in SEQ ID NO: 9 andcontain 4 mismatch bases relative thereto. For example, the effectorsequence may be substantially complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 9 and contain 3 mismatch bases relative thereto. Forexample, the effector sequence may be substantially complementary to aregion of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 9 and contain 2mismatch bases relative thereto. For example, the effector sequence maybe substantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 9 and contain 1 mismatch base relative thereto. For example, theeffector sequence may be 100% complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 9.

In one example, the shmiR comprises an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 10. For example, the effector sequence may be substantiallycomplementary to a region of corresponding length in an RNA transcriptcomprising or consisting of the sequence set forth in SEQ ID NO: 10 andcontain 4 mismatch bases relative thereto. For example, the effectorsequence may be substantially complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 10 and contain 3 mismatch bases relative thereto.For example, the effector sequence may be substantially complementary toa region of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 10 and contain 2mismatch bases relative thereto. For example, the effector sequence maybe substantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 10 and contain 1 mismatch base relative thereto. For example, theeffector sequence may be 100% complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 10.

In one example, the shmiR comprises an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 11. For example, the effector sequence may be substantiallycomplementary to a region of corresponding length in an RNA transcriptcomprising or consisting of the sequence set forth in SEQ ID NO: 11 andcontain 4 mismatch bases relative thereto. For example, the effectorsequence may be substantially complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 11 and contain 3 mismatch bases relative thereto.For example, the effector sequence may be substantially complementary toa region of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 11 and contain 2mismatch bases relative thereto. For example, the effector sequence maybe substantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 11 and contain 1 mismatch base relative thereto. For example, theeffector sequence may be 100% complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 11.

In one example, the shmiR comprises an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 12. For example, the effector sequence may be substantiallycomplementary to a region of corresponding length in an RNA transcriptcomprising or consisting of the sequence set forth in SEQ ID NO: 12 andcontain 4 mismatch bases relative thereto. For example, the effectorsequence may be substantially complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 12 and contain 3 mismatch bases relative thereto.For example, the effector sequence may be substantially complementary toa region of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 12 and contain 2mismatch bases relative thereto. For example, the effector sequence maybe substantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 12 and contain 1 mismatch base relative thereto. For example, theeffector sequence may be 100% complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 12.

In one example, the shmiR comprises an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 13. For example, the effector sequence may be substantiallycomplementary to a region of corresponding length in an RNA transcriptcomprising or consisting of the sequence set forth in SEQ ID NO: 13 andcontain 4 mismatch bases relative thereto. For example, the effectorsequence may be substantially complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 13 and contain 3 mismatch bases relative thereto.For example, the effector sequence may be substantially complementary toa region of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 13 and contain 2mismatch bases relative thereto. For example, the effector sequence maybe substantially complementary to a region of corresponding length in anRNA transcript comprising or consisting of the sequence set forth in SEQID NO: 13 and contain 1 mismatch base relative thereto. For example, theeffector sequence may be 100% complementary to a region of correspondinglength in an RNA transcript comprising or consisting of the sequence setforth in SEQ ID NO: 13.

In accordance with an example in which the effector sequence of a shmiRof the disclosure is substantially complementary to a region ofcorresponding length in a PABPN1 miRNA transcript described herein andcontains 1, 2, 3 or 4 mismatch base(s) relative thereto, it is preferredthat the mismatch(es) are not located within the region corresponding tothe seed region of the shmiR i.e., nucleotides 2-8 of the effectorsequence.

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR comprising: (i) an effector sequence which issubstantially complementary to the sequence set forth in SEQ ID NO:14with the exception of 1, 2, 3 or 4 base mismatches, provided that theeffector sequence is capable of forming a duplex with a sequence setforth in SEQ ID NO: 14; and (ii) an effector complement sequencecomprising a sequence which is substantially complementary to theeffector sequence. For example, the shmiR encoded by the nucleic acidmay comprise an effector sequence set forth in SEQ ID NO: 15 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO: 15 and capable of forming a duplextherewith. The effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:15 may be thesequence set forth in SEQ ID NO:14. A shmiR in accordance with thisexample is hereinafter designated “shmiR2”.

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR comprising: (i) an effector sequence which issubstantially complementary to the sequence set forth in SEQ ID NO:16with the exception of 1, 2, 3 or 4 base mismatches, provided that theeffector sequence is capable of forming a duplex with a sequence setforth in SEQ ID NO: 16; and (ii) an effector complement sequencecomprising a sequence which is substantially complementary to theeffector sequence. For example, the shmiR encoded by the nucleic acidmay comprise an effector sequence set forth in SEQ ID NO: 17 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO: 17 and capable of forming a duplextherewith. The effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:17 may be thesequence set forth in SEQ ID NO:16. A shmiR in accordance with thisexample is hereinafter designated “shmiR3”.

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR comprising: (i) an effector sequence which issubstantially complementary to the sequence set forth in SEQ ID NO:18with the exception of 1, 2, 3 or 4 base mismatches, provided that theeffector sequence is capable of forming a duplex with a sequence setforth in SEQ ID NO:18; and (ii) an effector complement sequencecomprising a sequence which is substantially complementary to theeffector sequence. For example, the shmiR encoded by the nucleic acidmay comprise an effector sequence set forth in SEQ ID NO: 19 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO: 19 and capable of forming a duplextherewith. The effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:19 may be thesequence set forth in SEQ ID NO:18. A shmiR in accordance with thisexample is hereinafter designated “shmiR4”.

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR comprising: (i) an effector sequence which issubstantially complementary to the sequence set forth in SEQ ID NO:20with the exception of 1, 2, 3 or 4 base mismatches, provided that theeffector sequence is capable of forming a duplex with a sequence setforth in SEQ ID NO:20; and (ii) an effector complement sequencecomprising a sequence which is substantially complementary to theeffector sequence. For example, the shmiR encoded by the nucleic acidmay comprise an effector sequence set forth in SEQ ID NO:21 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:21 and capable of forming a duplextherewith. The effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:21 may be thesequence set forth in SEQ ID NO:20. A shmiR in accordance with thisexample is hereinafter designated “shmiR5”.

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR comprising: (i) an effector sequence which issubstantially complementary to the sequence set forth in SEQ ID NO:22with the exception of 1, 2, 3 or 4 base mismatches, provided that theeffector sequence is capable of forming a duplex with a sequence setforth in SEQ ID NO:22; and (ii) an effector complement sequencecomprising a sequence which is substantially complementary to theeffector sequence. For example, the shmiR encoded by the nucleic acidmay comprise an effector sequence set forth in SEQ ID NO:23 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:23 and capable of forming a duplextherewith. The effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:23 may be thesequence set forth in SEQ ID NO:22. A shmiR in accordance with thisexample is hereinafter designated “shmiR6”.

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR comprising: (i) an effector sequence which issubstantially complementary to the sequence set forth in SEQ ID NO:24with the exception of 1, 2, 3 or 4 base mismatches, provided that theeffector sequence is capable of forming a duplex with a sequence setforth in SEQ ID NO:24; and (ii) an effector complement sequencecomprising a sequence which is substantially complementary to theeffector sequence. For example, the shmiR encoded by the nucleic acidmay comprise an effector sequence set forth in SEQ ID NO:25 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:25 and capable of forming a duplextherewith. The effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:25 may be thesequence set forth in SEQ ID NO:24. A shmiR in accordance with thisexample is hereinafter designated “shmiR7”.

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR comprising: (i) an effector sequence which issubstantially complementary to the sequence set forth in SEQ ID NO:26with the exception of 1, 2, 3 or 4 base mismatches, provided that theeffector sequence is capable of forming a duplex with a sequence setforth in SEQ ID NO:26; and (ii) an effector complement sequencecomprising a sequence which is substantially complementary to theeffector sequence. For example, the shmiR encoded by the nucleic acidmay comprise an effector sequence set forth in SEQ ID NO:27 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:27 and capable of forming a duplextherewith. The effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:27 may be thesequence set forth in SEQ ID NO:26. A shmiR in accordance with thisexample is hereinafter designated “shmiR9”.

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR comprising: (i) an effector sequence which issubstantially complementary to the sequence set forth in SEQ ID NO:28with the exception of 1, 2, 3 or 4 base mismatches, provided that theeffector sequence is capable of forming a duplex with a sequence setforth in SEQ ID NO:28; and (ii) an effector complement sequencecomprising a sequence which is substantially complementary to theeffector sequence. For example, the shmiR encoded by the nucleic acidmay comprise an effector sequence set forth in SEQ ID NO:29 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:29 and capable of forming a duplextherewith. The effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:29 may be thesequence set forth in SEQ ID NO:28. A shmiR in accordance with thisexample is hereinafter designated “shmiR11”.

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR comprising: (i) an effector sequence which issubstantially complementary to the sequence set forth in SEQ ID NO:30with the exception of 1, 2, 3 or 4 base mismatches, provided that theeffector sequence is capable of forming a duplex with a sequence setforth in SEQ ID NO:30; and (ii) an effector complement sequencecomprising a sequence which is substantially complementary to theeffector sequence. For example, the shmiR encoded by the nucleic acidmay comprise an effector sequence set forth in SEQ ID NO:31 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:31 and capable of forming a duplextherewith. The effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:31 may be thesequence set forth in SEQ ID NO:30. A shmiR in accordance with thisexample is hereinafter designated “shmiR13”.

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR comprising: (i) an effector sequence which issubstantially complementary to the sequence set forth in SEQ ID NO:32with the exception of 1, 2, 3 or 4 base mismatches, provided that theeffector sequence is capable of forming a duplex with a sequence setforth in SEQ ID NO:32; and (ii) an effector complement sequencecomprising a sequence which is substantially complementary to theeffector sequence. For example, the shmiR encoded by the nucleic acidmay comprise an effector sequence set forth in SEQ ID NO:33 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:33 and capable of forming a duplextherewith. The effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:33 may be thesequence set forth in SEQ ID NO:32. A shmiR in accordance with thisexample is hereinafter designated “shmiR14”.

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR comprising: (i) an effector sequence which issubstantially complementary to the sequence set forth in SEQ ID NO:34with the exception of 1, 2, 3 or 4 base mismatches, provided that theeffector sequence is capable of forming a duplex with a sequence setforth in SEQ ID NO:34; and (ii) an effector complement sequencecomprising a sequence which is substantially complementary to theeffector sequence. For example, the shmiR encoded by the nucleic acidmay comprise an effector sequence set forth in SEQ ID NO:35 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:35 and capable of forming a duplextherewith. The effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:35 may be thesequence set forth in SEQ ID NO:34. A shmiR in accordance with thisexample is hereinafter designated “shmiR15”.

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR comprising: (i) an effector sequence which issubstantially complementary to the sequence set forth in SEQ ID NO:36with the exception of 1, 2, 3 or 4 base mismatches, provided that theeffector sequence is capable of forming a duplex with a sequence setforth in SEQ ID NO:36; and (ii) an effector complement sequencecomprising a sequence which is substantially complementary to theeffector sequence. For example, the shmiR encoded by the nucleic acidmay comprise an effector sequence set forth in SEQ ID NO:37 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:37 and capable of forming a duplextherewith. The effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:37 may be thesequence set forth in SEQ ID NO:36. A shmiR in accordance with thisexample is hereinafter designated “shmiR16”.

In one example, the nucleic acid described herein may comprise a DNAsequence encoding a shmiR comprising: (i) an effector sequence which issubstantially complementary to the sequence set forth in SEQ ID NO:38with the exception of 1, 2, 3 or 4 base mismatches, provided that theeffector sequence is capable of forming a duplex with a sequence setforth in SEQ ID NO:38; and (ii) an effector complement sequencecomprising a sequence which is substantially complementary to theeffector sequence. For example, the shmiR encoded by the nucleic acidmay comprise an effector sequence set forth in SEQ ID NO:39 and aneffector complement sequence which is substantially complementary to thesequence set forth in SEQ ID NO:39 and capable of forming a duplextherewith. The effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO:39 may be thesequence set forth in SEQ ID NO:38. A shmiR in accordance with thisexample is hereinafter designated “shmiR17”.

In any of the examples described herein, the shmiR encoded by thenucleic acid of the disclosure may comprise, in a 5′ to 3′ direction:

a 5′ flanking sequence of the pri-miRNA backbone;

the effector complement sequence;

the stemloop sequence;

the effector sequence; and

a 3′ flanking sequence of the pri-miRNA backbone.

In any of the examples described herein, the shmiR encoded by thenucleic acid of the disclosure may comprise, in a 5′ to 3′ direction:

a 5′ flanking sequence of the pri-miRNA backbone;

the effector sequence;

the stemloop sequence;

the effector complement sequence; and

a 3′ flanking sequence of the pri-miRNA backbone.

Suitable loop sequences may be selected from those known in the art.However, an exemplary stemloop sequence is set forth in SEQ ID NO: 40.

Suitable primary micro RNA (pri-miRNA or pri-R) backbones for use in anucleic acid of the disclosure may be selected from those known in theart. For example, the pri-miRNA backbone may be selected from apri-miR-30a backbone, a pri-miR-155 backbone, a pri-miR-21 backbone anda pri-miR-136 backbone. Preferably, however, the pri-miRNA backbone is apri-miR-30a backbone. In accordance with an example in which thepri-miRNA backbone is a pri-miR-30a backbone, the 5′ flanking sequenceof the pri-miRNA backbone is set forth in SEQ ID NO: 41 and the 3′flanking sequence of the pri-miRNA backbone is set forth in SEQ ID NO:42. Thus, the nucleic acid encoding the shmiRs of the disclosure (e.g.,shmiR-1 to shmiR-16 described herein) may comprise DNA sequence encodingthe sequence set forth in SEQ ID NO: 41 and DNA sequence encoding thesequence set forth in SEQ ID NO: 42.

In one example, the nucleic acid described herein may comprise a DNAsequence selected from the sequence set forth in any one of SEQ ID NOs:56-68.

In one example, the nucleic acid described herein comprises or consistsof a DNA sequence set forth in SEQ ID NO: 56 and encodes a shmiR(shmiR2) comprising or consisting of the sequence set forth in SEQ IDNO: 43.

In one example, the nucleic acid described herein comprises or consistsof a DNA sequence set forth in SEQ ID NO: 57 and encodes a shmiR(shmiR3) comprising or consisting of the sequence set forth in SEQ IDNO: 44.

In one example, the nucleic acid described herein comprises or consistsof a DNA sequence set forth in SEQ ID NO: 58 and encodes a shmiR(shmiR4) comprising or consisting of the sequence set forth in SEQ IDNO: 45.

In one example, the nucleic acid described herein comprises or consistsof a DNA sequence set forth in SEQ ID NO: 59 and encodes a shmiR(shmiR5) comprising or consisting of the sequence set forth in SEQ IDNO: 46.

In one example, the nucleic acid described herein comprises or consistsof a DNA sequence set forth in SEQ ID NO: 60 and encodes a shmiR(shmiR6) comprising or consisting of the sequence set forth in SEQ IDNO: 47.

In one example, the nucleic acid described herein comprises or consistsof a DNA sequence set forth in SEQ ID NO: 61 and encodes a shmiR(shmiR7) comprising or consisting of the sequence set forth in SEQ IDNO: 48.

In one example, the nucleic acid described herein comprises or consistsof a DNA sequence set forth in SEQ ID NO: 62 and encodes a shmiR(shmiR9) comprising or consisting of the sequence set forth in SEQ IDNO: 49.

In one example, the nucleic acid described herein comprises or consistsof a DNA sequence set forth in SEQ ID NO: 63 and encodes a shmiR(shmiR11) comprising or consisting of the sequence set forth in SEQ IDNO: 50.

In one example, the nucleic acid described herein comprises or consistsof a DNA sequence set forth in SEQ ID NO: 64 and encodes a shmiR(shmiR13) comprising or consisting of the sequence set forth in SEQ IDNO: 51.

In one example, the nucleic acid described herein comprises or consistsof a DNA sequence set forth in SEQ ID NO: 65 and encodes a shmiR(shmiR14) comprising or consisting of the sequence set forth in SEQ IDNO: 52.

In one example, the nucleic acid described herein comprises or consistsof a DNA sequence set forth in SEQ ID NO: 66 and encodes a shmiR(shmiR15) comprising or consisting of the sequence set forth in SEQ IDNO: 53.

In one example, the nucleic acid described herein comprises or consistsof a DNA sequence set forth in SEQ ID NO: 67 and encodes a shmiR(shmiR16) comprising or consisting of the sequence set forth in SEQ IDNO: 54.

In one example, the nucleic acid described herein comprises or consistsof a DNA sequence set forth in SEQ ID NO: 68 and encodes a shmiR(shmiR17) comprising or consisting of the sequence set forth in SEQ IDNO: 55.

Exemplary nucleic acids of the disclosure encode a shmiR selected fromshmiR2, shmiR3, shmiR5, shmiR9, shmiR13, shmiR14 and shmiR17 asdescribed herein. Nucleic acids of the disclosure encoding shmiRsselected from shmiR3, shmiR13, shmiR14 and shmiR17 as described hereinare particularly preferred.

It will be understood by a person of skill in the art that a nucleicacid in accordance with the present disclosure may be combined or usedin conjunction with one or more other nucleic acids comprising a DNAsequence encoding a shRNA or shmiR comprising an effector sequence of atleast 17 contiguous nucleotides which is substantially complementary toa region of a RNA transcript corresponding to a PABPN1 protein which iscausative of OPMD. In one example, a plurality of nucleic acids areprovided comprising:

(a) at least one nucleic acid as described herein; and

(b) at least one further nucleic acid selected from:

-   -   (i) a nucleic acid comprising a DNA sequence encoding a shmiR as        described herein; or    -   (ii) a nucleic acid comprising a DNA sequence encoding a short        hairpin RNA (shRNA) comprising cognate effector and effector        complement sequences of a shmiR as described herein;

wherein the shmiR encoded by the nucleic acid at (a) and the shmiR orshRNA encoded by the nucleic acid at (b) comprise different effectorsequences.

Accordingly, in one example the plurality of nucleic acids of thedisclosure may comprise two or more nucleic acids encoding shmiRs asdescribed herein, such as two, or three, or four, or five, or six, orseven, or eight, or nine, or ten nucleic acids encoding shmiRs asdescribed herein.

In another example, the plurality of nucleic acids of the disclosurecomprises at least one nucleic acid encoding a shmiR as described hereinand at least one nucleic acid comprising a DNA sequence encoding a shRNAcomprising cognate effector and effector complement sequences of a shmiRas described herein. For example, a shRNA comprising the effectorsequence and effector complement sequence of shmiR2 is hereinafterdesignated “shRNA2”. For example, a shRNA comprising the effectorsequence and effector complement sequence of shmiR3 is hereinafterdesignated “shRNA3”. For example, a shRNA comprising the effectorsequence and effector complement sequence of shmiR4 is hereinafterdesignated “shRNA4”. For example, a shRNA comprising the effectorsequence and effector complement sequence of shmiR5 is hereinafterdesignated “shRNA5”. For example, a shRNA comprising the effectorsequence and effector complement sequence of shmiR6 is hereinafterdesignated “shRNA6”. For example, a shRNA comprising the effectorsequence and effector complement sequence of shmiR7 is hereinafterdesignated “shRNA7”. For example, a shRNA comprising the effectorsequence and effector complement sequence of shmiR9 is hereinafterdesignated “shRNA9”. For example, a shRNA comprising the effectorsequence and effector complement sequence of shmiR11 is hereinafterdesignated “shRNA1”. For example, a shRNA comprising the effectorsequence and effector complement sequence of shmiR13 is hereinafterdesignated “shRNA13”. For example, a shRNA comprising the effectorsequence and effector complement sequence of shmiR14 is hereinafterdesignated “shRNA14”. For example, a shRNA comprising the effectorsequence and effector complement sequence of shmiR15 is hereinafterdesignated “shRNA15”. For example, a shRNA comprising the effectorsequence and effector complement sequence of shmiR16 is hereinafterdesignated “shRNA16”. For example, a shRNA comprising the effectorsequence and effector complement sequence of shmiR17 is hereinafterdesignated “shRNA17”.

According to any example in which one or more of the nucleic acid in theplurality of nucleic acids described herein encodes a shRNA, the shRNAmay comprise a loop or stem loop sequence positioned between the cognateeffector and the effector complement sequences. Suitable loop sequencesmay be selected from those known in the art. Alternatively, suitablestem loops may be developed de novo. In one example, a nucleic acid ofthe plurality described herein encoding a shRNA may comprise a DNAsequence encoding a stem loop positioned between the DNA sequencesencoding the effector sequence and the effector complement sequencerespectively.

In one example, the plurality of nucleic acids described hereincomprises a nucleic acid comprising or consisting of a DNA sequenceencoding shmiR2, and at least one other nucleic acid of the disclosurewhich encodes a shmiR or shRNA targeting a region of a PABPN1 mRNAtranscript. Exemplary nucleic acids encoding shmiR2 are described hereinand shall be taken to apply mutatis mutandis to this example of thedisclosure. In one example, the plurality of nucleic acids describedherein comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 56 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 43, and at leastone other nucleic acid of the disclosure which encodes a shmiR or shRNAtargeting a region of a PABPN1 mRNA transcript. For example, theplurality of nucleic acids described herein may comprise (i) a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:56 (shmiR2), and (ii) a nucleic acid comprising or consisting of a DNAsequence encoding one of shmiR3-shmiR7, shmiR9, shmiR11 orshmiR13-shmiR17 or the corresponding shRNA of any thereof.

In one example, the plurality of nucleic acids described hereincomprises a nucleic acid comprising or consisting of a DNA sequenceencoding shmiR3, and at least one other nucleic acid of the disclosurewhich encodes a shmiR or shRNA targeting a region of a PABPN1 mRNAtranscript. Exemplary nucleic acids encoding shmiR3 are described hereinand shall be taken to apply mutatis mutandis to this example of thedisclosure. In one example, the plurality of nucleic acids describedherein comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 57 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 44, and at leastone other nucleic acid of the disclosure which encodes a shmiR or shRNAtargeting a region of a PABPN1 mRNA transcript. For example, theplurality of nucleic acids described herein may comprise (i) a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:57 (shmiR3), and (ii) a nucleic acid comprising or consisting of a DNAsequence encoding one of shmiR2, shmiR4-shmiR7, shmiR9, shmiR11 orshmiR13-shmiR17 or the corresponding shRNA of any thereof.

In one example, the plurality of nucleic acids described hereincomprises a nucleic acid comprising or consisting of a DNA sequenceencoding shmiR4, and at least one other nucleic acid of the disclosurewhich encodes a shmiR or shRNA targeting a region of a PABPN1 mRNAtranscript. Exemplary nucleic acids encoding shmiR4 are described hereinand shall be taken to apply mutatis mutandis to this example of thedisclosure. In one example, the plurality of nucleic acids describedherein comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 58 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 45, and at leastone other nucleic acid of the disclosure which encodes a shmiR or shRNAtargeting a region of a PABPN1 mRNA transcript. For example, theplurality of nucleic acids described herein may comprise (i) a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:58 (shmiR4), and (ii) a nucleic acid comprising or consisting of a DNAsequence encoding one of shmiR2, shmiR3, shmiR5-shmiR7, shmiR9, shmiR11or shmiR13-shmiR17 or the corresponding shRNA of any thereof.

In one example, the plurality of nucleic acids described hereincomprises a nucleic acid comprising or consisting of a DNA sequenceencoding shmiR5, and at least one other nucleic acid of the disclosurewhich encodes a shmiR or shRNA targeting a region of a PABPN1 mRNAtranscript. Exemplary nucleic acids encoding shmiR5 are described hereinand shall be taken to apply mutatis mutandis to this example of thedisclosure. In one example, the plurality of nucleic acids describedherein comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 59 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 46, and at leastone other nucleic acid of the disclosure which encodes a shmiR or shRNAtargeting a region of a PABPN1 mRNA transcript. For example, theplurality of nucleic acids described herein may comprise (i) a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:59 (shmiR5), and (ii) a nucleic acid comprising or consisting of a DNAsequence encoding one of shmiR2-shmiR4, shmiR6-shmiR7, shmiR9, shmiR11or shmiR13-shmiR17 or the corresponding shRNA of any thereof.

In one example, the plurality of nucleic acids described hereincomprises a nucleic acid comprising or consisting of a DNA sequenceencoding shmiR6, and at least one other nucleic acid of the disclosurewhich encodes a shmiR or shRNA targeting a region of a PABPN1 mRNAtranscript. Exemplary nucleic acids encoding shmiR6 are described hereinand shall be taken to apply mutatis mutandis to this example of thedisclosure. In one example, the plurality of nucleic acids describedherein comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 60 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 47, and at leastone other nucleic acid of the disclosure which encodes a shmiR or shRNAtargeting a region of a PABPN1 mRNA transcript. For example, theplurality of nucleic acids described herein may comprise (i) a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:60 (shmiR6), and (ii) a nucleic acid comprising or consisting of a DNAsequence encoding one of shmiR2-shmiR5, shmiR7, shmiR9, shmiR11 orshmiR13-shmiR17 or the corresponding shRNA of any thereof.

In one example, the plurality of nucleic acids described hereincomprises a nucleic acid comprising or consisting of a DNA sequenceencoding shmiR7, and at least one other nucleic acid of the disclosurewhich encodes a shmiR or shRNA targeting a region of a PABPN1 mRNAtranscript. Exemplary nucleic acids encoding shmiR7 are described hereinand shall be taken to apply mutatis mutandis to this example of thedisclosure. In one example, the plurality of nucleic acids describedherein comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 61 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 48, and at leastone other nucleic acid of the disclosure which encodes a shmiR or shRNAtargeting a region of a PABPN1 mRNA transcript. For example, theplurality of nucleic acids described herein may comprise (i) a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:61 (shmiR7), and (ii) a nucleic acid comprising or consisting of a DNAsequence encoding one of shmiR2-shmiR6, shmiR9, shmiR11 orshmiR13-shmiR17 or the corresponding shRNA of any thereof.

In one example, the plurality of nucleic acids described hereincomprises a nucleic acid comprising or consisting of a DNA sequenceencoding shmiR9, and at least one other nucleic acid of the disclosurewhich encodes a shmiR or shRNA targeting a region of a PABPN1 mRNAtranscript. Exemplary nucleic acids encoding shmiR9 are described hereinand shall be taken to apply mutatis mutandis to this example of thedisclosure. In one example, the plurality of nucleic acids describedherein comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 62 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 49, and at leastone other nucleic acid of the disclosure which encodes a shmiR or shRNAtargeting a region of a PABPN1 mRNA transcript. For example, theplurality of nucleic acids described herein may comprise (i) a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:62 (shmiR9), and (ii) a nucleic acid comprising or consisting of a DNAsequence encoding one of shmiR2-shmiR7, shmiR11 or shmiR13-shmiR17 orthe corresponding shRNA of any thereof.

In one example, the plurality of nucleic acids described hereincomprises a nucleic acid comprising or consisting of a DNA sequenceencoding shmiR11, and at least one other nucleic acid of the disclosurewhich encodes a shmiR or shRNA targeting a region of a PABPN1 mRNAtranscript. Exemplary nucleic acids encoding shmiR11 are describedherein and shall be taken to apply mutatis mutandis to this example ofthe disclosure. In one example, the plurality of nucleic acids describedherein comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 63 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 50, and at leastone other nucleic acid of the disclosure which encodes a shmiR or shRNAtargeting a region of a PABPN1 mRNA transcript. For example, theplurality of nucleic acids described herein may comprise (i) a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:63 (shmiR11), and (ii) a nucleic acid comprising or consisting of a DNAsequence encoding one of shmiR2-shmiR7, shmiR9 or shmiR13-shmiR17 or thecorresponding shRNA of any thereof.

In one example, the plurality of nucleic acids described hereincomprises a nucleic acid comprising or consisting of a DNA sequenceencoding shmiR13, and at least one other nucleic acid of the disclosurewhich encodes a shmiR or shRNA targeting a region of a PABPN1 mRNAtranscript. Exemplary nucleic acids encoding shmiR13 are describedherein and shall be taken to apply mutatis mutandis to this example ofthe disclosure. In one example, the plurality of nucleic acids describedherein comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 64 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 51, and at leastone other nucleic acid of the disclosure which encodes a shmiR or shRNAtargeting a region of a PABPN1 mRNA transcript. For example, theplurality of nucleic acids described herein may comprise (i) a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:64 (shmiR13), and (ii) a nucleic acid comprising or consisting of a DNAsequence encoding one of shmiR2-shmiR7, shmiR9, shmiR11 orshmiR14-shmiR17 or the corresponding shRNA of any thereof.

In one example, the plurality of nucleic acids described hereincomprises a nucleic acid comprising or consisting of a DNA sequenceencoding shmiR14, and at least one other nucleic acid of the disclosurewhich encodes a shmiR or shRNA targeting a region of a PABPN1 mRNAtranscript. Exemplary nucleic acids encoding shmiR14 are describedherein and shall be taken to apply mutatis mutandis to this example ofthe disclosure. In one example, the plurality of nucleic acids describedherein comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 65 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 52, and at leastone other nucleic acid of the disclosure which encodes a shmiR or shRNAtargeting a region of a PABPN1 mRNA transcript. For example, theplurality of nucleic acids described herein may comprise (i) a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:65 (shmiR14), and (ii) a nucleic acid comprising or consisting of a DNAsequence encoding one of shmiR2-shmiR7, shmiR9, shmiR11 or shmiR13,shmiR15-shmiR17 or the corresponding shRNA of any thereof.

In one example, the plurality of nucleic acids described hereincomprises a nucleic acid comprising or consisting of a DNA sequenceencoding shmiR15, and at least one other nucleic acid of the disclosurewhich encodes a shmiR or shRNA targeting a region of a PABPN1 mRNAtranscript. Exemplary nucleic acids encoding shmiR15 are describedherein and shall be taken to apply mutatis mutandis to this example ofthe disclosure. In one example, the plurality of nucleic acids describedherein comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 66 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 53, and at leastone other nucleic acid of the disclosure which encodes a shmiR or shRNAtargeting a region of a PABPN1 mRNA transcript. For example, theplurality of nucleic acids described herein may comprise (i) a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:66 (shmiR15), and (ii) a nucleic acid comprising or consisting of a DNAsequence encoding one of shmiR2-shmiR7, shmiR9, shmiR11 orshmiR13-shmiR14, or shmiR16-shmiR17 or the corresponding shRNA of anythereof.

In one example, the plurality of nucleic acids described hereincomprises a nucleic acid comprising or consisting of a DNA sequenceencoding shmiR16, and at least one other nucleic acid of the disclosurewhich encodes a shmiR or shRNA targeting a region of a PABPN1 mRNAtranscript. Exemplary nucleic acids encoding shmiR16 are describedherein and shall be taken to apply mutatis mutandis to this example ofthe disclosure. In one example, the plurality of nucleic acids describedherein comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 67 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 54, and at leastone other nucleic acid of the disclosure which encodes a shmiR or shRNAtargeting a region of a PABPN1 mRNA transcript. For example, theplurality of nucleic acids described herein may comprise (i) a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:67 (shmiR16), and (ii) a nucleic acid comprising or consisting of a DNAsequence encoding one of shmiR2-shmiR7, shmiR9, shmiR11 orshmiR13-shmiR15, or shmiR17 or the corresponding shRNA of any thereof.

In one example, the plurality of nucleic acids described hereincomprises a nucleic acid comprising or consisting of a DNA sequenceencoding shmiR17, and at least one other nucleic acid of the disclosurewhich encodes a shmiR or shRNA targeting a region of a PABPN1 mRNAtranscript. Exemplary nucleic acids encoding shmiR17 are describedherein and shall be taken to apply mutatis mutandis to this example ofthe disclosure. In one example, the plurality of nucleic acids describedherein comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 68 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 55, and at leastone other nucleic acid of the disclosure which encodes a shmiR or shRNAtargeting a region of a PABPN1 mRNA transcript. For example, theplurality of nucleic acids described herein may comprise (i) a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:68 (shmiR17), and (ii) a nucleic acid comprising or consisting of a DNAsequence encoding one of shmiR2-shmiR7, shmiR9, shmiR11 orshmiR13-shmiR16 or the corresponding shRNA of any thereof.

In accordance with any example of a plurality of nucleic acids asdescribed herein, the plurality of nucleic acids may comprise two ormore nucleic acids encoding shmiRs or shRNAs as described herein, suchas two, or three, or four, or five, or six, or seven, or eight, or nine,or ten nucleic acids encoding shmiRs as described herein, provided atthat at least one of the nucleic acids encodes a shmiRs of thedisclosure.

In one example, the plurality of nucleic acids comprises two nucleicacids encoding a shmiR or shRNA described herein, with the proviso thatat least one of the nucleic acids encodes a shmiR as described herein.In one example, the plurality of nucleic acids comprises three nucleicacids encoding a shmiR or shRNA described herein, with the proviso thatat least one of the nucleic acids encodes a shmiR as described herein.In one example, the plurality of nucleic acids comprises four nucleicacids encoding a shmiR or shRNA described herein, with the proviso thatat least one of the nucleic acids encodes a shmiR as described herein.In one example, the plurality of nucleic acids comprises five nucleicacids encoding a shmiR or shRNA described herein, with the proviso thatat least one of the nucleic acids encodes a shmiR as described herein.In one example, the plurality of nucleic acids comprises six nucleicacids encoding a shmiR or shRNA described herein, with the proviso thatat least one of the nucleic acids encodes a shmiR as described herein.In one example, the plurality of nucleic acids comprises seven nucleicacids encoding a shmiR or shRNA described herein, with the proviso thatat least one of the nucleic acids encodes a shmiR as described herein.In one example, the plurality of nucleic acids comprises eight nucleicacids encoding a shmiR or shRNA described herein, with the proviso thatat least one of the nucleic acids encodes a shmiR as described herein.In one example, the plurality of nucleic acids comprises nine nucleicacids encoding a shmiR or shRNA described herein, with the proviso thatat least one of the nucleic acids encodes a shmiR as described herein.In one example, the plurality of nucleic acids comprises ten nucleicacids encoding a shmiR or shRNA described herein, with the proviso thatat least one of the nucleic acids encodes a shmiR as described herein.

In one example of a plurality of nucleic acids described herein, one ofthe nucleic acids comprises a DNA sequence encoding a shmiR having aneffector sequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 1. Suitable nucleic acids encodinga shmiR having an effector sequence which is substantially complementaryto a region of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 1 are describedherein e.g., for shmiR2.

In one example of a plurality of nucleic acids described herein, one ofthe nucleic acids comprises a DNA sequence encoding a shmiR having aneffector sequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 2. Suitable nucleic acids encodinga shmiR having an effector sequence which is substantially complementaryto a region of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 2 are describedherein e.g., for shmiR3.

In one example of a plurality of nucleic acids described herein, one ofthe nucleic acids comprises a DNA sequence encoding a shmiR having aneffector sequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 4. Suitable nucleic acids encodinga shmiR having an effector sequence which is substantially complementaryto a region of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 4 are describedherein e.g., for shmiR5.

In one example of a plurality of nucleic acids described herein, one ofthe nucleic acids comprises a DNA sequence encoding a shmiR having aneffector sequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 7. Suitable nucleic acids encodinga shmiR having an effector sequence which is substantially complementaryto a region of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 7 are describedherein e.g., for shmiR9.

In one example of a plurality of nucleic acids described herein, one ofthe nucleic acids comprises a DNA sequence encoding a shmiR having aneffector sequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 9. Suitable nucleic acids encodinga shmiR having an effector sequence which is substantially complementaryto a region of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 9 are describedherein e.g., for shmiR13.

In one example of a plurality of nucleic acids described herein, one ofthe nucleic acids comprises a DNA sequence encoding a shmiR having aneffector sequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 10. Suitable nucleic acids encodinga shmiR having an effector sequence which is substantially complementaryto a region of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 10 are describedherein e.g., for shmiR14.

In one example of a plurality of nucleic acids described herein, one ofthe nucleic acids comprises a DNA sequence encoding a shmiR having aneffector sequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 13. Suitable nucleic acids encodinga shmiR having an effector sequence which is substantially complementaryto a region of corresponding length in an RNA transcript comprising orconsisting of the sequence set forth in SEQ ID NO: 13 are describedherein e.g., for shmiR17.

An exemplary plurality of nucleic acids of the disclosure comprises atleast two nucleic acids, each comprising a DNA sequence encoding a shmiRof the disclosure, wherein each shmiR comprises a different effectorsequence.

In one example, each of the at least two nucleic acids encode a shmiRcomprising an effector sequence which is substantially complementary toa region of corresponding length in an RNA transcript set forth in oneof SEQ ID NOs: 1, 2, 4, 7, 9, 10 and 13. Exemplary nucleic acids of thedisclosure encoding shmiRs comprising effector sequences which aresubstantially complementary to regions of corresponding length in theRNA transcripts set forth in SEQ ID NO: 1, 2, 4, 7, 9, 10 and 13 aredescribed herein and shall be taken to apply mutatis mutandis to thisexample of the disclosure.

In one example, the at least two nucleic acids are selected from thegroup consisting of:

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 15 and aneffector complement sequence set forth in SEQ ID NO: 14 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:56 (shmiR2);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 17 and aneffector complement sequence set forth in SEQ ID NO: 16 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:57 (shmiR3);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 21 and aneffector complement sequence set forth in SEQ ID NO: 20 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:59 (shmiR5);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 27 and aneffector complement sequence set forth in SEQ ID NO: 26 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:62 (shmiR9);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 31 and aneffector complement sequence set forth in SEQ ID NO: 30 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:64 (shmiR13);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 33 and aneffector complement sequence set forth in SEQ ID NO: 32 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:65 (shmiR14); and

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 39 and aneffector complement sequence set forth in SEQ ID NO: 38 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:68 (shmiR17).

In one example, each of the at least two nucleic acids encode a shmiRcomprising an effector sequence which is substantially complementary toa region of corresponding length in an RNA transcript set forth in oneof SEQ ID NOs: 2, 9, 10 and 13. Exemplary nucleic acids of thedisclosure encoding shmiRs comprising effector sequences which aresubstantially complementary to regions of corresponding length in theRNA transcripts set forth in SEQ ID NO: 2, 9, 10 and 13 are describedherein and shall be taken to apply mutatis mutandis to this example ofthe disclosure.

In one example, the at least two nucleic acids are selected from thegroup consisting of:

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 17 and aneffector complement sequence set forth in SEQ ID NO: 16 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:57 (shmiR3);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 31 and aneffector complement sequence set forth in SEQ ID NO: 30 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:64 (shmiR13);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 33 and aneffector complement sequence set forth in SEQ ID NO: 32 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:65 (shmiR14); and

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 39 and aneffector complement sequence set forth in SEQ ID NO: 38 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:68 (shmiR17).

In one example, the plurality of nucleic acids comprises a nucleic acidencoding a shmiR comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 10, and a nucleic acid encoding a shmiRcomprising an effector sequence which is substantially complementary toa region of corresponding length in an RNA transcript set forth in SEQID NO: 13. For example, the plurality of nucleic acids may comprise:

(a) a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 31 and aneffector complement sequence set forth in SEQ ID NO: 30 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:64 (shmiR13); and(b) a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 39 and aneffector complement sequence set forth in SEQ ID NO: 38 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:68 (shmiR17).

An exemplary plurality of nucleic acids of the disclosure comprises anucleic acid comprising or consisting of a DNA sequence set forth in SEQID NO: 64 (shmiR13) and a nucleic acid comprising or consisting of a DNAsequence set forth in SEQ ID NO: 68 (shmiR17).

In one example, the plurality of nucleic acids comprises a nucleic acidencoding a shmiR comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 2, and a nucleic acid encoding a shmiRcomprising an effector sequence which is substantially complementary toa region of corresponding length in an RNA transcript set forth in SEQID NO: 9. For example, the plurality of nucleic acids may comprise:

(a) a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 17 and aneffector complement sequence set forth in SEQ ID NO: 16, e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:57 (shmiR3); and(b) a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 33 and aneffector complement sequence set forth in SEQ ID NO: 32 e.g., a nucleicacid comprising or consisting of the sequence set forth in SEQ ID NO:65(shmiR14).

An exemplary plurality of nucleic acids of the disclosure comprises anucleic acid comprising or consisting of a DNA sequence set forth in SEQID NO: 64 (shmiR13) and a nucleic acid comprising or consisting of a DNAsequence set forth in SEQ ID NO: 68 (shmiR17).

In accordance with an example in which a plurality of nucleic acids isprovided, two or more of the nucleic acids may form separate parts ofthe same polynucleotide. In another example, two or more of the nucleicacids in the plurality form parts of different polynucleotides,respectively. In another example, the plurality of nucleic acidsdescribed herein are provided as multiple components e.g., multiplecompositions. For example, each of the nucleic acids of the pluralitymay be provided separately. Alternatively, in an example where three ormore nucleic acids of the disclosure are provided, at least one of thenucleic acids may be provided separately and two or more of theplurality provided together.

In some examples, the or each nucleic acid in accordance with thepresent disclosure may comprise, or be in operable linkage with,additional elements e.g., to facilitate transcription of the shmiR orshRNA. For example, the or each nucleic acid may comprise a promoteroperably linked to the sequence encoding a shmiR or shRNA describedherein. Other elements e.g., transcriptional terminators and initiators,are known in the art and/or described herein.

Alternatively, or in addition, the or each nucleic acid in accordancewith the present disclosure may comprise one or more restriction sitese.g., to facilitate cloning of the nucleic acid(s) into cloning orexpression vectors. For example, the nucleic acids described herein mayinclude a restriction site upstream and/or downstream of the sequenceencoding a shmiR or shRNA of the disclosure. Suitable restriction enzymerecognition sequences will be known to a person of skill in the art.However, in one example, the nucleic acid(s) of the disclosure mayinclude a BamH1 restriction site (GGATCC) at the 5′ terminus i.e.,upstream of the sequence encoding the shmiR or shRNA, and a EcoR1restriction site (GAATTC) at the 3′ terminus i.e., downstream of thesequence encoding the shmiR or shRNA.

ddRNAi Constructs

In one example, the or each nucleic acid of the disclosure is providedin the form of, or is comprised in, a DNA-directed RNAi (ddRNAi)construct. Accordingly, in one example, the present disclosure providesa ddRNAi construct comprising a nucleic acid as described herein. Inanother example, the present disclosure provides a ddRNAi constructcomprising a plurality of nucleic acids described herein. In yet anotherexample, the present disclosure provides a plurality of ddRNAiconstructs, each comprising a nucleic acid of the plurality of nucleicacids as described herein (i.e., such that all of the nucleic acids ofthe plurality are represented in the plurality of ddRNAi constructs).Exemplary nucleic acids encoding shmiRs or shRNAs comprising effectorsequences targeting a mRNA transcript of PABPN1 which is causative ofOPMD are described herein and shall be taken to apply mutatis mutandisto this example of the disclosure.

In one example, the ddRNAi construct comprises a nucleic acid of thedisclosure operably linked to a promoter.

In accordance with an example in which the ddRNAi construct comprises aplurality of the nucleic acids described herein, each of the nucleicacids may be operably-linked to a promoter. In one example, the nucleicacids in the ddRNAi construct may be operably linked to the samepromoter. In one example, the nucleic acids in the ddRNAi construct maybe operably linked to different promoters.

In one example, a ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR2. Forexample, the ddRNAi construct may comprise a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR having an effectorsequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 1. Exemplary nucleic acids encodingshmiR2 are described herein and shall be taken to apply mutatis mutandisto this example of the disclosure. In one example, the ddRNAi constructcomprises a nucleic acid which comprises or consists of a DNA sequenceset forth in SEQ ID NO: 56 and which encodes a shmiR comprising orconsisting of the sequence set forth in SEQ ID NO: 43. The ddRNAiconstruct may comprise one or more further nucleic acids of thedisclosure comprising a DNA sequence encoding a shmiR or shRNA targetinga region of a PABPN1 mRNA transcript, such as a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR3-shmiR7, shmiR9,shmiR11 or shmiR13-shmiR17 or the corresponding shRNA of any thereof, asdescribed herein. For example, the ddRNAi construct described herein maycomprise (i) a nucleic acid comprising or consisting of a DNA sequenceset forth in SEQ ID NO: 56 (shmiR2), and (ii) a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR3-shmiR7, shmiR9,shmiR11 or shmiR13-shmiR17 or the corresponding shRNA of any thereof.Exemplary nucleic acids encoding shmiRs designated shmiR3-shmiR7,shmiR9, shmiR11 and shmiR13-shmiR17 are described herein and shall betaken to apply mutatis mutandis to this example of the disclosure.

In one example, a ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR3. Forexample, the ddRNAi construct may comprise a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR having an effectorsequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 2. Exemplary nucleic acids encodingshmiR3 are described herein and shall be taken to apply mutatis mutandisto this example of the disclosure. In one example, the ddRNAi constructcomprises a nucleic acid which comprises or consists of a DNA sequenceset forth in SEQ ID NO: 57 and which encodes a shmiR comprising orconsisting of the sequence set forth in SEQ ID NO: 44. The ddRNAiconstruct may comprise one or more further nucleic acids of thedisclosure comprising a DNA sequence encoding a shmiR or shRNA targetinga region of a PABPN1 mRNA transcript, such as a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2, shmiR4-shmiR7,shmiR9, shmiR11 or shmiR13-shmiR17 or the corresponding shRNA of anythereof, as described herein. For example, the ddRNAi constructdescribed herein may comprise (i) a nucleic acid comprising orconsisting of a DNA sequence set forth in SEQ ID NO: 57 (shmiR3), and(ii) a nucleic acid comprising or consisting of a DNA sequence encodingone of shmiR2, shmiR4-shmiR7, shmiR9, shmiR11 or shmiR13-shmiR17 or thecorresponding shRNA of any thereof. Exemplary nucleic acids encodingshmiRs designated shmiR2, shmiR4-shmiR7, shmiR9, shmiR11 orshmiR13-shmiR17 are described herein and shall be taken to apply mutatismutandis to this example of the disclosure.

In one example, a ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR4. Forexample, the ddRNAi construct may comprise a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR having an effectorsequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 3. Exemplary nucleic acids encodingshmiR4 are described herein and shall be taken to apply mutatis mutandisto this example of the disclosure. In one example, the ddRNAi constructcomprises a nucleic acid which comprises or consists of a DNA sequenceset forth in SEQ ID NO: 58 and which encodes a shmiR comprising orconsisting of the sequence set forth in SEQ ID NO: 45. The ddRNAiconstruct may comprise one or more further nucleic acids of thedisclosure comprising a DNA sequence encoding a shmiR or shRNA targetinga region of a PABPN1 mRNA transcript, such as a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2, shmiR3,shmiR5-shmiR7, shmiR9, shmiR11 or shmiR13-shmiR17 or the correspondingshRNA of any thereof, as described herein. For example, the ddRNAiconstruct described herein may comprise (i) a nucleic acid comprising orconsisting of a DNA sequence set forth in SEQ ID NO: 58 (shmiR4), and(ii) a nucleic acid comprising or consisting of a DNA sequence encodingone of shmiR2, shmiR3, shmiR5-shmiR7, shmiR9, shmiR11 or shmiR13-shmiR17or the corresponding shRNA of any thereof. Exemplary nucleic acidsencoding shmiRs designated shmiR2, shmiR3, shmiR5-shmiR7, shmiR9,shmiR11 or shmiR13-shmiR17 are described herein and shall be taken toapply mutatis mutandis to this example of the disclosure.

In one example, a ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR5. Forexample, the ddRNAi construct may comprise a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR having an effectorsequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 4. Exemplary nucleic acids encodingshmiR5 are described herein and shall be taken to apply mutatis mutandisto this example of the disclosure. In one example, the ddRNAi constructcomprises a nucleic acid which comprises or consists of a DNA sequenceset forth in SEQ ID NO: 59 and which encodes a shmiR comprising orconsisting of the sequence set forth in SEQ ID NO: 46. The ddRNAiconstruct may comprise one or more further nucleic acids of thedisclosure comprising a DNA sequence encoding a shmiR or shRNA targetinga region of a PABPN1 mRNA transcript, such as a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2-shmiR4,shmiR6-shmiR7, shmiR9, shmiR11 or shmiR13-shmiR17 or the correspondingshRNA of any thereof, as described herein. For example, the ddRNAiconstruct described herein may comprise (i) a nucleic acid comprising orconsisting of a DNA sequence set forth in SEQ ID NO: 59 (shmiR5), and(ii) a nucleic acid comprising or consisting of a DNA sequence encodingone of shmiR2-shmiR4, shmiR6-shmiR7, shmiR9, shmiR11 or shmiR13-shmiR17or the corresponding shRNA of any thereof. Exemplary nucleic acidsencoding shmiRs designated shmiR2-shmiR4, shmiR6-shmiR7, shmiR9, shmiR11or shmiR13-shmiR17 are described herein and shall be taken to applymutatis mutandis to this example of the disclosure.

In one example, a ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR6. Forexample, the ddRNAi construct may comprise a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR having an effectorsequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 5. Exemplary nucleic acids encodingshmiR6 are described herein and shall be taken to apply mutatis mutandisto this example of the disclosure. In one example, the ddRNAi constructcomprises a nucleic acid which comprises or consists of a DNA sequenceset forth in SEQ ID NO: 60 and which encodes a shmiR comprising orconsisting of the sequence set forth in SEQ ID NO: 47. The ddRNAiconstruct may comprise one or more further nucleic acids of thedisclosure comprising a DNA sequence encoding a shmiR or shRNA targetinga region of a PABPN1 mRNA transcript, such as a nucleic acid comprisingor consisting of a DNA sequence encoding one of s shmiR2-shmiR5, shmiR7,shmiR9, shmiR11 or shmiR13-shmiR17 or the corresponding shRNA of anythereof, as described herein. For example, the ddRNAi constructdescribed herein may comprise (i) a nucleic acid comprising orconsisting of a DNA sequence set forth in SEQ ID NO: 60 (shmiR6), and(ii) a nucleic acid comprising or consisting of a DNA sequence encodingone of shmiR2-shmiR5, shmiR7, shmiR9, shmiR11 or shmiR13-shmiR17 or thecorresponding shRNA of any thereof. Exemplary nucleic acids encodingshmiRs designated shmiR2-shmiR5, shmiR7, shmiR9, shmiR11 orshmiR13-shmiR17 are described herein and shall be taken to apply mutatismutandis to this example of the disclosure.

In one example, a ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR7. Forexample, the ddRNAi construct may comprise a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR having an effectorsequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 6. Exemplary nucleic acids encodingshmiR7 are described herein and shall be taken to apply mutatis mutandisto this example of the disclosure. In one example, the ddRNAi constructcomprises a nucleic acid which comprises or consists of a DNA sequenceset forth in SEQ ID NO: 61 and which encodes a shmiR comprising orconsisting of the sequence set forth in SEQ ID NO: 48. The ddRNAiconstruct may comprise one or more further nucleic acids of thedisclosure comprising a DNA sequence encoding a shmiR or shRNA targetinga region of a PABPN1 mRNA transcript, such as a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2-shmiR6, shmiR9,shmiR11 or shmiR13-shmiR17 or the corresponding shRNA of any thereof, asdescribed herein. For example, the ddRNAi construct described herein maycomprise (i) a nucleic acid comprising or consisting of a DNA sequenceset forth in SEQ ID NO: 61 (shmiR7), and (ii) a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2-shmiR6, shmiR9,shmiR11 or shmiR13-shmiR17 or the corresponding shRNA of any thereof.Exemplary nucleic acids encoding shmiRs designated shmiR2-shmiR6,shmiR9, shmiR11 or shmiR13-shmiR17 are described herein and shall betaken to apply mutatis mutandis to this example of the disclosure.

In one example, a ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR9. Forexample, the ddRNAi construct may comprise a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR having an effectorsequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 7. Exemplary nucleic acids encodingshmiR9 are described herein and shall be taken to apply mutatis mutandisto this example of the disclosure. In one example, the ddRNAi constructcomprises a nucleic acid which comprises or consists of a DNA sequenceset forth in SEQ ID NO: 62 and which encodes a shmiR comprising orconsisting of the sequence set forth in SEQ ID NO: 49. The ddRNAiconstruct may comprise one or more further nucleic acids of thedisclosure comprising a DNA sequence encoding a shmiR or shRNA targetinga region of a PABPN1 mRNA transcript, such as a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2-shmiR7, shmiR11or shmiR13-shmiR17 or the corresponding shRNA of any thereof, asdescribed herein. For example, the ddRNAi construct described herein maycomprise (i) a nucleic acid comprising or consisting of a DNA sequenceset forth in SEQ ID NO: 62 (shmiR9), and (ii) a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2-shmiR7, shmiR11or shmiR13-shmiR17 or the corresponding shRNA of any thereof. Exemplarynucleic acids encoding shmiRs designated shmiR2-shmiR7, shmiR11 orshmiR13-shmiR17 are described herein and shall be taken to apply mutatismutandis to this example of the disclosure.

In one example, a ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR11. Forexample, the ddRNAi construct may comprise a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR having an effectorsequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 8. Exemplary nucleic acids encodingshmiR11 are described herein and shall be taken to apply mutatismutandis to this example of the disclosure. In one example, the ddRNAiconstruct comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 63 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 50. The ddRNAiconstruct may comprise one or more further nucleic acids of thedisclosure comprising a DNA sequence encoding a shmiR or shRNA targetinga region of a PABPN1 mRNA transcript, such as a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2-shmiR7, shmiR9 orshmiR13-shmiR17 or the corresponding shRNA of any thereof, as describedherein. For example, the ddRNAi construct described herein may comprise(i) a nucleic acid comprising or consisting of a DNA sequence set forthin SEQ ID NO: 63 (shmiR11), and (ii) a nucleic acid comprising orconsisting of a DNA sequence encoding one of shmiR2-shmiR7, shmiR9 orshmiR13-shmiR17 or the corresponding shRNA of any thereof. Exemplarynucleic acids encoding shmiRs designated shmiR2-shmiR7, shmiR9 orshmiR13-shmiR17 are described herein and shall be taken to apply mutatismutandis to this example of the disclosure.

In one example, a ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR13. Forexample, the ddRNAi construct may comprise a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR having an effectorsequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 9. Exemplary nucleic acids encodingshmiR13 are described herein and shall be taken to apply mutatismutandis to this example of the disclosure. In one example, the ddRNAiconstruct comprises a nucleic acid which comprises or consists of a DNAsequence set forth in SEQ ID NO: 64 and which encodes a shmiR comprisingor consisting of the sequence set forth in SEQ ID NO: 51. The ddRNAiconstruct may comprise one or more further nucleic acids of thedisclosure comprising a DNA sequence encoding a shmiR or shRNA targetinga region of a PABPN1 mRNA transcript, such as a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2-shmiR7, shmiR9,shmiR11 or shmiR14-shmiR17 or the corresponding shRNA of any thereof, asdescribed herein. For example, the ddRNAi construct described herein maycomprise (i) a nucleic acid comprising or consisting of a DNA sequenceset forth in SEQ ID NO: 64 (shmiR13), and (ii) a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2-shmiR7, shmiR9,shmiR11 or shmiR14-shmiR17 or the corresponding shRNA of any thereof.Exemplary nucleic acids encoding shmiRs designated shmiR2-shmiR7,shmiR9, shmiR11 or shmiR14-shmiR17 are described herein and shall betaken to apply mutatis mutandis to this example of the disclosure.

In one example, a ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR14. Forexample, the ddRNAi construct may comprise a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR having an effectorsequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 10. Exemplary nucleic acidsencoding shmiR14 are described herein and shall be taken to applymutatis mutandis to this example of the disclosure. In one example, theddRNAi construct comprises a nucleic acid which comprises or consists ofa DNA sequence set forth in SEQ ID NO: 65 and which encodes a shmiRcomprising or consisting of the sequence set forth in SEQ ID NO: 52. TheddRNAi construct may comprise one or more further nucleic acids of thedisclosure comprising a DNA sequence encoding a shmiR or shRNA targetinga region of a PABPN1 mRNA transcript, such as a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2-shmiR7, shmiR9,shmiR11 or shmiR13, shmiR15-shmiR17 or the corresponding shRNA of anythereof, as described herein. For example, the ddRNAi constructdescribed herein may comprise (i) a nucleic acid comprising orconsisting of a DNA sequence set forth in SEQ ID NO: 65 (shmiR14), and(ii) a nucleic acid comprising or consisting of a DNA sequence encodingone of shmiR2-shmiR7, shmiR9, shmiR11 or shmiR13, shmiR15-shmiR17 or thecorresponding shRNA of any thereof. Exemplary nucleic acids encodingshmiRs designated shmiR2-shmiR7, shmiR9, shmiR11 or shmiR13,shmiR15-shmiR17 are described herein and shall be taken to apply mutatismutandis to this example of the disclosure.

In one example, a ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR15. Forexample, the ddRNAi construct may comprise a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR having an effectorsequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 11. Exemplary nucleic acidsencoding shmiR15 are described herein and shall be taken to applymutatis mutandis to this example of the disclosure. In one example, theddRNAi construct comprises a nucleic acid which comprises or consists ofa DNA sequence set forth in SEQ ID NO: 66 and which encodes a shmiRcomprising or consisting of the sequence set forth in SEQ ID NO: 53. TheddRNAi construct may comprise one or more further nucleic acids of thedisclosure comprising a DNA sequence encoding a shmiR or shRNA targetinga region of a PABPN1 mRNA transcript, such as a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2-shmiR7, shmiR9,shmiR11 or shmiR13-shmiR14, or shmiR16-shmiR17 or the correspondingshRNA of any thereof, as described herein. For example, the ddRNAiconstruct described herein may comprise (i) a nucleic acid comprising orconsisting of a DNA sequence set forth in SEQ ID NO: 66 (shmiR15), and(ii) a nucleic acid comprising or consisting of a DNA sequence encodingone of shmiR2-shmiR7, shmiR9, shmiR11 or shmiR13-shmiR14, orshmiR16-shmiR17 or the corresponding shRNA of any thereof. Exemplarynucleic acids encoding shmiRs designated shmiR2-shmiR7, shmiR9, shmiR11or shmiR13-shmiR14, or shmiR16-shmiR17 are described herein and shall betaken to apply mutatis mutandis to this example of the disclosure.

In one example, a ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR16. Forexample, the ddRNAi construct may comprise a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR having an effectorsequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 12. Exemplary nucleic acidsencoding shmiR16 are described herein and shall be taken to applymutatis mutandis to this example of the disclosure. In one example, theddRNAi construct comprises a nucleic acid which comprises or consists ofa DNA sequence set forth in SEQ ID NO: 67 and which encodes a shmiRcomprising or consisting of the sequence set forth in SEQ ID NO: 54. TheddRNAi construct may comprise one or more further nucleic acids of thedisclosure comprising a DNA sequence encoding a shmiR or shRNA targetinga region of a PABPN1 mRNA transcript, such as a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2-shmiR7, shmiR9,shmiR11 or shmiR13-shmiR15, or shmiR17 or the corresponding shRNA of anythereof, as described herein. For example, the ddRNAi constructdescribed herein may comprise (i) a nucleic acid comprising orconsisting of a DNA sequence set forth in SEQ ID NO: 67 (shmiR16), and(ii) a nucleic acid comprising or consisting of a DNA sequence encodingone of shmiR2-shmiR7, shmiR9, shmiR11 or shmiR13-shmiR15, or shmiR17 orthe corresponding shRNA of any thereof. Exemplary nucleic acids encodingshmiRs designated shmiR2-shmiR7, shmiR9, shmiR11 or shmiR13-shmiR15, orshmiR17 are described herein and shall be taken to apply mutatismutandis to this example of the disclosure.

In one example, a ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR17. Forexample, the ddRNAi construct may comprise a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR having an effectorsequence which is substantially complementary to a region ofcorresponding length in an RNA transcript comprising or consisting ofthe sequence set forth in SEQ ID NO: 13. Exemplary nucleic acidsencoding shmiR17 are described herein and shall be taken to applymutatis mutandis to this example of the disclosure. In one example, theddRNAi construct comprises a nucleic acid which comprises or consists ofa DNA sequence set forth in SEQ ID NO: 68 and which encodes a shmiRcomprising or consisting of the sequence set forth in SEQ ID NO: 55. TheddRNAi construct may comprise one or more further nucleic acids of thedisclosure comprising a DNA sequence encoding a shmiR or shRNA targetinga region of a PABPN1 mRNA transcript, such as a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2-shmiR7, shmiR9,shmiR11 or shmiR13-shmiR16 or the corresponding shRNA of any thereof, asdescribed herein. For example, the ddRNAi construct described herein maycomprise (i) a nucleic acid comprising or consisting of a DNA sequenceset forth in SEQ ID NO: 68 (shmiR17), and (ii) a nucleic acid comprisingor consisting of a DNA sequence encoding one of shmiR2-shmiR7, shmiR9,shmiR11 or shmiR13-shmiR16 or the corresponding shRNA of any thereof.Exemplary nucleic acids encoding shmiRs designated shmiR2-shmiR7,shmiR9, shmiR11 or shmiR13-shmiR16 are described herein and shall betaken to apply mutatis mutandis to this example of the disclosure.

In accordance with any example of a ddRNAi construct comprising aplurality of nucleic acids as described herein, the ddRNAi construct maycomprise two or more nucleic acids encoding shmiRs or shRNAs asdescribed herein, such as two, or three, or four, or five, or six, orseven, or eight, or nine, or ten nucleic acids encoding shmiRs or shRNAsas described herein, provided that at least one of the nucleic acidsencodes a shmiR as described herein.

In one example, the ddRNAi construct comprises two nucleic acidsencoding a shmiR or shRNA described herein, with the proviso that atleast one of the nucleic acids encodes a shmiR as described herein. Inone example, the ddRNAi construct comprises three nucleic acids encodinga shmiR or shRNA described herein, with the proviso that at least one ofthe nucleic acids encodes a shmiR as described herein. In one example,the ddRNAi construct comprises four nucleic acids encoding a shmiR orshRNA described herein, with the proviso that at least one of thenucleic acids encodes a shmiR as described herein. In one example, theddRNAi construct comprises five nucleic acids encoding a shmiR or shRNAdescribed herein, with the proviso that at least one of the nucleicacids encodes a shmiR as described herein. In one example, the ddRNAiconstruct comprises six nucleic acids encoding a shmiR or shRNAdescribed herein, with the proviso that at least one of the nucleicacids encodes a shmiR as described herein. In one example, the ddRNAiconstruct comprises seven nucleic acids encoding a shmiR or shRNAdescribed herein, with the proviso that at least one of the nucleicacids encodes a shmiR as described herein. In one example, the ddRNAiconstruct comprises eight nucleic acids encoding a shmiR or shRNAdescribed herein, with the proviso that at least one of the nucleicacids encodes a shmiR as described herein. In one example, the ddRNAiconstruct comprises nine nucleic acids encoding a shmiR or shRNAdescribed herein, with the proviso that at least one of the nucleicacids encodes a shmiR as described herein. In one example, the ddRNAiconstruct comprises ten nucleic acids encoding a shmiR or shRNAdescribed herein, with the proviso that at least one of the nucleicacids encodes a shmiR as described herein.

An exemplary ddRNAi construct of the disclosure comprises at least twonucleic acids, each comprising a DNA sequence encoding a shmiR of thedisclosure, wherein each shmiR comprises a different effector sequence.In one example, each of the at least two nucleic acids in the ddRNAiconstruct encode a shmiR comprising an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript set forth in one of SEQ ID NOs: 1, 2, 4, 7, 9, 10 and 13.Exemplary nucleic acids of the disclosure encoding shmiRs comprisingeffector sequences which are substantially complementary to regions ofcorresponding length in the RNA transcripts set forth in SEQ ID NO: 1,2, 4, 7, 9, 10 and 13 are described herein and shall be taken to applymutatis mutandis to this example of the disclosure describing ddRNAiconstructs.

In one example, the ddRNAi construct comprises at least two nucleicacids selected from the group consisting of:

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 15 and aneffector complement sequence set forth in SEQ ID NO: 14 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:56 (shmiR2);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 17 and aneffector complement sequence set forth in SEQ ID NO: 16 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:57 (shmiR3);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 21 and aneffector complement sequence set forth in SEQ ID NO: 20 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:59 (shmiR5);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 27 and aneffector complement sequence set forth in SEQ ID NO: 26 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:62 (shmiR9);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 31 and aneffector complement sequence set forth in SEQ ID NO: 30 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:64 (shmiR13);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 33 and aneffector complement sequence set forth in SEQ ID NO: 32 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:65 (shmiR14); and

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 39 and aneffector complement sequence set forth in SEQ ID NO: 38 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:68 (shmiR17).

In one example, each of the at least two nucleic acids in the ddRNAiconstruct encode a shmiR comprising an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript set forth in one of SEQ ID NOs: 2, 9, 10 and 13.Exemplary nucleic acids of the disclosure encoding shmiRs comprisingeffector sequences which are substantially complementary to regions ofcorresponding length in the RNA transcripts set forth in SEQ ID NO: 2,9, 10 and 13 are described herein and shall be taken to apply mutatismutandis to this example of the disclosure describing ddRNAi constructs.

In one example, the ddRNAi construct comprises at least two nucleicacids selected from the group consisting of:

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 17 and aneffector complement sequence set forth in SEQ ID NO: 16 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:57 (shmiR3);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 31 and aneffector complement sequence set forth in SEQ ID NO: 30 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:64 (shmiR13);

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 33 and aneffector complement sequence set forth in SEQ ID NO: 32 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:65 (shmiR14); and

a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 39 and aneffector complement sequence set forth in SEQ ID NO: 38 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:68 (shmiR17).

In one example, the ddRNAi construct of the disclosure comprises anucleic acid encoding a shmiR comprising an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript set forth in SEQ ID NO: 10, and a nucleic acid encoding ashmiR comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 13. For example, the ddRNAi construct maycomprise:

(a) a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 31 and aneffector complement sequence set forth in SEQ ID NO: 30 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:64 (shmiR13); and(b) a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 39 and aneffector complement sequence set forth in SEQ ID NO: 38 e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:68 (shmiR17).

An exemplary ddRNAi construct of the disclosure comprises a nucleic acidcomprising or consisting of a DNA sequence set forth in SEQ ID NO: 64(shmiR13) and a nucleic acid comprising or consisting of a DNA sequenceset forth in SEQ ID NO: 68 (shmiR17).

In one example, the ddRNAi construct comprises a nucleic acid encoding ashmiR comprising an effector sequence which is substantiallycomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 2, and a nucleic acid encoding a shmiRcomprising an effector sequence which is substantially complementary toa region of corresponding length in an RNA transcript set forth in SEQID NO: 9. For example, the ddRNAi construct may comprise:

(a) a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 17 and aneffector complement sequence set forth in SEQ ID NO: 16, e.g., a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:57 (shmiR3); and(b) a nucleic acid comprising or consisting of a DNA sequence encoding ashmiR comprising an effector sequence set forth in SEQ ID NO: 33 and aneffector complement sequence set forth in SEQ ID NO: 32 e.g., a nucleicacid comprising or consisting of the sequence set forth in SEQ ID NO:65(shmiR14).

An exemplary ddRNAi construct of the disclosure comprises a nucleic acidcomprising or consisting of a DNA sequence set forth in SEQ ID NO: 64(shmiR13) and a nucleic acid comprising or consisting of a DNA sequenceset forth in SEQ ID NO: 68 (shmiR17).

In each of the foregoing examples describing a ddRNAi construct of thedisclosure, the or each nucleic acid comprised therein may be operablylinked to a promoter. For example, the ddRNAi construct as describedherein may comprise a single promoter which is operably-linked to the oreach nucleic acid comprised therein e.g., to drive expression of one ormore shmiRs and/or shRNAs from the ddRNAi construct.

In another example, each nucleic acid encoding a shmiR or shRNA of thedisclosure comprised in the ddRNAi construct is operably-linked to aseparate promoter.

According to an example in which multiple promoters are present, thepromoters can be the same or different. For example, the construct maycomprise multiple copies of the same promoter with each copy operablylinked to a different nucleic acid of the disclosure. In anotherexample, each promoter operably linked to a nucleic acid of thedisclosure is different. For example, in a ddRNAi construct encoding twoshmiRs, the two nucleic acids encoding the shmiRs are each operablylinked to a different promoter. Equally, in an example in which a ddRNAiconstruct encodes one shmiR and one shRNA, the respective nucleic acidsencoding the shmiR and shRNA are each operably linked to a differentpromoter.

In one example, the promoter is a constitutive promoter. The term“constitutive” when made in reference to a promoter means that thepromoter is capable of directing transcription of an operably linkednucleic acid sequence in the absence of a specific stimulus (e.g., heatshock, chemicals, light, etc.). Typically, constitutive promoters arecapable of directing expression of a coding sequence in substantiallyany cell and any tissue. The promoters used to transcribe shmiRs orshRNAs from the nucleic acid(s) of the disclosure include promoters forubiquitin, CMV, β-actin, histone H4, EF-1α or pgk genes controlled byRNA polymerase II, or promoter elements controlled by RNA polymerase I.

In one example, a Pol II promoter such as CMV, SV40, U1, β-actin or ahybrid Pol II promoter is employed. Other suitable Pol II promoters areknown in the art and may be used in accordance with this example of thedisclosure. For example, a Pol II promoter system may be preferred in addRNAi construct of the disclosure which expresses a pri-miRNA which, bythe action of the enzymes Drosha and Pasha, is processed into one ormore shmiRs. A Pol II promoter system may also be preferred in a ddRNAiconstruct of the disclosure comprising sequence encoding a plurality ofshRNAs or shmiRs under control of a single promoter. A Pol II promotersystem may also be preferred where tissue specificity is desired.

In another example, a promoter controlled by RNA polymerase III is used,such as a U6 promoter (U6-1, U6-8, U6-9), H1 promoter, 7SL promoter, ahuman Y promoter (hY1, hY3, hY4 (see Maraia, et al., Nucleic Acids Res22(15):3045-52 (1994)) and hY5 (see Maraia, et al., Nucleic Acids Res24(18):3552-59 (1994)), a human MRP-7-2 promoter, an Adenovirus VA1promoter, a human tRNA promoter, or a 5s ribosomal RNA promoter.

Suitable promoters for use in a ddRNAi construct of the disclosure aredescribed in U.S. Pat. Nos. 8,008,468 and 8,129,510.

In one example, the promoter is a RNA pol III promoter. For example, thepromoter is a U6 promoter (e.g., a U6-1, U6-8 or U6-9 promoter). Inanother example, the promoter is a H1 promoter.

In the case of a ddRNAi construct of the disclosure encoding a pluralityof shmiRs, or encoding one or more shmiRs and a shRNA, as describedherein, each of the nucleic acids in the ddRNAi construct is operablylinked to a U6 promoter e.g., a separate U6 promoter.

In one example, the promoter in a construct is a U6 promoter. Forexample, the promoter is a U6-1 promoter. For example, the promoter is aU6-8 promoter. For example, the promoter is a U6-9 promoter.

In some examples, promoters of variable strength are employed. Forexample, use of two or more strong promoters (such as a Pol III-typepromoter) may tax the cell, by, e.g., depleting the pool of availablenucleotides or other cellular components needed for transcription. Inaddition, or alternatively, use of several strong promoters may cause atoxic level of expression of RNAi agents e.g., shmiRs or shRNAs, in thecell. Thus, in some examples one or more of the promoters in themultiple-promoter ddRNAi construct is weaker than other promoters in theconstruct, or all promoters in the construct may express the shmiRs orshRNAs at less than a maximum rate. Promoters may also be modified usingvarious molecular techniques, or otherwise, e.g., through modificationof various regulatory elements, to attain weaker levels or strongerlevels of transcription. One means of achieving reduced transcription isto modify sequence elements within promoters known to control promoteractivity. For example the Proximal Sequence Element (PSE) is known toeffect the activity of human U6 promoters (see Domitrovich, et al.,Nucleic Acids Res 31: 2344-2352 (2003). Replacing the PSE elementspresent in strong promoters, such as the human U6-1, U6-8 or U6-9promoters, with the element from a weak promoter, such as the human U6-7promoter, reduces the activity of the hybrid U6-1, U6-8 or U6-9promoters. This approach has been used in the examples described in thisapplication, but other means to achieve this outcome are known in theart.

Promoters useful in some examples of the present disclosure can betissue-specific or cell-specific. The term “tissue specific” as itapplies to a promoter refers to a promoter that is capable of directingselective transcription of a nucleic acid of interest to a specific typeof tissue (e.g., tissue of the eye or muscle) in the relative absence ofexpression of the same nucleotide sequence of interest in a differenttype of tissue (e.g., liver). The term “cell-specific” as applied to apromoter refers to a promoter which is capable of directing selectivetranscription of a nucleic acid of interest in a specific type of cellin the relative absence of expression of the same nucleotide sequence ofinterest in a different type of cell within the same tissue. Accordingto one example, a muscle-specific promoter is used, such as Spc512 orCK8. However, other muscle-specific promoters are known in the art andare contemplated for use in a ddRNAi construct of the disclosure.

In one example, a ddRNAi construct of the disclosure may additionallycomprise one or more enhancers to increase expression of the shmiRs orshRNAs encoded by the nucleic acids described herein. Enhancersappropriate for use in examples of the present disclosure include theApo E HCR enhancer, a CMV enhancer (Xia et al, Nucleic Acids Res 31-17(2003)), and other enhancers known to those skilled in the art. Suitableenhancers for use in a ddRNAi construct of the disclosure are describedin U.S. Pat. No. 8,008,468.

In a further example, a ddRNAi construct of the disclosure may comprisea transcriptional terminator linked to a nucleic acid encoding a shmiRor shRNA of the disclosure. In the case of a ddRNAi construct comprisinga plurality of nucleic acids described herein i.e., encoding multipleshmiRs and/or shRNAs, the terminators linked to each nucleic acid can bethe same or different. For example, in a ddRNAi construct of thedisclosure in which a RNA pol III promoter is employed, the terminatormay be a contiguous stretch of 4 or more or 5 or more or 6 or more Tresidues. However, where different promoters are used, the terminatorscan be different and are matched to the promoter from the gene fromwhich the terminator is derived. Such terminators include, but are notlimited to, the SV40 poly A, the AdV VA1 gene, the 5S ribosomal RNAgene, and the terminators for human t-RNAs. Other promoter andterminator combinations are known in the art and are contemplated foruse in a ddRNAi construct of the disclosure.

In addition, promoters and terminators may be mixed and matched, as iscommonly done with RNA pol II promoters and terminators.

In one example, the promoter and terminator combinations used for eachnucleic acid in a ddRNAi construct comprising a plurality of nucleicacids is different to decrease the likelihood of DNA recombinationevents between components.

One exemplary ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR13 asdescribed herein operably linked to a promoter, and a nucleic acidcomprising or consisting of a DNA sequence encoding shmiR17 as describedherein operably linked to a promoter. For example, an exemplary ddRNAiconstruct of the disclosure comprises a nucleic acid comprising orconsisting of a DNA sequence set forth in SEQ ID NO: 64 operably linkedto a promoter, and a nucleic acid comprising or consisting of a DNAsequence set forth in SEQ ID NO: 68 operably linked to a promoter. Inone example, each nucleic acid in the ddRNAi construct encoding a shmiRis operably linked to a separate promoter. In another example, eachnucleic acid in the ddRNAi construct encoding a shmiR is operably linkedto the same promoter. For example, the or each promoter may be a U6promoter e.g., a U6-1, U6-8 or U6-9 promoter. For example, the or eachpromoter may be a muscle specific promoter e.g., a Spc512 or CK8promoter.

In accordance with an example in which the nucleic acids in the ddRNAiconstruct encoding shmiR13 and shmiR17 are operably-linked to the sameSpc512 promoter, the ddRNAi construct comprises or consists of the DNAsequence set forth in SEQ ID NO: 72. In accordance with an example inwhich the nucleic acids in the ddRNAi construct encoding shmiR13 andshmiR17 are operably-linked to the same CK8 promoter, the ddRNAiconstruct comprises or consists of the DNA sequence set forth in SEQ IDNO: 70.

Another exemplary ddRNAi construct of the disclosure comprises a nucleicacid comprising or consisting of a DNA sequence encoding shmiR3 asdescribed herein operably linked to a promoter, and a nucleic acidcomprising or consisting of a DNA sequence encoding shmiR14 as describedherein operably linked to a promoter. For example, an exemplary ddRNAiconstruct of the disclosure comprises a nucleic acid comprising orconsisting of a DNA sequence set forth in SEQ ID NO: 57 operably linkedto a promoter, and a nucleic acid comprising or consisting of a DNAsequence set forth in SEQ ID NO: 65 operably linked to a promoter. Inone example, each nucleic acid in the ddRNAi construct encoding a shmiRis operably linked to a separate promoter. In another example, eachnucleic acid in the ddRNAi construct encoding a shmiR is operably linkedto the same promoter. For example, the or each promoter may be a U6promoter e.g., a U6-1, U6-8 or U6-9 promoter. For example, the or eachpromoter may be a muscle specific promoter e.g., a Spc512 or CK8promoter.

In accordance with an example in which the nucleic acids in the ddRNAiconstruct encoding shmiR3 and shmiR14 are operably-linked to the sameSpc512 promoter, the ddRNAi construct comprises or consists of the DNAsequence set forth in SEQ ID NO: 71. In accordance with an example inwhich the nucleic acids in the ddRNAi construct encoding shmiR3 andshmiR14 are operably-linked to the same CK8 promoter, the ddRNAiconstruct comprises or consists of the DNA sequence set forth in SEQ IDNO: 69.

Also provided is a plurality of ddRNAi constructs. For example, aplurality of nucleic acids as encoding shmiRs as described herein may beprovided within a plurality of ddRNAi constructs, wherein each ddRNAiconstruct comprises one or more of the plurality of nucleic acidsdescribed herein. Combinations of nucleic acids encoding shmiR have beendescribed and shall be taken to apply mutatis mutandis to this exampleof the disclosure. In one example, each nucleic acid in the plurality ofnucleic acids described herein is provided within its own ddRNAiconstruct.

According to any example in which a plurality of ddRNAi constructs isprovided, each ddRNAi construct may also comprise one or more promotersoperably linked to the nucleic acid(s) encoding the shmiR(s) comprisedtherein. In one example, each ddRNAi construct comprises a singlenucleic acid encoding a shmiR and a promoter operably linked thereto.According to an example in which one or more of the plurality of ddRNAiconstructs comprises two or more nucleic acid encoding shmiRs, eachnucleic acid in the one or more ddRNAi constructs is operably linked toa separate promoter. In another example in which one or more of theplurality of ddRNAi constructs comprises two or more nucleic acidencoding shmiRs, the two or more nucleic acids are operably linked tothe same promoter in the ddRNAi construct.

One exemplary plurality of ddRNAi constructs of the disclosure comprisesa ddRNAi construct comprising a nucleic acid comprising or consisting ofa DNA sequence encoding shmiR13 as described herein operably linked to apromoter, and a ddRNAi construct comprising a nucleic acid comprising orconsisting of a DNA sequence encoding shmiR17 as described hereinoperably linked to a promoter. For example, an exemplary plurality ofddRNAi constructs of the disclosure comprises a ddRNAi constructcomprising a nucleic acid comprising or consisting of a DNA sequence setforth in SEQ ID NO: 64 operably linked to a promoter, and a ddRNAiconstruct comprising a nucleic acid comprising or consisting of a DNAsequence set forth in SEQ ID NO: 68 operably linked to a promoter. Inone example, the promoters are U6 promoters e.g., selected from a U6-1,U6-8 or U6-9 promoter. In another example, the promoters are musclespecific promoters e.g., Spc512 or CK8 promoters.

Another exemplary plurality of ddRNAi constructs of the disclosurecomprises a ddRNAi construct comprising a nucleic acid comprising orconsisting of a DNA sequence encoding shmiR3 as described hereinoperably linked to a promoter, and a ddRNAi construct comprising anucleic acid comprising or consisting of a DNA sequence encoding shmiR14as described herein operably linked to a promoter. For example, anexemplary plurality of ddRNAi constructs of the disclosure comprises addRNAi construct comprising a nucleic acid comprising or consisting of aDNA sequence set forth in SEQ ID NO: 57 operably linked to a promoter,and a ddRNAi construct comprising a nucleic acid comprising orconsisting of a DNA sequence set forth in SEQ ID NO: 65 operably linkedto a promoter. In one example, the promoters are U6 promoters e.g.,selected from a U6-1, U6-8 or U6-9 promoter. In another example, thepromoters are muscle specific promoters e.g., Spc512 or CK8 promoters.

In addition, the or each ddRNAi construct can comprise one or moremultiple cloning sites and/or unique restriction sites that are locatedstrategically, such that the promoter, nucleic acid encoding the shmiRor shRNA and/or other regulator elements are easily removed or replaced.The or each ddRNAi construct can be assembled from smalleroligonucleotide components using strategically located restriction sitesand/or complementary sticky ends. The base vector for one approachaccording to the present disclosure comprises plasmids with amultilinker in which all sites are unique (though this is not anabsolute requirement). Sequentially, each promoter is inserted betweenits designated unique sites resulting in a base cassette with one ormore promoters, all of which can have variable orientation.Sequentially, again, annealed primer pairs are inserted into the uniquesites downstream of each of the individual promoters, resulting in asingle-, double- or multiple-expression cassette construct. The insertcan be moved into e.g., an AdV backbone or an AAV backbone using twounique restriction enzyme sites (the same or different ones) that flankthe single-, double- or multiple-expression cassette insert.

Generation of the or each ddRNAi construct can be accomplished using anysuitable genetic engineering techniques known in the art, includingwithout limitation, the standard techniques of PCR, oligonucleotidesynthesis, restriction endonuclease digestion, ligation, transformation,plasmid purification, and DNA sequencing. If the or each construct is aviral construct, the construct comprises, for example, sequencesnecessary to package the ddRNAi construct into viral particles and/orsequences that allow integration of the ddRNAi construct into the targetcell genome. In some examples, the or each viral construct additionallycontains genes that allow for replication and propagation of virus,however such genes will be supplied in trans. Additionally, the or eachviral construct cam contain genes or genetic sequences from the genomeof any known organism incorporated in native form or modified. Forexample, a viral construct may comprise sequences useful for replicationof the construct in bacteria.

The or each construct also may contain additional genetic elements. Thetypes of elements that may be included in the construct are not limitedin any way and may be chosen by one with skill in the art. For example,additional genetic elements may include a reporter gene, such as one ormore genes for a fluorescent marker protein such as GFP or RFP; aneasily assayed enzyme such as beta-galactosidase, luciferase,beta-glucuronidase, chloramphenical acetyl transferase or secretedembryonic alkaline phosphatase; or proteins for which immunoassays arereadily available such as hormones or cytokines.

Other genetic elements that may find use in embodiments of the presentdisclosure include those coding for proteins which confer a selectivegrowth advantage on cells such as adenosine deaminase, aminoglycodicphosphotransferase, dihydrofolate reductase,hygromycin-B-phosphotransferase, drug resistance, or those genes codingfor proteins that provide a biosynthetic capability missing from anauxotroph. If a reporter gene is included along with the or eachconstruct, an internal ribosomal entry site (IRES) sequence can beincluded. In one example, the additional genetic elements are operablylinked with and controlled by an independent promoter/enhancer. Inaddition a suitable origin of replication for propagation of theconstruct in bacteria may be employed. The sequence of the origin ofreplication generally is separated from the ddRNAi construct and othergenetic sequences. Such origins of replication are known in the art andinclude the pUC, ColE1, 2-micron or SV40 origins of replication.

Expression Vectors

In one example, a ddRNAi construct of the disclosure is included withinan expression vector.

In one example, the expression vector is a plasmid e.g., as is known inthe art. In one example, a suitable plasmid expression vector is a pAAVvector e.g., a self-complementary pAAV (pscAAV) plasmid vector orsingle-stranded pAAV (pssAAV) plasmid vector. As described herein, theplasmid may comprise one or more promoters (suitable examples of whichare described) to drive expression of one or more shmiRs of thedisclosure.

In one example, the expression vector is mini-circle DNA. Mini-circleDNA is described in U.S. Patent Publication No. 2004/0214329.Mini-circle DNA are useful for persistently high levels of nucleic acidtranscription. The circular vectors are characterized by being devoid ofexpression-silencing bacterial sequences. For example, mini-circlevectors differ from bacterial plasmid vectors in that they lack anorigin of replication, and lack drug selection markers commonly found inbacterial plasmids, e.g. β-lactamase, tet, and the like. Consequently,minicircle DNA becomes smaller in size, allowing more efficientdelivery.

In one example, the expression vector is a viral vector.

A viral vector based on any appropriate virus may be used to deliver addRNAi of the disclosure. In addition, hybrid viral systems may be ofuse. The choice of viral delivery system will depend on variousparameters, such as the tissue targeted for delivery, transductionefficiency of the system, pathogenicity, immunological and toxicityconcerns, and the like.

Commonly used classes of viral systems used in gene therapy can becategorized into two groups according to whether their genomes integrateinto host cellular chromatin (oncoretroviruses and lentiviruses) orpersist in the cell nucleus predominantly as extrachromosomal episomes(adeno-associated virus, adenoviruses and herpesviruses). In oneexample, a viral vector of the disclosure integrates into a host cell'schromatin. In another example, a viral vector of the disclosure persistsin a host cell's nucleus as an extrachomosomal episome.

In one example, a viral vector is an adenoviral (AdV) vector.Adenoviruses are medium-sized double-stranded, non-enveloped DNA viruseswith linear genomes that is between 26-48 Kbp. Adenoviruses gain entryto a target cell by receptor-mediated binding and internalization,penetrating the nucleus in both non-dividing and dividing cells.Adenoviruses are heavily reliant on the host cell for survival andreplication and are able to replicate in the nucleus of vertebrate cellsusing the host's replication machinery.

In one example, a viral vector is from the Parvoviridae family. TheParvoviridae is a family of small single-stranded, non-enveloped DNAviruses with genomes approximately 5000 nucleotides long. Included amongthe family members is adeno-associated virus (AAV). In one example, aviral vector of the disclosure is an AAV. AAV is a dependent parvovirusthat generally requires co-infection with another virus (typically anadenovirus or herpesvirus) to initiate and sustain a productiveinfectious cycle. In the absence of such a helper virus, AAV is stillcompetent to infect or transduce a target cell by receptor-mediatedbinding and internalization, penetrating the nucleus in bothnon-dividing and dividing cells. Because progeny virus is not producedfrom AAV infection in the absence of helper virus, the extent oftransduction is restricted only to the initial cells that are infectedwith the virus. It is this feature which makes AAV a desirable vectorfor the present disclosure. Furthermore, unlike retrovirus, adenovirus,and herpes simplex virus, AAV appears to lack human pathogenicity andtoxicity (Kay, et al., Nature. 424: 251 (2003)). Since the genomenormally encodes only two genes it is not surprising that, as a deliveryvehicle, AAV is limited by a packaging capacity of 4.5 single strandedkilobases (kb). However, although this size restriction may limit thegenes that can be delivered for replacement gene therapies, it does notadversely affect the packaging and expression of shorter sequences suchas shmiRs and shRNAs.

Another viral delivery system useful with the ddRNAi constructs of thedisclosure is a system based on viruses from the family Retroviridae.Retroviruses comprise single-stranded RNA animal viruses that arecharacterized by two unique features. First, the genome of a retrovirusis diploid, consisting of two copies of the RNA. Second, this RNA istranscribed by the virion-associated enzyme reverse transcriptase intodouble-stranded DNA. This double-stranded DNA or provirus can thenintegrate into the host genome and be passed from parent cell to progenycells as a stably-integrated component of the host genome.

In some examples, a viral vector is a lentivirus. Lentivirus vectors areoften pseudotyped with vesicular somatitis virus glycoprotein (VSV-G),and have been derived from the human immunodeficiency virus (HIV);visan-maedi, which causes encephalitis (visna) or pneumonia in sheep;equine infectious anemia virus (EIAV), which causes autoimmune hemolyticanemia and encephalopathy in horses; feline immunodeficiency virus(FIV), which causes immune deficiency in cats; bovine immunodeficiencyvirus (BIV) which causes lymphadenopathy and lymphocytosis in cattle;and simian immunodeficiency virus (SIV), which causes immune deficiencyand encephalopathy in non-human primates. Vectors that are based on HIVgenerally retain <5% of the parental genome, and <25% of the genome isincorporated into packaging constructs, which minimizes the possibilityof the generation of reverting replication-competent HIV. Biosafety hasbeen further increased by the development of self-inactivating vectorsthat contain deletions of the regulatory elements in the downstreamlong-terminal-repeat sequence, eliminating transcription of thepackaging signal that is required for vector mobilization. One of themain advantages to the use of lentiviral vectors is that gene transferis persistent in most tissues or cell types, even following celldivision of the transduced cell.

A lentiviral-based construct used to express shmiRs and/or shRNAs fromthe nucleic acids and ddRNAi constructs of the disclosure comprisessequences from the 5′ and 3′ long terminal repeats (LTRs) of alentivirus. In one example, the viral construct comprises an inactivatedor self-inactivating 3′ LTR from a lentivirus. The 3′ LTR may be madeself-inactivating by any method known in the art. For example, the U3element of the 3′ LTR contains a deletion of its enhancer sequence,e.g., the TATA box, Sp1 and NF-kappa B sites. As a result of theself-inactivating 3′ LTR, the provirus that is integrated into the hostgenome will comprise an inactivated 5′ LTR. The LTR sequences may be LTRsequences from any lentivirus from any species. The lentiviral-basedconstruct also may incorporate sequences for MMLV or MSCV, RSV ormammalian genes. In addition, the U3 sequence from the lentiviral 5′ LTRmay be replaced with a promoter sequence in the viral construct. Thismay increase the titer of virus recovered from the packaging cell line.An enhancer sequence may also be included.

Other viral or non-viral systems known to those skilled in the art maybe used to deliver the ddRNAi or nucleic acid of the present inventionto cells of interest, including but not limited to gene-deletedadenovirus-transposon vectors (see Yant, et al., Nature Biotech.20:999-1004 (2002)); systems derived from Sindbis virus or Semlikiforest virus (see Perri, et al, J. Virol. 74(20):9802-07 (2002));systems derived from Newcastle disease virus or Sendai virus.

Testing a shmiR or ddRNAi Construct of the Disclosure

Cell Culture Models

An example of cell line useful as a cell culture model for OPMD is theHEK293T cell line (HEK293T, ATCC, Manassas, USA) which has beentransfected with a vector expressing normal Ala10-humanPABPN1-FLAG(Ala10) or mutant Ala17-humanPABPN1-FLAG (Ala17), the latter beinghallmark of OPMD.

Further examples of cell lines useful as cell culture models for OPMDare the C2C12 mouse muscle cell and the ARPE-19 human retinal cellse.g., as described in Example 5

Another example of a cell line useful as a cell culture model for OPMDis the primary mouse myoblast (IM2) cell line stably transfected toexpress either normal Ala10-humanPABPN1-FLAG (Ala10) or mutantAla17-humanPABPN1-FLAG (Ala17). An exemplary IM2 derived cell line whichstably expresses mutant Ala17-humanPABPN1-FLAG (Ala17) is the H2 kB-D7ecell line. The H2 kB-D7e cell line is also described in Raz et al.,(2011) American Journal of Pathology, 179(4):1988-2000.

Other cell lines suitable for cell culture models of OPMD are known inthe art, such as described in Fan et al., (2001) Human MolecularGenetics, 10:2341-2351, Bao et al., (2002) The Journal of BiologicalChemistry, 277:12263-12269, and Abu-Baker et al., (2003) Human MolecularGenetics, 12:2609-2623.

As exemplified herein, activity of a shmiR of the disclosure isdetermined by administering a nucleic acid encoding the shmiR, or addRNAi construct or expression vector comprising same, to the cell andsubsequently measuring the level of expression of a RNA or proteinencoded by the PABPN1 gene. For example, intracellular PABPN1 geneexpression can be assayed by any one or more of RT-PCR, quantitativePCR, semi-quantitative PCR, or in-situ hybridization under stringentconditions, using one or more probes or primers which are specific forPABPN1. PABPN1 mRNA or DNA can also be assayed either by PCR using oneor more probes or primers which are specific for PABPN1 or ELISA can beused to detect PABPN1 protein.

Polynucleotides which may be used in RT-PCR, quantitative PCR orsemi-quantitative PCR techniques for detecting PABPN1 expression areknown and commercially available (Thermo Fisher). However,polynucleotides useful for PCR-based detection methods can be designedbased on sequence information available for PABPN1 using method and/orsoftware known in the art. In one example, the presence or absence ofPABPN1 mRNA may be detected using RT-PCR using standard methodologiesknown in the art. In one example, the presence or absence or relativeamount of PABPN1 polypeptide or protein may be detected using any one ormore of Western blotting, ELISA, or other standard quantitative orsemiquantitative techniques available in the art, or a combination ofsuch techniques. Techniques relying on antibody recognition of PABPN1are contemplated and are described herein e.g., in Example 4. In oneexample, the presence or absence or relative abundance of PABPN1polypeptide may be detected with techniques which comprise antibodycapture of PABPN1 polypeptides in combination with electrophoreticresolution of captured PABPN1 polypeptides, for example using theIsonostic™ Assay (Target Discovery, Inc.). Antibodies are commerciallyavailable for PABPN1 protein.

Various means for normalizing differences in transfection ortransduction efficiency and sample recovery are known in the art.

A nucleic acid, ddRNAi construct or expression vector of the disclosurethat reduces expression of a mRNA or protein encoded by PABPN1 or thatreduces the presence of nuclear aggregates of PABPN1 protein, relativeto a level of mRNA expression or protein encoded by PABPN1 or an amountof nuclear aggregates of PABPN1 protein in the absence of the RNA of thedisclosure, is considered to be useful for therapeutic applicationse.g., such as treating OPMD by reducing expression of endogenous PABPN1and replacing some or all of the endogenous PABPN1 with a PABPN1 proteinwhich is not causative of OPMD as described herein.

Animal Models

There are several small animal models available for studying OPMD,examples of which are described in Uyama et al., (2005) Acta Myologica,24(2):84-88 and Chartier and Simonelig (2013) Drug Discovery Today:technologies, 10:e103-107. An exemplary animal model is the A17.1transgenic mouse model which has been described previously in Davies etal., (2005) Nature Medicine, 11:672-677 and Trollet et al., (2010) HumanMolecular Genetics, 19(11):2191-2207.

Any of the foregoing animal models can be used to determine the efficacyof a shmiR or ddRNAi construct of the disclosure to knockdown, reduce orinhibit expression of a RNA or protein encoded by the PABPN1 gene.

Methods for assaying PABPN1 gene expression have been described hereinwith respect to cell models and shall be taken to apply mutatis mutandisto this example of the disclosure.

Agents for Replacement of Functional PABPN1

In one example, the present disclosure provides an agent for replacementof functional PABPN1 protein e.g., to a cell or animal. The functionalPABPN1 protein will not be causative of OPMD, nor will it be encoded bya mRNA transcript which is targeted by the shmiR(s) or shRNA(s) of thedisclosure.

In one example, the agent for replacement of functional PABPN1 proteinto a cell or animal is a nucleic acid e.g., such as DNA or cDNA,encoding the functional PABPN1 protein. For example, the nucleic acidencoding the functional PABPN1 protein may be codon optimised e.g.,contain one or more degenerate or wobble bases relative to the wild typePABPN1 nucleic acid but which encodes for identical amino acids, so thatthe corresponding mRNA sequence coding for the functional PABPN1 proteinis not recognised by the shmiR(s) or shRNA(s) of the disclosure. Forexample, a codon optimised nucleic acid encoding the functional PABPN1protein may comprise one or more degenerate or wobble bases relative tothe wild type PABPN1 nucleic acid within the region targeted by theshmiR(s) or shRNA(s) of the disclosure. In one example, the one or moredegenerate or wobble bases resides within a seed region of an effectorsequence a shmiR or shRNA of the disclosure.

In one example, a nucleic acid encoding the functional PABPN1 protein iscodon optimised such that its corresponding mRNA sequence is notrecognised by the shmiR(s) or shRNA(s) of the disclosure. Preferably,the functional PABPN1 protein encoded by the codon optimised nucleicacid sequence comprises the amino acid sequence set forth in SEQ ID NO:74 i.e., the amino acid sequence of the wild-type human PABPN1 protein.A skilled person will appreciate that there are a number of nucleotidesequence combinations which may be used to encode functional PABPN1protein, and the choice of nucleotide sequence will ultimately depend onthe effector sequence of the shmiR(s) or shRNA(s) i.e., such that thecodon-optimised nucleic acid is not recognised by the shmiR(s) orshRNA(s). In one example, the agent for replacement of functional PABPN1protein is a nucleic acid comprising the sequence set forth in SEQ IDNO: 73. In one example, the nucleic acid encoding the functional PABPN1protein may also comprise a Kozak sequence.

In one example, the codon-optimised nucleic acid encoding the functionalPABPN1 protein is operably-linked to a promoter suitable for expressionof the functional PABPN1 protein. Promoters suitable for expression ofthe functional PABPN1 protein in tissue or the eye or muscle may beparticularly suitable. One exemplary promoter suitable for use with thenucleic acid encoding the functional PABPN1 protein is a Spc512promoter. Another exemplary promoter suitable for use with the nucleicacid encoding the functional PABPN1 protein is a CK8 promoter. However,any suitable promoter known in the art may be used. For example, othersuitable promoters for use with the nucleic acid encoding the functionalPABPN1 protein are described in US 20110212529 A1.

As described herein, promoters useful in some examples of the presentdisclosure can be tissue-specific or cell-specific.

In one example, a codon-optimised nucleic acid encoding the functionalPABPN1 protein of the disclosure may additionally comprise one or moreenhancers to increase expression of the functional PABPN1 protein andits corresponding mRNA transcript. Enhancers appropriate for use in thisexample of the present disclosure will be known to those skilled in theart.

A nucleic acid encoding the functional PABPN1 protein may be comprisedwithin an expression vector. Exemplary expression vectors have beendescribed in the context of nucleic acid and ddRNAi constructs of thedisclosure and shall be taken to apply mutatis mutandis to this example.

Accordingly, in one example, an agent for replacement of functionalPABPN1 protein to a cell or animal may be an expression vectorcomprising a codon-optimised nucleic acid encoding the functional PABPN1protein. For example, an expression vector of the disclosure maycomprise the codon-optimised nucleic acid encoding the functional PABPN1protein and a promoter for expression therefor e.g., a SpC512 promoteror a CK8 promoter. In one example, the codon optimised nucleic acidencoding the functional PABPN1 protein may also comprise a Kozaksequence.

In one example, the nucleic acid encoding the functional PABPN1 proteinas described herein may be comprised within a plasmid expression vector.Suitable plasmid expression vectors have been described herein and willbe known in the art. In one example, a suitable plasmid expressionvector is a pAAV vector e.g., a pscAAV plasmid vector or pssAAV plasmidvector.

In one example, the expression vector is mini-circle DNA. Mini-circleDNA vectors have been described herein.

In one example, the expression vector is a viral vector. For example, aviral vector based on any appropriate virus may be used to deliver acodon optimised nucleic acid encoding the functional PABPN1 protein ofthe disclosure. In addition, hybrid viral systems may be of use. Thechoice of viral delivery system will depend on various parameters, suchas the tissue targeted for delivery, transduction efficiency of thesystem, pathogenicity, immunological and toxicity concerns, and thelike.

Exemplary viral systems for delivery of genetic material to a cell oranimal have been described in the context of the RNAs and ddRNAiconstructs of the disclosure and shall be taken to apply mutatismutandis to this example.

In one example, the viral vector is an AAV.

In one example, the viral vector is an AdV vector.

In one example, the viral vector is a lentivirus.

Other viral or non-viral systems known to those skilled in the art maybe used to deliver the codon-optimised nucleic acid encoding functionalPABPN1 protein of the present disclosure to cells of interest, includingbut not limited to gene-deleted adenovirus-transposon vectors (see Yant,et al., Nature Biotech. 20:999-1004 (2002)); systems derived fromSindbis virus or Semliki forest virus (see Perri, et al, J. Virol.74(20):9802-07 (2002)); systems derived from Newcastle disease virus orSendai virus.

In accordance with an example in which the codon-optimised nucleic acidencoding the functional PABPN1 protein as described herein is providedwith a nucleic acid, ddRNAi construct or expression vector of thedisclosure, the codon-optimised nucleic acid encoding the functionalPABPN1 protein may be comprised within the same expression vector as thenucleic acid or ddRNAi construct. Thus, the codon-optimised nucleic acidencoding the functional PABPN1 protein and the nucleic acid or ddRNAiconstruct of the disclosure may be provided as a single DNA constructe.g., within an expression vector.

In an alternative example in which a codon-optimised nucleic acidencoding functional PABPN1 protein of the disclosure and a nucleic acidor ddRNAi construct of the disclosure are to be provided together, thecodon-optimised nucleic acid encoding functional PABPN1 protein and thenucleic acid or ddRNAi construct may be comprised within differentexpression vectors. Where the codon-optimised nucleic acid encodingfunctional PABPN1 protein and the nucleic acid or ddRNAi construct arecomprised within different expression vectors, the respective expressionvectors may be the same type of vector or be different types of vectors.

Testing for Functional PABPN1

Cell Culture Models

Exemplary cell culture models of OPMD have been described herein,including in the working examples e.g., Examples 4 and 5. Such cellculture models of OPMD may be used for assessing the ability of an agentof the disclosure to replace functional PABPN1 protein in the presenceof one or more nucleic acids encoding shmiRs of the disclosure targetingendogenous PABPN1.

Exemplary methods of detecting the presence or absence or relativeamount of PABPN1 protein have also been described and apply mutatismutandis to this example. For example, the presence or absence orrelative amount of PABPN1 protein may be detected using any one or moreof Western blotting, ELISA, or other standard quantitative orsemiquantitative techniques available in the art, or a combination ofsuch techniques. Techniques relying on antibody recognition of PABPN1are contemplated and are described herein. The mutant and functionalPABPN1 proteins may be expressed with appropriate protein tags e.g., mycor flag tags, to facilitate differential detection of mutant andfunctional PABPN1 proteins using appropriate antibodies which arecommercially available. For example, the mutant human PABPN1 protein maybe expressed with a FLAG tag. In this way, the presence or absence orrelative amount of both mutant and functional PABPN1 protein may bedetected independently in a cell following transfection or transductionof the cell with one or more nucleic acid(s), ddRNAi construct(s) orexpression vector(s) of the disclosure and an agent for replacingfunctional PABPN1 protein of the disclosure (which may be providedseparately or together as described herein).

In one example, the presence or absence or relative abundance of PABPN1polypeptide may be detected with techniques which comprise antibodycapture of PABPN1 polypeptides in combination with electrophoreticresolution of captured PABPN1 polypeptides, for example using theIsonostic™ Assay (Target Discovery, Inc.). Antibodies are commerciallyavailable for PABPN1 protein.

An agent of the disclosure that expresses a PABPN1 protein which is notcausative of OPMD in a cell in the presence of the nucleic acid(s),ddRNAi construct(s) or expression vector(s) of the disclosure(expressing one or more shmiR(s) of the disclosure) is considered to beuseful for treating OPMD.

Animal Models

Exemplary animal models for studying OPMD have been described.

Any of the foregoing animal models can be used to determine the efficacyof an agent of the disclosure to replace functional PABPN1 protein invivo in the presence of one or more nucleic acid(s), ddRNAi construct(s)or expression vector(s) of the disclosure (expressing one or moreshmiR(s) of the disclosure).

Methods for assaying PABPN1 expression have been described herein withrespect to cell models and shall be taken to apply mutatis mutandis tothis example of the disclosure.

In one example, histological and morphological analyses may be used todetermine the efficacy of an agent of the disclosure to replacefunctional PABPN1 protein in vivo in the presence one or more nucleicacid(s), ddRNAi construct(s) or expression vector(s) of the disclosure(expressing one or more shmiR(s) of the disclosure). Further assayswhich may be used to determine efficacy of an agent of the disclosure toreplace functional PABPN1 protein in vivo are described in Trollet etal., (2010) Human Molecular Genetics, 19(11): 2191-2207.

Single DNA Constructs for ddRNAi and Replacement of Functional PABPN1

The present disclosure also provides a single DNA construct comprisingthe nucleic acid encoding the functional PABPN1 protein as describedherein and one or more ddRNAi construct(s) of the disclosure. Anexemplary DNA construct comprising a nucleic acid encoding thefunctional PABPN1 protein and the ddRNAi construct of the disclosure isdescribed in Example 7. In one example, the DNA construct may comprise asingle ddRNAi construct as described herein in combination with thenucleic acid encoding the functional PABPN1 protein. In another example,the DNA construct may comprise a plurality of ddRNAi constructs incombination with the nucleic acid encoding the functional PABPN1protein. In each example of the DNA construct, the DNA sequence encodingthe functional PABPN1 protein is codon optimised such that its mRNAtranscript is not targeted by the shmiR(s) of the ddRNAi construct(s).

In one example, functional PABPN1 protein is a wild-type human PABPN1protein e.g., having a sequence set forth in SEQ ID NO: 74. It will beappreciated that the codon optimised DNA sequence encoding thefunctional PABPN1 protein may vary depending on the shmiR(s) encoded bythe ddRNAi construct. That is, the specific codons within the PABPN1mRNA transcript to be modified may vary depending on the effectorsequence(s) of shmiR(s) encoded by the ddRNAi construct. In one examplea codon optimised DNA sequence encoding the functional PABPN1 protein isset forth in SEQ ID NO: 73.

The DNA construct may also comprise one or more promoters e.g., to driveexpression of the functional PABPN1 protein and/or shmiRs encoded by theddRNAi construct. Promoters useful in some examples of the presentdisclosure can be tissue-specific or cell-specific. Exemplary promotersfor use in the DNA constructs of the disclosure are muscle-specificpromoter, such as for example, Spc512 and CK8. However, any suitablepromoter known in the art is contemplated for use in the DNA constructdescribed herein e.g., such as those described in US 20110212529 A1.

The DNA construct may be provided in the form of an expression vector ormay be comprised within an expression vector. Suitable expressionvectors have been described herein and will be known in the art.

In one example, the expression vector is a viral vector. For example, aviral vector based on any appropriate virus may be used to deliver thesingle DNA construct of the disclosure. In addition, hybrid viralsystems may be of use. The choice of viral delivery system will dependon various parameters, such as the tissue targeted for delivery,transduction efficiency of the system, pathogenicity, immunological andtoxicity concerns, and the like.

In another example, a suitable plasmid expression vector is a pAAVvector e.g., a pscAAV plasmid vector or pssAAV plasmid vector. Otherexemplary viral systems for delivery of genetic material to a cell oranimal have been described in the context of the ddRNAi constructs ofthe disclosure and shall be taken to apply mutatis mutandis to thisexample.

In one example, the DNA construct is provided in the form of a pAAVexpression vector comprising, in a 5′ to 3′ direction, a muscle-specificpromoter e.g., a Spc512 promoter, a ddRNAi construct as described hereinand a PABPN1 construct described herein, e.g., wherein the ddRNAiconstruct is positioned in the 3′ untranslated region (UTR) of nucleicacid encoding the functional PABPN1 protein. A DNA construct inaccordance with this example is illustrated in FIG. 12A.

An exemplary DNA construct in accordance with this example is a pAAVexpression vector comprising, in a 5′ to 3′ direction:

(a) a muscle-specific promoter e.g., Spc512;

(b) a PABPN1 construct as described herein comprising a DNA sequenceencoding a functional PABPN1 protein having a mRNA transcript which isnot targeted by the shmiRs encoded by the ddRNAi construct; and

(c) a ddRNAi construct of the disclosure comprising a nucleic acidcomprising a DNA sequence encoding shmiR17 as described herein and anucleic acid comprising a DNA sequence encoding shmiR13 as describedherein.

In accordance with this example, the DNA construct may comprise orconsist of the DNA sequence set forth in SEQ ID NO: 72.

Another exemplary DNA construct in accordance with this example is apAAV expression vector comprising, in a 5′ to 3′ direction:

(a) a muscle-specific promoter e.g., Spc512;

(b) a PABPN1 construct as described herein comprising a DNA sequenceencoding a functional PABPN1 protein having a mRNA transcript which isnot targeted by the shmiRs encoded by the ddRNAi construct; and

(c) a ddRNAi construct of the disclosure comprising a nucleic acidcomprising a DNA sequence encoding shmiR3 as described herein and anucleic acid comprising a DNA sequence encoding shmiR14 as describedherein.

In accordance with this example, DNA construct may comprise or consistof the DNA sequence set forth in SEQ ID NO: 71.

In another example, the DNA construct is provided in the form of a pAAVexpression vector comprising, in a 5′ to 3′ direction, a firstmuscle-specific promoter e.g., a CK8 promoter, a PABPN1 construct asdescribed herein, a second muscle-specific promoter e.g., a Spc512promoter, and a ddRNAi construct as described herein, wherein the firstand second muscle-specific promoters are in operable linkage with thePABPN1 construct and the ddRNAi construct respectively. A DNA constructin accordance with this example is illustrated in FIG. 12B. For example,the promoter which is in operable linkage with the PABPN1 construct willbe operably linked to the DNA sequence encoding a functional PABPN1protein comprised therein, the promoter which is in operable linkagewith the ddRNAi construct will be operably-linked with one or morenucleic acids encoding a shmiR of the disclosure. A DNA construct inaccordance with this example is illustrated in FIG. 12A.

An exemplary DNA construct in accordance with this example is a pAAVexpression vector comprising, in a 5′ to 3′ direction:

(a) a muscle-specific promoter e.g., CK8 promoter, positioned upstreamof a ddRNAi construct of the disclosure comprising a nucleic acidcomprising a DNA sequence encoding shmiR17 as described herein and anucleic acid comprising a DNA sequence encoding shmiR13 as describedherein; and(b) a muscle-specific promoter e.g., Spc512 promoter, positionedupstream of a PABPN1 construct as described herein comprising a DNAsequence encoding a functional PABPN1 protein having a mRNA transcriptwhich is not targeted by the shmiRs encoded by the ddRNAi construct.

In accordance with this example, the DNA construct may comprise orconsist of the DNA sequence set forth in SEQ ID NO: 70.

Another exemplary DNA construct in accordance with this example is apAAV expression vector comprising, in a 5′ to 3′ direction:

(a) a muscle-specific promoter e.g., CK8 promoter, positioned upstreamof a ddRNAi construct of the disclosure comprising a nucleic acidcomprising a DNA sequence encoding shmiR3 as described herein and anucleic acid comprising a DNA sequence encoding shmiR14 as describedherein; and(b) a muscle-specific promoter e.g., Spc512 promoter, positionedupstream of a PABPN1 construct as described herein comprising a DNAsequence encoding a functional PABPN1 protein having a mRNA transcriptwhich is not targeted by the shmiRs encoded by the ddRNAi construct.

In accordance with this example, the DNA construct may comprise orconsist of the DNA sequence set forth in SEQ ID NO: 69.

An exemplary ddRNAi construct encoding shmiR13 and shmiR17 for inclusionin a DNA construct of the disclosure comprises a nucleic acid comprisingor consisting of a DNA sequence encoding a shmiR comprising an effectorsequence set forth in SEQ ID NO: 31 and an effector complement sequencewhich is substantially complementary to the sequence set forth in SEQ IDNO: 31 e.g., an effector complement sequence set forth in SEQ ID NO: 30(shmiR13), and a nucleic acid comprising or consisting of a DNA sequenceencoding a shmiR comprising an effector sequence set forth in SEQ ID NO:39 and an effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO: 39 e.g., aneffector complement sequence set forth in SEQ ID NO: 38 (shmiR17). Forexample, the ddRNAi construct in accordance with this example of the DNAconstruct may comprise a nucleic acid comprising or consisting of theDNA sequence set forth in SEQ ID NO: 64 (shmiR13), and a nucleic acidcomprising or consisting of the DNA sequence set forth in SEQ ID NO: 68(shmiR17).

An exemplary ddRNAi construct encoding shmiR3 and shmiR14 for inclusionin a DNA construct of the disclosure comprises a nucleic acid comprisingor consisting of a DNA sequence encoding a shmiR comprising an effectorsequence set forth in SEQ ID NO: 17 and an effector complement sequencewhich is substantially complementary to the sequence set forth in SEQ IDNO: 17 e.g., an effector complement sequence set forth in SEQ ID NO: 16(shmiR3), and a nucleic acid comprising or consisting of a DNA sequenceencoding a shmiR comprising an effector sequence set forth in SEQ ID NO:33 and an effector complement sequence which is substantiallycomplementary to the sequence set forth in SEQ ID NO: 33 e.g., aneffector complement sequence set forth in SEQ ID NO: 34 (shmiR14). Forexample, the ddRNAi construct in accordance with this example of the DNAconstruct may comprise a nucleic acid comprising or consisting of theDNA sequence set forth in SEQ ID NO: 57 (shmiR3), and a nucleic acidcomprising or consisting of the DNA sequence set forth in SEQ ID NO: 65(shmiR14).

Whilst certain examples have been described, it will be appreciated thata DNA construct in accordance with the present disclosure may includeany ddRNAi construct described herein encoding one or more shmiRs. Forexample, ddRNAi constructs encoding shmiRs described in Examples 1 to 5may be particularly suitable for inclusion in a DNA construct of thedisclosure.

Compositions and Carriers

In some examples, the nucleic acid(s), ddRNAi construct(s) or expressionvector(s) of the disclosure is/are provided in a composition. In someexamples, a nucleic acid encoding a functional PABPN1 protein of thedisclosure is provided in a composition. In some example, the nucleicacid(s), ddRNAi construct(s) or expression vector(s) of the disclosureis/are provided in a composition together with a nucleic acid encoding afunctional PABPN1 protein of the disclosure. In some examples, the oneor more nucleic acid(s) or ddRNAi construct(s) and the nucleic acidencoding a functional PABPN1 protein are provided in the same expressionvector within a composition.

As described herein, the expression vector may comprise a ddRNAiconstruct of the disclosure alone or in combination with acodon-optimised nucleic acid encoding the functional PABPN1 protein ofthe disclosure. Reference herein to an expression vector and/or acomposition comprising same will therefore be understood to encompass:(i) an expression vector comprising a ddRNAi construct of thedisclosure, or a composition comprising same; (ii) an expression vectorcomprising both of a ddRNAi construct of the disclosure and acodon-optimised nucleic acid encoding the functional PABPN1 protein ofthe disclosure, or a composition comprising same; or (iii) an expressionvector comprising a codon-optimised nucleic acid encoding the functionalPABPN1 protein of the disclosure, or a composition comprising same.

Accordingly, a composition of the disclosure may comprise (i) anexpression vector comprising a ddRNAi construct of the disclosure, and(ii) an expression vector comprising a codon-optimised nucleic acidencoding the functional PABPN1 protein of the disclosure. Alternatively,a composition of the disclosure may comprise a single expression vectorcomprising ddRNAi construct of the disclosure and a codon-optimisednucleic acid encoding the functional PABPN1 protein of the disclosure.

In yet another example, an expression vector comprising a ddRNAiconstruct of the disclosure may be provided in one composition and anexpression vector comprising a codon-optimised nucleic acid encoding thefunctional PABPN1 protein of the disclosure may be provided withinanother composition e.g., which are packaged together.

A composition of the disclosure may also comprise one or morepharmaceutically acceptable carriers or diluents. For example, thecomposition may comprise a carrier suitable for delivery of the nucleicacid(s), ddRNAi construct(s), or expression vector(s) of the disclosureto muscle of a subject following administration thereto.

In some examples, the carrier is a lipid-based carrier, cationic lipid,or liposome nucleic acid complex, a liposome, a micelle, a virosome, alipid nanoparticle or a mixture thereof.

In some examples, the carrier is a biodegradable polymer-based carrier,such that a cationic polymer-nucleic acid complex is formed. Forexample, the carrier may be a cationic polymer microparticle suitablefor delivery of one or more nucleic acid(s), ddRNAi construct(s), orexpression vector(s) of the disclosure to muscle cells or tissue of theeye. Use of cationic polymers for delivery compositions to cells isknown in the art, such as described in Judge et al. Nature 25: 457-462(2005), the contents of which is incorporated herein by reference. Anexemplary cationic polymer-based carrier is a cationic DNA bindingpolymer, such as polyethylenimine. Other cationic polymers suitable forcomplexing with, and delivery of nucleic acid(s), ddRNAi construct(s),or expression vector(s) of the disclosure include poly(L-lysine) (PLL),chitosan, PAMAM dendrimers, and poly(2-dimethylamino)ethyl methacrylate(pDMAEMA). Other polymers include poly beta-amino esters. These areother suitable cationic polymers are known in the art and are describedin Mastrobattista and Hennink, Nature Materials, 11:10-12 (2012),WO/2003/097107 and WO/2006/041617, the full contents of which areincorporated herein by reference. Such carrier formulations have beendeveloped for various delivery routes including parenteral subcutaneousinjection, intravenous injection and inhalation.

In a further example, the carrier is a cyclodextrin-based carrier suchas a cyclodextrin polymer-nucleic acid complex.

In a further example, the carrier is a protein-based carrier such as acationic peptide-nucleic acid complex.

In another example, the carrier is a lipid nanoparticle. Exemplarynanoparticles are described, for example, in U.S. Pat. No. 7,514,099.

In some examples, the nucleic acid(s), ddRNAi construct(s), orexpression vector(s) of the disclosure is/are formulated with a lipidnanoparticle composition comprising a cationiclipid/Cholesterol/PEG-C-DMA/DSPC (e.g., in a 40/48/2/10 ratio), acationic lipid/Cholesterol/PEG-DMG/DSPC (e.g., in a 40/48/2/10 ratio),or a cationic lipid/Cholesterol/PEG-DMG (e.g., in a 60/38/2 ratio). Insome examples, the cationic lipid is Octyl CL in DMA, DL in DMA, L-278,DLinKC2DMA, or MC3.

In another example, the nucleic acid(s), ddRNAi construct(s), orexpression vector(s) of the disclosure is/are formulated with any of thecationic lipid formulations described in WO 2010/021865; WO 2010/080724;WO 2010/042877; WO 2010/105209 or WO 2011/022460.

In another example, the nucleic acid(s) or ddRNAi construct(s), orexpression vector(s) of the disclosure is/are conjugated to or complexedwith another compound, e.g., to facilitate delivery of the nucleicacid(s), ddRNAi construct(s), or expression vector(s). Non-limiting,examples of such conjugates are described in US 2008/0152661 and US2004/0162260 (e.g., CDM-LBA, CDM-Pip-LBA, CDM-PEG, CDM-NAG, etc.).

In another example, polyethylene glycol (PEG) is covalently attached toa RNA or ddRNAi or expression vector of the disclosure. The attached PEGcan be any molecular weight, e.g., from about 100 to about 50,000daltons (Da).

In yet other example, the nucleic acid(s), ddRNAi construct(s), orexpression vector(s) of the disclosure is/are formulated with a carriercomprising surface-modified liposomes containing poly(ethylene glycol)lipids (PEG-modified, or long-circulating liposomes or stealthliposomes), such as is disclosed in for example, WO 96/10391; WO96/10390; or WO 96/10392.

In some examples, the nucleic acid(s), ddRNAi construct(s), orexpression vector(s) of the disclosure can also be formulated orcomplexed with polyethyleneimine or a derivative thereof, such aspolyethyleneimine-polyethyleneglycol-N-acetylgalactosamine (PEI-PEG-GAL)or polyethyleneimine-polyethyleneglycol-tri-N-acetylgalactosamine(PEI-PEG-triGAL) derivatives.

In other examples, the nucleic acid(s), ddRNAi construct(s), orexpression vector(s) of the disclosure is/are complexed with membranedisruptive agents such as those described in U.S. Patent ApplicationPublication No. 2001/0007666.

Other carriers include cyclodextrins (see for example, Gonzalez et al.,1999, Bioconjugate Chem., 10, 1068-1074; or WO 03/46185),poly(lactic-co-glycolic)acid (PLGA) and PLCA microspheres (see forexample US 2002130430).

Compositions will desirably include materials that increase thebiological stability of the nucleic acid(s), ddRNAi construct(s), orexpression vector(s) of the disclosure and/or materials that increasethe ability of the compositions to localise to and/or penetrate musclecells selectively. The therapeutic compositions of the disclosure may beadministered in pharmaceutically acceptable carriers (e.g.,physiological saline), which are selected on the basis of the mode androute of administration, and standard pharmaceutical practice. Onehaving ordinary skill in the art can readily formulate a pharmaceuticalcomposition that comprises one or more nucleic acid(s), ddRNAiconstruct(s), or expression vector(s) of the disclosure. In some cases,an isotonic formulation is used. Generally, additives for isotonicitycan include sodium chloride, dextrose, mannitol, sorbitol and lactose.In some cases, isotonic solutions such as phosphate buffered saline arepreferred. Stabilizers include gelatin and albumin. In some examples, avasoconstriction agent is added to the formulation. The compositionsaccording to the present disclosure are provided sterile and pyrogenfree. Suitable pharmaceutical carriers, as well as pharmaceuticalnecessities for use in pharmaceutical formulations, are described inRemington: The Science and Practice of Pharmacy (formerly Remington'sPharmaceutical Sciences), Mack Publishing Co., a standard reference textin this field, and in the USP/NF.

The volume, concentration, and formulation of the pharmaceuticalcomposition, as well as the dosage regimen may be tailored specificallyto maximize cellular delivery while minimizing toxicity such as aninflammatory response e.g, relatively large volumes (5, 10, 20, 50 ml ormore) with corresponding low concentrations of active ingredients, aswell as the inclusion of an anti-inflammatory compound such as acorticosteroid, may be utilized if desired.

Compositions of the disclosure may be formulated for administration byany suitable route. For example, routes of administration include, butare not limited to, intramuscular, intraperitoneal, intradermal,subcutaneous, intravenous, intraarterially, intraocularly and oral aswell as transdermal or by inhalation or suppository. Exemplary routes ofadministration include intravenous (IV), intramuscular (IM), oral,intraperitoneal, intradermal, intraarterial and subcutaneous injection.In one example, the composition of the disclosure is formulated for IMadministration. Such compositions are useful for pharmaceuticalapplications and may readily be formulated in a suitable sterile,non-pyrogenic vehicle, e.g., buffered saline for injection, forparenteral administration e.g., IM, intravenously (including intravenousinfusion), SC, and for intraperitoneal administration. Some routes ofadministration, such as IM, IV injection or infusion, may achieveeffective delivery to muscle tissue and transfection of a ddRNAiconstructs and/or codon-optimised nucleic acids encoding PABPN1 of thedisclosure, and expression of RNA and/or the codon-optimised nucleicacid therein.

Methods of Treatment

In one example, one or more nucleic acid(s), ddRNAi construct(s),expression vector(s) or composition(s) comprising same as describedherein be used for inhibiting expression of endogenous PABPN1 protein,including a PABPN1 protein which is causative of OPMD, in a subject.

In one example, one or more nucleic acid(s), ddRNAi construct(s),expression vector(s) or composition(s) comprising same as describedherein may be used to treat OPMD in a subject suffering therefrom.Similarly, one or more nucleic acid(s), ddRNAi construct(s), expressionvector(s) or composition(s) comprising same as described herein may beused to prevent the development or progression of one or more symptomsof OPMD in a subject suffering therefrom or predisposed thereto.

In each of the foregoing examples, the expression vector and/orcomposition of the disclosure may comprise both a ddRNAi construct ofthe disclosure and a codon-optimised nucleic acid encoding functionalPABPN1 protein of the disclosure. Accordingly, administration of theexpression vector or composition may be effective to (i) inhibit, reduceor knockdown expression of endogenous PABPN1, including the PABPN1protein comprising an expanded polyalanine tract which is causative ofOPMD, and (ii) provide for expression of a functional PABPN1 proteinwhich is not targeted by shmiRs or shRNAs which inhibit, reduce orknockdown expression of endogenous PABPN1. A composition of thedisclosure may thus restore PABPN1 protein function e.g.,post-transcriptional processing of RNA, in a cell or animal to which itis administered.

In another example, treatment of OPMD may comprise administeringseparately to a subject (i) one or more agents for inhibiting expressionof a PABPN1 protein which is causative of OPMD, and (ii) an expressionvector comprising a codon-optimised nucleic acid encoding functionalPABPN1 protein of the disclosure or composition comprising same. Asdescribed herein, the one or more agents for inhibiting expression of aPABPN1 protein which is causative of OPMD may be a nucleic acid, addRNAi construct, an expression vector or composition comprising same asdescribed herein or a plurality of any one or more thereof. The subjectmay be administered components (i) and (ii) together, simultaneously orconsecutively.

For example, treatment of OPMD may comprise administering to a subject acodon-optimised nucleic acid encoding a functional PABPN1 protein of thedisclosure, wherein the subject has previously been administered one ormore agents for inhibiting expression of a PABPN1 protein which iscausative of OPMD but which does not inhibit expression of thecodon-optimised nucleic acid. For example, the subject may have beenpreviously administered a nucleic acid, a ddRNAi construct, anexpression vector or composition comprising same as described herein ora plurality of any one or more thereof.

As discussed above, routes of administration include, but are notlimited to, intramuscular, intraperitoneal, intradermal, subcutaneous,intravenous, intraarterially, intraocularly and oral as well astransdermal or by inhalation or suppository. Exemplary routes ofadministration include intravenous (IV), intramuscular (IM), oral,intraperitoneal, intradermal, intraarterial and subcutaneous injection.Some routes of administration, such as IM, IV injection or infusion, mayachieve effective delivery to muscle tissue and transfection of a ddRNAiconstructs and/or codon-optimised nucleic acids encoding PABPN1 of thedisclosure, and expression of shmiRs or shRNA and/or the codon-optimisednucleic acid therein.

One skilled in the art would be able, by routine experimentation, todetermine an effective, non-toxic amount of a nucleic acid, a ddRNAiconstruct, an expression vector or composition comprising same asdescribed herein, or a plurality of any one or more thereof, which wouldbe required to treat a subject suffering from OPMD. The therapeuticallyeffective dose level for any particular patient will depend upon avariety of factors including: the composition employed; the age, bodyweight, general health, sex and diet of the patient; the time ofadministration; the route of administration; the rate of sequestrationof the nucleic acid, a ddRNAi construct, an expression vector orcomposition comprising same as described herein, or a plurality of anyone or more thereof, the duration of the treatment, together with otherrelated factors well known in medicine.

Efficacy of a nucleic acid, a ddRNAi construct, an expression vector orcomposition comprising same of the disclosure to reduce or inhibitexpression of the PABPN1 protein causative of OPMD and to expressfunctional PABPN1 protein which is not causative of OPMD in an amountsufficient to restore PABPN1 function, may be determined by evaluatingmuscle contractile properties and/or swallowing difficulties in thesubject treated. Methods for testing swallowing ability and musclecontractile properties are known in the art. For example, swallowingdifficulties may be evaluated using videofluoroscopy, UGI endoscopy oroesophageal manometry and impedance testing. Other methods for assessingclinical features of OPMD are described in Ruiegg et al, (2005) SwissMedical Weekly, 135:574-586.

Kits

The present disclosure also provides one or more nucleic acid(s), ddRNAiconstruct(s), expression vector(s) or composition comprising same of thedisclosure in the form of a kit. The kit may comprise a container. Thekit typically contains one or more nucleic acid(s), ddRNAi construct(s),expression vector(s) or composition comprising same of the disclosurewith instructions for its, or their, administration. In some examples,the kit contains more than one nucleic acid, ddRNAi construct,expression vector or composition comprising same of the disclosure. Inone example, the kit comprises (i) a first kit component for reducing orinhibiting expression of a PABPN1 protein causative of OPMD, comprisingone or more nucleic acid(s), ddRNAi construct(s), expression vector(s)or composition comprising same of the disclosure, and (ii) an expressionvector comprising a codon-optimised nucleic acid encoding the functionalPABPN1 protein of the disclosure or composition comprising same, as asecond kit component. The first and second kit components may bepackaged together in a kit.

TABLE 1 Targeted regions in PABPN1 Region SEQ ID IDRegion sequence (5′-3′) NO: Region GAGAAGCAGAUGAAUAUGAGUCCACCUC SEQ ID 2NO: 1 Region GAACGAGGUAGAGAAGCAGAUGAAUAUG SEQ ID 3 NO: 2 RegionGAAGCUGAGAAGCUAAAGGAGCUACAGA SEQ ID 4 NO: 3 RegionGGGCUAGAGCGACAUCAUGGUAUUCCCC SEQ ID 5 NO: 4 RegionCUGUGUGACAAAUUUAGUGGCCAUCCCA SEQ ID 6 NO: 5 RegionGACUAUGGUGCAACAGCAGAAGAGCUGG SEQ ID 7 NO: 6 RegionCGAGGUAGAGAAGCAGAUGAAUAUGAGU SEQ ID 9 NO: 7 RegionCAGUGGUUUUAACAGCAGGCCCCGGGGU SEQ ID 11 NO: 8 RegionAGAGCGACAUCAUGGUAUUCCCCUUACU SEQ ID 13 NO: 9 RegionGGUAGAGAAGCAGAUGAAUAUGAGUCCA SEQ ID 14 NO: 10 RegionAUUGAGGAGAAGAUGGAGGCUGAUGCCC SEQ ID 15 NO: 11 RegionGGAGGAAGAAGCUGAGAAGCUAAAGGAG SEQ ID 16 NO: 12 RegionAACGAGGUAGAGAAGCAGAUGAAUAUGA SEQ ID 17 NO: 13

TABLE 2 shmiR effector and effector complement sequences Effectorcomplement Effector shmiR sequence SEQ ID sequence SEQ ID ID (5′-3′) NO:(5′-3′) NO: shmiR2 AGCAGAUGAA SEQ ID UGGACUCAUAU SEQ ID UAUGAGUCCANO: 14 UCAUCUGCUU NO: 15 shmiR3 GAGGUAGAGA SEQ ID UUCAUCUGCUU SEQ IDAGCAGAUGAA NO: 16 CUCUACCUCG NO: 17 shmiR4 CUGAGAAGCU SEQ ID UAGCUCCUUUASEQ ID AAAGGAGCUA NO: 18 GCUUCUCAGC NO: 19 shmiR5 UAGAGCGACA SEQ IDAAUACCAUGAU SEQ ID UCAUGGUAUU NO: 20 GUCGCUCUAG NO: 21 shmiR6 GUGACAAAUUSEQ ID AUGGCCACUAA SEQ ID UAGUGGCCAU NO: 22 AUUUGUCACA NO: 23 shmiR7AUGGUGCAAC SEQ ID CUCUUCUGCUG SEQ ID AGCAGAAGAG NO: 24 UUGCACCAUA NO: 25shmiR9 GUAGAGAAGC SEQ ID AUAUUCAUCUG SEQ ID AGAUGAAUAU NO: 26 CUUCUCUACCNO: 27 shmiR11 GGUUUUAACA SEQ ID CGGGGCCUGCU SEQ ID GCAGGCCCCG NO: 28GUUAAAACCA NO: 29 shmiR13 CGACAUCAUG SEQ ID AGGGGAAUACC SEQ IDGUAUUCCCCU NO: 30 AUGAUGUCGC NO: 31 shmiR14 GAGAAGCAGA SEQ IDCUCAUAUUCAU SEQ ID UGAAUAUGAG NO: 32 CUGCUUCUCU NO: 33 shmiR15AGGAGAAGAU SEQ ID AUCAGCCUCCA SEQ ID GGAGGCUGAU NO: 34 UCUUCUCCUC NO: 35shmiR16 GAAGAAGCUG SEQ ID UUUAGCUUCUC SEQ ID AGAAGCUAAA NO: 36AGCUUCUUCC NO: 37 shmiR17 AGGUAGAGAA SEQ ID AUUCAUCUGCU SEQ IDGCAGAUGAAU NO: 38 UCUCUACCUC NO: 39

TABLE 3 shmiR sequences SEQ ID shmiR shmiR sequences (5′-3′) NO: shmiR2GGUAUAUUGCUGUUGACAGUGAGCGUAGCAGAU SEQ IDGAAUAUGAGUCCAACUGUGAAGCAGAUGGGUUG NO: 43GACUCAUAUUCAUCUGCUUCGCCUACUGCCUCG GACUUCAA shmiR3GGUAUAUUGCUGUUGACAGUGAGCGAGAGGUAG SEQ IDAGAAGCAGAUGAAACUGUGAAGCAGAUGGGUUU NO: 44CAUCUGCUUCUCUACCUCGCGCCUACUGCCUCG GACUUCAA shmiR4GGUAUAUUGCUGUUGACAGUGAGCGACUGAGAA SEQ IDGCUAAAGGAGCUAACUGUGAAGCAGAUGGGUUA NO: 45GCUCCUUUAGCUUCUCAGCCGCCUACUGCCUCG GACUUCAA shmiR5GGUAUAUUGCUGUUGACAGUGAGCGAUAGAGCG SEQ IDACAUCAUGGUAUUACUGUGAAGCAGAUGGGUAA NO: 46UACCAUGAUGUCGCUCUAGCGCCUACUGCCUCG GACUUCAA shimR6GGUAUAUUGCUGUUGACAGUGAGCGAGUGACAA SEQ IDAUUUAGUGGCCAUACUGUGAAGCAGAUGGGUAU NO: 47GGCCACUAAAUUUGUCACACGCCUACUGCCUCG GACUUCAA shimR7GGUAUAUUGCUGUUGACAGUGAGCGAAUGGUGC SEQ IDAACAGCAGAAGAGACUGUGAAGCAGAUGGGUCU NO: 48CUUCUGCUGUUGCACCAUACGCCUACUGCCUCG GACUUCAA shimR9GGUAUAUUGCUGUUGACAGUGAGCGAGUAGAGA SEQ IDAGCAGAUGAAUAUACUGUGAAGCAGAAUGGGUA NO: 49UAUUCAUCUGCUUCUCUACCCGCCUACUGCCUC GGACUUCAA shimR11GGUAUAUUGCUGUUGACAGUGAGCGAGGUUUUA SEQ IDACAGCAGGCCCCGACUGUGAAGCAGAUGGGUCG NO: 50GGGCCUGCUGUUAAAACCACGCCUACUGCCUCG GACUUCAA shmiR13GGUAUAUUGCUGUUGACAGUGAGCGACGACAUC SEQ IDAUGGUAUUCCCCUACUGUGAAGCAGAUGGGUAG NO: 51GGGAAUACCAUGAUGUCGCCGCCUACUGCCUCG GACUUCAA shmiR14GGUAUAUUGCUGUUGACAGUGAGCGUGAGAAGC SEQ IDAGAUGAAUAUGAGACUGUGAAGCAGAUGGGUCU NO: 52CAUAUUCAUCUGCUUCUCUCGCCUACUGCCUCG GACUUCAA shmiR15GGUAUAUUGCUGUUGACAGUGAGCGAAGGAGAA SEQ IDGAUGGAGGCUGAUACUGUGAAGCAGAUGGGUAU NO: 53CAGCCUCCAUCUUCUCCUCCGCCUACUGCCUCG GACUUCAA shmiR16GGUAUAUUGCUGUUGACAGUGAGCGAGAAGAAG SEQ IDCUGAGAAGCUAAAACUGUGAAGCAGAUGGGUUU NO: 54UAGCUUCUCAGCUUCUUCCCGCCUACUGCCUCG GACUUCAA shmiR17GGUAUAUUGCUGUUGACAGUGAGCGAAGGUAGA SEQ IDGAAGCAGAUGAAUACUGUGAAGCAGAUGGGUAU NO: 55UCAUCUGCUUCUCUACCUCCGCCUACUGCCUCG GACUUCAA

TABLE 4 Shmir encoding cassettes SEQ ID shmiRShmir encoding cassettes (5′-3′) NO: shmiR2GGTATATTGCTGTTGACAGTGAGCGTAGCAGAT SEQ IDGAATATGAGTCCAACTGTGAAGCAGATGGGTTG NO: 56GACTCATATTCATCTGCTTCGCCTACTGCCTCG GACTTCAA shmiR3GGTATATTGCTGTTGACAGTGAGCGAGAGGTAG SEQ IDAGAAGCAGATGAAACTGTGAAGCAGATGGGTTT NO: 57CATCTGCTTCTCTACCTCGCGCCTACTGCCTCG GACTTCAA shmiR4GGTATATTGCTGTTGACAGTGAGCGACTGAGAA SEQ IDGCTAAAGGAGCTAACTGTGAAGCAGATGGGTTA NO: 58GCTCCTTTAGCTTCTCAGCCGCCTACTGCCTCG GACTTCAA shmiR5GGTATATTGCTGTTGACAGTGAGCGATAGAGCG SEQ IDACATCATGGTATTACTGTGAAGCAGATGGGTAA NO: 59TACCATGATGTCGCTCTAGCGCCTACTGCCTCG GACTTCAA shmiR6GGTATATTGCTGTTGACAGTGAGCGAGTGACAA SEQ IDATTTAGTGGCCATACTGTGAAGCAGATGGGTAT NO: 60GGCCACTAAATTTGTCACACGCCTACTGCCTCG GACTTCAA shmiR7GGTATATTGCTGTTGACAGTGAGCGAATGGTGC SEQ IDAACAGCAGAAGAGACTGTGAAGCAGATGGGTCT NO: 61CTTCTGCTGTTGCACCATACGCCTACTGCCTCG GACTTCAA shmiR9GGTATATTGCTGTTGACAGTGAGCGAGTAGAGA SEQ IDAGCAGATGAATATACTGTGAAGCAGATGGGTAT NO: 62ATTCATCTGCTTCTCTACCCGCCTACTGCCTCG GACTTCAA shmiR11GGTATATTGCTGTTGACAGTGAGCGAGGTTTTA SEQ IDACAGCAGGCCCCGACTGTGAAGCAGATGGGTCG NO: 63GGGCCTGCTGTTAAAACCACGCCTACTGCCTCG GACTTCAA shmiR13GGTATATTGCTGTTGACAGTGAGCGACGACATC SEQ IDATGGTATTCCCCTACTGTGAAGCAGATGGGTAG NO: 64GGGAATACCATGATGTCGCCGCCTACTGCCTCG GACTTCAA shmiR14GGTATATTGCTGTTGACAGTGAGCGTGAGAAGC SEQ IDAGATGAATATGAGACTGTGAAGCAGATGGGTCT NO: 65CATATTCATCTGCTTCTCTCGCCTACTGCCTCG GACTTCAA shmiR15GGTATATTGCTGTTGACAGTGAGCGAAGGAGAA SEQ IDGATGGAGGCTGATACTGTGAAGCAGATGGGTAT NO: 66CAGCCTCCATCTTCTCCTCCGCCTACTGCCTCG GACTTCAA shmiR16GGTATATTGCTGTTGACAGTGAGCGAGAAGAAG SEQ IDCTGAGAAGCTAAAACTGTGAAGCAGATGGGTTT NO: 67TAGCTTCTCAGCTTCTTCCCGCCTACTGCCTCG GACTTCAA shmiR17GGTATATTGCTGTTGACAGTGAGCGAAGGTAGA SEQ IDGAAGCAGATGAATACTGTGAAGCAGATGGGTAT NO: 68TCATCTGCTTCTCTACCTCCGCCTACTGCCTCG GACTTCAA

Example 1—Design of shmiRs Targeting PABN1

Sequences representing potential targets for design of siRNA constructswere identified from the PABPN1 mRNA sequence using publicly availablesiRNA design algorithms (including Ambion, Promega, Invitrogen, Origeneand MWG): the selected sequences were conserved in humans, non-humanprimates, bovine and mice species. Sequences encoding the candidatesiRNAs were incorporated into a pre-miR30a scaffold in order to create asequence encoding a short-hairpin microRNA (shmiR) comprising a 5′flanking region (SEQ ID NO: 41), a siRNA sense strand sequence (effectorcomplement sequence), a stem/loop junction sequence (SEQ ID NO: 40), asiRNA anti-sense strand (effector sequence), and a 3′ flanking region(SEQ ID NO:42). The predicted secondary structure of a representativeshmiR is shown in FIG. 1. The target regions of the PABPN1 mRNAtranscript for the designed shmiRs are presented in Table 1 andcorresponding shmiR effector sequences (antisense strand) are presentedin Table 2.

Example 2—Activity of shmiRs in Dual-Luciferase Reporter Assay

To test the efficacy of the shmiRs of the disclosure to knockdownexpression of PABPN1 transcripts, dual-luciferase reporter assays wereperformed in HEK293 cells.

pGL3 Luciferase reporter vectors were constructed. The Luciferasereporters were generated by inserting the complete coding sequence ofeither wild-type or codon-optimised PABPN1 (wtPABPN1 or optPABPN1) intothe pGL3-control vector (Promega, Madison, Wis.). The inserts weresubcloned into the 3′ UTR of the luciferase reporter gene using FseI andXbaI restriction enzyme sites. Constructs containing the PABPN1targeting shmiR sequences (listed in Table 3), driven by the U6 pol IIIpromoter, were synthesized at DNA2.0 (Newark, Calif.) and subcloned intothe pSilencer plasmid backbone.

The HEK293 cell line was purchased from ATCC (Manassas, Va.). HEK293cells were cultured in DMEM medium containing 10% fetal bovine serum, 2mM glutamine, penicillin (100 U/mL), and streptomycin (100 μg/mL) at 37°C. humid incubator with 5% CO2. Briefly, the HEK293 cell were seeded ata density of 2×10⁴ cells per well into 96-well culture plate one dayprior to transfection.

The PABPN1 shmiR-expressing constructs and their corresponding antisenseor sense Luciferase reporter and Renilla control reporter constructswere co-transfected into HEK293 cells using Fugene 6 (Promega, Madison,Wis.) according to manufacturer's instructions. For each well oftransfection, 100 ng of one of the PABPN1 shmiRs, 10 ng of thecorresponding Luciferase reporter construct and Ing of Renilla controlreporter construct (served as transfection control) were co-transfectedusing 0.3 uL of Fugene 6. 48 hour post-transfection, cell lysates werecollected and analyzed using Dual Luciferase Reporter Assay System(Promega, Madison, Wis.). The firefly/Renilla activity ratios weredetermined for each well, and the inhibition efficiency of shmiRs werecalculated by normalizing to a non-targeting siRNA, pSilencer control(Thermo Fisher, USA). Percent inhibition of wtPABPN1 or optPABPN1reporter constructs in HEK293 cells for the sense and antisense strandsof each of the shmiRs relative to the psilencer control are illustratedin FIGS. 2 and 3.

As is evident in FIGS. 2 and 3, all except one of the exemplary shmiRs(shmiR11) designated in Table 2 downregulated the level of luciferaseexpressed from the wtPABPN1 Luciferase reporter vector (FIG. 2) but didnot downregulate the expression from the coPABPN1 (FIG. 3) reporter. Inparticular, shmiR-3, shmiR-4, shmiR-13, shmiR-14, shmiR-16, and shmiR-17were shown to have potent inhibitory activity (defined as greater than70% inhibition of luciferase activity relative to cells treated with anunrelated shRNA as a negative control) against the PABPN1 target mRNAsequences, while possessing weak activity (less than 35% inhibition)against their cognate reporters containing a target sequence recognisedby the passenger strand.

Example 3—In Vitro Downregulation of PABPN1 Protein Expression

Based on the downregulation of PABPN1 expression measured by theLuciferase activity assay described above, shmiRs 2, 3, 5, 9, 13, 14,16, and 17 were selected for further analysis. In order to examine theirability to downregulate PABPN1 in vitro, the shmiR containing plasmidsdriven by the U6 promoter described in example 2 were used along withtwo additional expression plasmids. One coding for a FLAG-tagged humanwtPABPN1 (wt-PABPN1-FLAG; SEQ ID NO: 75), and the other comprising acodon-optimised sequence coding for human PABPN1 with a FLAG tag(co-PABPN1-FLAG; SEQ ID NO: 76).

Cells

Human embryonic kidney cells (HEK293T, ATCC, Manassas, USA) were grownin Dulbecco's modified Eagle's medium (DMEM) containing 20 mM HEPES, 2mM glutamine, 10% foetal bovine serum (FBS), 1× Penstrep.

Treatment

Briefly, HEK293T cells were seeded at 1×10⁶ cells/well and transfectedthe next day with one of the shmiR plasmids described above (300ng/well), with or without plasmids expressing wild-type human PABPN1(wt-PABPN1-FLAG) (100 ng/well) (SEQ ID NO:75) or codon-optimized PABPN1(co-PABPN1-FLAG) (100 ng/well) (SEQ ID NO:76). As a control, HEK293Tcells were transfected with the pSilencer control plasmid expressing anon-targeting siRNA sequence (Thermo Fisher, USA). The HEK293T cellswere incubated at 37° C. in complete DMEM media for 72 hours, afterwhich time the cells were harvested and cell lysates were analyzed byWestern blot.

Western Blot Analysis

Cell lysates were prepared by incubating cells in RIPA buffercontaining: NaCl 0.15M, 0.1% SDS, 50 mM Tris (pH8), 2 mM EDTA and 10%Triton-X-100 with protease inhibitor cocktail (Complete, RocheDiagnostics).

Proteins were separated on 4-12% Bis-Tris gel (Invitrogen) andtransferred to the nitrocellulose membrane using the iBlot 2 dryblotting system (Life Technologies). Blots were blocked and probed withprimary and secondary antibodies using the iBind Western System(Invitrogen). Primary antibodies (anti-flag (GenScript) and anti-Hsp90(Sigma)) were used at 1:500 dilution while secondary AP-conjugatedantibodies (anti-mouse and anti-rabbit, Sigma) were used at 1:6000dilutions. Bands were detected using DDAO dye and visualized using aFLA-3000 scanner (Fuji).

The resulting blots and quantification of percent inhibition of PABPN1expression relative to the control using ImageJ are shown in FIGS. 4 and5. As is evidenced from FIG. 4, all of the selected shmiRs from Example3 knocked down the expression of wild-type PABPN1 with percentinhibition >90%, and 7 of the 8 shmiRs tested inhibited expression ofwild-type PABPN1 protein at levels of >95%. In contrast, the shmiRs didnot inhibit the expression of the codon optimized PABPN1 construct (FIG.5).

Example 4—shmiR Targeted Gene Silencing of PABPN1 in HEK293T Cells

This example demonstrates the ability of the PABPN1 shmiR plasmids toknockdown the endogenous expression of PABPN1 in vitro.

Cells

Human embryonic kidney cells (HEK293T, ATCC, Manassas, USA) were grownin Dulbecco's modified Eagle's medium (DMEM) containing 20 mM HEPES, 2mM glutamine, 10% foetal bovine serum (FBS), 1× Penstrep.

Treatment

Briefly, HEK293T cells were seeded at 1×10⁶ cells/well and transfectedthe next day with one of the shmiR plasmids described in Example 2 (300ng/well). As a control, HEK293T cells were transfected with thepsilencer plasmid expressing a non-targeting siRNA sequence (ThermoFisher, USA). The HEK293T cells were incubated at 37° C. in completeDMEM media for 72 hours, after which time the cells were harvested andRNA was extracted reverse transcribed and analyzed by qPCR.

qPCR Analysis

qPCR analysis was performed on extracted RNA samples in order toquantify the level of inhibition of PABPN1 at the mRNA level by theshmiRs described above.

In order to differentiate the codon optimized PABPN1 from the wild-typePABPN1, TaqMan Primers and Probes were designed to specifically amplifywild-type PABPN1 or codon optimized PABPN1. Primers were designed usingGenScript TaqMan primer design tool(https://www.genscript.com/ssl-bin/app/primer)

The resulting sequences of primers used for quantitative RT-PCR are asfollows:

wtPABPN1-Fwd (SEQ ID NO: 77) 5′-ATGGTGCAACAGCAGAAGAG-3′ wtPABPN1-Rev(SEQ ID NO: 78) 5′-CTTTGGGATGGCCACTAAAT-3′ wtPABPN1-Probe(SEQ ID NO: 79) 5′-CGGTTGACTGAACCACAGCCATG-3′ optPABPN1-Fwd(SEQ ID NO: 80) 5′-ACCGACAGAGGCTTCCCTA-3′ opt5PABPN1-Rev (SEQ ID NO: 81)5′-TTCTGCTGCTGTTGTAGTTGG-3′ optPABPN1-Probe (SEQ ID NO: 82)5′-TGGTCCGGGCTCTGTACCTAGCC-3′

Total RNA was extracted from cell lysates using Trizol (Invitrogen)according to the manufacturer's instructions. RNA samples werequantified using a ND-1000 NanoDrop spectrophotometer (NanoDropTechnologies). RNA (100 ng) was reverse transcribed using Multiscribereverse transcriptase (ABI) according to the manufacturer'sinstructions. cDNA was used for quantitative PCR reaction using TaqmanqPCR master mix in a total of 10 ul reaction volume. PCR reaction wascarried out as follows: 2 minutes at 50° C., 10 minutes at 95° C.followed by 40 cycles: 15 seconds at 95° C., 1 minute at 60° C.

The expression level of each mRNA was normalized to GAPDH. Expressionlevels were calculated according to the total copies as determine by astandard curve and converted to percent inhibition relative to thepSilencer control.

The resulting percent inhibition of wild type PABPN1 expression inHEK293 cells by the exemplified shmiRs is presented in FIG. 6. As shownin FIG. 6, the shmiRs downregulated the expression of PABPN1 withpercent inhibition ranging between 16.4% to 49.1% (mean 35.5%).

Example 5—shmiR Targeted Gene Silencing of PABPN1 in C2C12 Mouse MuscleCells and ARPE-19 Human Retinal Cells

In order to determine whether the low percent inhibition by theexemplified shmiRs on PABPN1 expression in HEK293 cells measured by qPCRwas due to cell line variation in gene expression of PABPN1, additionalcell lines were chosen for analysis which are relevant to OPMD, namelyC2C12 mouse muscle and ARPE-19 human retinal cells.

Cells

C2C12 mouse muscle cells were grown in Dulbecco's modified Eagle'smedium (DMEM) containing 20 mM HEPES, 2 mM glutamine, 10% foetal bovineserum (FBS), 1× Penstrep.

ARPE-19 human retinal cells were grown in Dulbecco's modified Eagle'smedium/Ham's Nutrient Mixture F-12 (DMEM/F12), 10% foetal bovine serum(FBS), 1× Penstrep.

Treatment

Briefly, 2×10⁵ C2C12 cells were electroporated using the NeonElectroporation system (Pulse voltage: 1650, Pulse width: 10, Pulsenumber: 3). Both single shmiRs and combinations of two shmiRs describedabove (2 μg/well) were analyzed. As a control, C2C12 cells wereelectroporated with the pSilencer plasmid expressing a non-targetingsiRNA sequence (Thermo Fisher, USA). The C2C12 cells were incubated at37° C. in complete DMEM media for 24 hours, after which time 50 ug/mLHygromycin was added to slow the growth of non-transfected cells,followed by another addition of 100 ug/mL at 48 hours postelectroporation. At 72 hours, the cells were harvested and total RNA wasextracted for qPCR.

5×10⁶ ARPE-19 cells were electroporated with the Neon electroporationsystem using the following conditions: Pulse voltage: 1350, Pulse width:20, Pulse number: 2. Cells were treated as above for C2C12 cells exceptthat 50 ug/mL of Hygromycin was added at 24 hours with no furtheradditions. ARPE-19 cells were harvested at both 48 and 72 hours for RNAextraction and qPCR analysis.

qPCR Analysis

Reverse Transcriptase qPCR was performed as described for the HEK293cells of Example 4 with the wtPABPN1 primers and probes used to measurethe expression of endogenous PABPN1 in response to inhibition by theshmiRs selected in Example 3. qPCR was performed in triplicate forshmiRs 3, 13, 14, 17 and in duplicate for shmiRs 2, 5, 9, 16 in theC2C12 cells. A single measurement was used at two time points (48 and 72hours) for the ARPE-19 cells.

As shown in FIG. 7, all of the individual shmiRs, with the exception ofshmiR 16 (percentage inhibition of ˜43%), downregulated the expressionof PABPN1 in C2C12 cells with a mean percentage inhibition ofapproximately 80% relative to the pSilencer control.

The best performing shmiRs, as measured by percent inhibition of PABPN1,were selected for analysis of their ability to inhibit the expressionPABPN1 in combination. The combinations of shmiRs 13/17 and shmiRs 3/14were co-electroporated into the cells and expression of PABPN1 wasmeasured by qPCR as described above for the individual shmiRs.

FIG. 8 demonstrates the effect these combinations of shmiRs had on theexpression of PABPN1 in C2C12 cells. The shmiR 13/17 co-transfectionresulted in a percent inhibition of PABPN1 expression of 84.4% comparedto 92.5% and 76.7% for individual shmiRs 13 and 17 respectively. TheshmiR 3/14 co-transfection resulted in 79.0% percent inhibition comparedto 76.2% and 80.4% for individual shmiRs 3 and 14 respectively.

The same combination of shmiRs as above were tested for their ability toinhibit PABPN1 expression in a human cell line, namely ARPE-19 cells.Cells were treated as described above and the resulting inhibition ofPABPN1 expression measured by qPCR at 48 and 72 hours is shown in FIG.9. After 72 hours, the shmiR 13/17 co-transfection resulted in a percentinhibition of PABPN1 expression of 87.9% compared to 83.9% and 89.8% forindividual shmiRs 13 and 17 respectively. The shmiR 3/14 co-transfectionresulted in 87.4% percent inhibition compared to 82.2% and 81.6% forindividual shmiRs 3 and 14. On average, the percent inhibition of PABPN1expression increased 1.14 fold between 48 and 72 hours in ARPE-19 cells.

Example 6—Measurement of shmiR Expression by qPCR

In order to determine the total number of shmiRs expressed in C2C12cells transfected with the best performing shmiRs as described above, amiScript assay was developed.

Production of shmiRs 3, 13, 14, and 17 by the U6 shmiR expressionconstructs was measured using Qiagen's miScript PCR system (Valencia,Calif.). For each RT-qPCR analysis, 50 ng of total RNA was convertedinto cDNA using Qiagen's miScript II RT kit. Quantitative PCR of shRNAwas then carried out using Qiagen miScript SYBR green PCR kit withcustom forward primers set forth below:

shmiR3-FWD (SEQ ID NO: 83) 5′-TTCATCTGCTTCTCTACCTCG-3′ shmiR13-FWD(SEQ ID NO: 84) 5′-AGGGGAATACCATGATGTCGC-3′ shmiR14-FWD (SEQ ID NO: 85)5′-CTCATATTCATCTGCTTCTCT-3′ shmiR17-FWD (SEQ ID NO: 86)5′-ATTCATCTGCTTCTCTACCTC-3′

Reverse primers were provided in the Qiagen miScript SYBR green PCR kit.The following real-time PCR conditions were used: initial denaturationat 95° C. for 15 min followed by 40 cycles of 94° C. for 15 sec, 55° C.for 30 sec and 70° C. for 30 sec.

Standard curves for these assays were generated by amplifying knownamounts of the selected shmiRs and are presented in FIG. 10. shmiR3(FIG. 10B) produced a non-linear standard curve and varied according tothe qPCR buffer used.

RNA copy numbers per cell were calculated based on the estimate of 10 ngtotal RNA in 333 C2C12 cells. shmiR copies per cell were determined foreach of shmiR3, shmiR13, shmiR14 and shmiR17 when expressedindividually. As presented in FIG. 11, individual shRNA expressionlevels in C2C12 cells transduced with the shmiR vectors were estimatedto be 51,663, 13,826, 11,576, and 14,791 copies per cell for shmiRs 3,13, 14, and 17 respectively.

Example 7—Generation of Vectors for Simultaneous Gene Silencing ofEndogenous PABPN1 and Replacement with Codon Optimised PABPN1

In order to direct the simultaneous gene silencing of endogenouswild-type PABN1 (wtPABN1) and replacement with codon optimised PABPN1(coPABN1), single stranded adeno-associated virus type 2 (ssAAV2)plasmids expressing one or more of the selected shmiRs in combinationwith the optPABPN1 sequence are created. Two alternative constructs arepresented in FIGS. 12A and 12B.

The first construct, version 2, (FIG. 12A) is generated by subcloningtwo shmiRs targeting wtPABPN1 into the 3′ untranslated region of theoptPABPN1 transcript in the pAAV2 vector backbone. Expression of bothoptPABPN1 and the two shmiRs in a single transcript is driven by theMuscle specific promoter Spc512. The second construct, version 1, (FIG.12B) is generated by subcloning two shmiRs targeting wtPABPN1 into thesequence upstream of the optPABPN1 transcript. In this construct, twotranscripts are expressed, the first encoding the two shmiRs undercontrol of the CK8 promoter and the second encoding optPABPN1 under theSpc512 promoter.

Recombinant pseudotyped AAV vector stocks are generated. Briefly,HEK293T cells are cultured in cell factories in Dulbecco's modifiedEagle's medium, supplemented with 10% FBS, and incubated at 37° C. and5% CO₂. The pAAV-shmiR viral plasmids as described in this example and apAAVhelper and pAAVrepcap8 plasmid or pAAVhelper and pAAV repcap9plasmid are complexed with Calcium Phosphate according to themanufacturer's instructions. Triple-transfections are then performedwith each of the pAAV-shmiR plasmids in combination with, pAAVhelper andpAAVrepcap8 or pAAVrepcap9 in the HEK293T cells. The HEK293T cells arecultured for a period of 72 hours at 37° C. and 5% CO₂, after which timethe cells are lysed and ssAAV shmiR-expressing particles for each of theviral plasmids are purified by iodixanol (Sigma-Aldrich) step-gradientultracentrifugation followed by cesium chloride ultracentrifugation. Thenumber of vector genomes was quantified by quantitative polymerase chainreaction (Q-PCR).

Example 8—In Vivo Efficacy Studies in a Murine Model of OPMD

Animals

Pre-clinical efficacy studies were performed in the most common murinemodel of OPMD, the A17 mouse model. This mouse model was generated inthe FvB background by over expressing a bovine expanded (17 alanineresidues) PABPN1. Expression of this mutant PABPN1 in skeletal musclewas placed under control of the human alpha actin muscle-specificpromoter (HSA1). Both endogenous murine PABPN1 alleles are functionaland express normal murine PABPN1. Therefore, the mouse phenotype was dueto the overexpression of the mutant PABPN1 over the normal protein. Mostimportantly, A17 mice display many of the clinical signs of OPMDincluding the presence of intranuclear inclusions (INIs), fibrosis, andloss of muscle strength. In vivo mouse efficacy studies focused ondosing and analyses of the Tibialis anterior (TA) muscles, amongst thelargest muscles that can be easily manipulated and/or isolated from themice, making it easier to observe phenotypic improvements.

Treatment

Adeno Associated Virus Serotype 9 (AAV9) capsid was selected foradministration of the recombinant expression constructs via localintramuscular injection. In addition to AAV9, a number of differentserotypes of AAV capsids, including AAV8, AAVRh74, were tested. Muscletransduction was assessed using a recombinant AAV9 construct thatexpressed the fluorescent protein GFP under the control of the Spc512synthetic muscle promoter (AAV9-eGFP). Mice from both sexes wereinjected in each TA muscle with 50 μl of the single stranded vector at adose of 2e11 total vector genomes. After twenty days, the mice weresacrificed and the injected limbs were examined by in vivo imaging.

Results

As shown in FIG. 13, direct injection of the TA muscle with theAAV9-eGFP construct resulted in a significant amount of localfluorescence being detected in the limb, suggesting that both the vectoris effective at transducing muscle cells and results in transgeneexpression following a direct injection.

Example 9—Generation of a Single “Silence and Replace Construct” forSimultaneous Gene Silencing of Endogenous PABPN1 and Replacement withCodon Optimised PABPN1

A single stranded adeno-associated virus type 2 (ssAAV2) plasmidexpressing shmiR17 and shmiR13 (e.g., as described in Tables 3 and 4) incombination with the optPABPN1 sequence was created.

The silence and replace construct (hereinafter “SR-construct”) wasgenerated by subcloning DNA sequences encoding shmiR17 and shmiR13 (asdescribed in Table 4) into the 3′ untranslated region of the optPABPN1transcript in the pAAV2 vector backbone (pAAV-shmiR viral plasmid).Expression of both optPABPN1 and the two shmiRs in a single transcriptis driven by the muscle specific promoter Spc512. A schematic of theSR-construct is provided in FIG. 14.

Recombinant pseudotyped AAV vector stocks were then generated. Briefly,HEK293T cells were cultured in cell factories in Dulbecco's modifiedEagle's medium, supplemented with 10% FBS, and incubated at 37° C. and5% CO₂. The pAAV-shmiR viral plasmid and a pAAVhelper and pAAVrepcap8plasmid or pAAVhelper and pAAV repcap9 or pAAV helper and pAAVRH74plasmid were complexed with Calcium Phosphate according to themanufacturer's instructions. Triple-transfections were then performedwith the pAAV-shmiR plasmid in combination with the pAAVhelper and oneof the following capsids; pAAVrepcap8, pAAVrepcap9 or pAAVRH74, in theHEK293T cells. The HEK293T cells were then cultured for a period of 72hours at 37° C. and 5% CO₂, after which time the cells were lysed andssAAV shmiR-expressing particles were purified by iodixanol(Sigma-Aldrich) step-gradient ultracentrifugation followed by cesiumchloride ultracentrifugation. The number of vector genomes wasquantified by quantitative polymerase chain reaction (Q-PCR).

Example 10—In Vivo Efficacy Studies with a Single Vector “Silence andReplace” Approach

Treatment

In order to test the in vivo efficacy of the SR-construct described inExample 9 in a relevant disease model of OPMD, the SR-construct wasadministered individually, at a high and low dose, via intramuscularinjection into the TA muscle of 10-12 week old A17 mice. The low dosewas set at 1×10¹⁰ vector genomes per muscle. The high dose was set at6×10¹⁰ vector genomes per muscle. Saline injected age-matched A17 miceserved as the untreated group whilst FVB wildtype mice were alsoincluded as healthy comparators. In addition to examining the impact ofdifferent doses of the SR-construct on disease, separate cohorts of micewere sacrificed at either 14 or 20 weeks post treatment to evaluateefficacy related to different time points. At sacrifice, the TA muscleswere harvested and RNA and proteins extracted.

qPCR Analysis

To verify knockdown of PABPN1 levels, RNA isolated from the TA muscleswas evaluated by QPCR analysis. The QPCR primers used were unable todiscriminate between the wildtype PABPN1 and the mutant PABPN1transcripts, but did not recognize or amplify sequences corresponding tothe codon optimized PABPN1 species. Robust knockdown was observed withthe SR-construct at both the high and low doses resulting in thereduction of PABPN1 transcripts at 88.3% and 68.3% respectively (FIG.15). Additional analyses from these tissues demonstrated the presence ofthe shmiR transgenes in ratios consistent with the different levels ofadministered vectors.

Similarly, QPCR analyses using a set of primers that can selectivelyamplify the codon optimized PABPN1 sequences and discriminate againstthe normal wildtype and mutant PABPN1 sequences were used to verifyexpression of the codon optimized PABPN1 moiety.

These QPCR analyses demonstrated that animals administered theSR-construct expressed codon optimized PABPN1 levels at 90.9% and 13.7%,on average, of normal PABPN1 levels in FvB mice in the high and low doserespectively (FIG. 16).

Combined, the analyses confirm that a single transcript can producefunctional shmiRs that have the capability to knock down PABPN1 levels,including the mutant form, in the A17 mouse model. Likewise, thesevectors simultaneously produce adequate levels of codon optimized PABPN1as a replacement in order to restore PABPN1 function.

Intranuclear Inclusions (INIs)

The impact of the SR-construct on the persistence of intranuclearinclusions (INIs) was tested in the week 14 animals. As is evident fromFIG. 17, nearly 35% of all TA muscle cells in the A17 mice showed thegreen punctate staining representative of INIs. Red Laminin (an abundantprotein in the extracellular matrix of muscle cells) and Blue DAPIcounterstains were used to define cell shape and nuclei respectively(FIG. 18). Through a range of serial sections, treatment with both highand low doses of the SR-construct demonstrated a significant reductionof INIs.

Muscle Weight

The impact of the SR-construct on the restoration of muscle weight wasalso tested on week 20 animals.

The TA muscle cells from A17 mice weigh roughly 25% less than similarmuscles from their FvB wildtype counterparts. At both doses tested, theSR-construct showed a significant restoration of muscle weight to nearwild type levels of the FVB animals (FIG. 19).

Muscle Strength

Finally, the impact of SR-construct on restoration of muscle strength onweek 20 animals was assessed by maximal force measurements.

Using the 150 mHz frequency as a calibration point, A17 mice had roughly30% less maximal force than their wildtype FvB counterparts at 1050 nmvs 1500 nm respectively. Treatment with the SR-construct led to modestincreases in maximal force, restoring roughly 66% of the reducedstrength difference noted in the A17 mouse versus FVB wildtype animals(FIG. 20). Statistics in FIG. 20 are shown as unpaired t-test relativeto A17 Saline mice (*p<0.05, **p<0.01).

Collectively, the data presented herein from this in vivo studydemonstrate that treatment with the SR-construct has an impact onphysiological hallmark of the OPMD disease in the A17 model system.

It will be appreciated by persons skilled in the art that numerousvariations and/or modifications may be made to the above-describedembodiments, without departing from the broad general scope of thepresent disclosure. The present embodiments are, therefore, to beconsidered in all respects as illustrative and not restrictive.

We claim:
 1. A nucleic acid comprising a DNA sequence which encodes ashort hairpin micro-RNA (shmiR) targeting a transcript of PABPN1, saidshmiR comprising: an effector sequence of at least 17 nucleotides inlength; an effector complement sequence; a stemloop sequence; and aprimary micro RNA (pri-miRNA) backbone; wherein the effector sequence iscomplementary to a region of corresponding length in an RNA transcriptset forth in SEQ ID NO: 13 or complementary to a region of correspondinglength in an RNA transcript set forth in SEQ ID NO: 13 with theexception of 1, 2, 3 or 4 base mismatches relative to the RNA transcriptset forth in SEQ ID NO:
 13. 2. The nucleic acid according to claim 1,wherein the shmiR comprises an effector sequence set forth in SEQ ID NO:39 and an effector complement sequence set forth in SEQ ID NO:
 38. 3.The nucleic acid according to claim 1, wherein the shmiR comprises, in a5′ to 3′ direction: (a) a 5′ flanking sequence of the pri-miRNAbackbone; the effector complement sequence; the stemloop sequence; theeffector sequence; and a 3′ flanking sequence of the pri-miRNA backbone;or (b) a 5′ flanking sequence of the pri-miRNA backbone; the effectorsequence; the stemloop sequence; the effector complement sequence; and a3′ flanking sequence of the pri-miRNA backbone.
 4. The nucleic acidaccording to claim 1, wherein: (a) the stemloop sequence is the sequenceset forth in SEQ ID NO: 40; (b) the pri-miRNA backbone is a pri-miR-30abackbone; and/or (c) the 5′ flanking sequence of the pri-miRNA backboneis set forth in SEQ ID NO: 41 and the 3′ flanking sequence of thepri-miRNA backbone is set forth in SEQ ID NO:
 42. 5. The nucleic acidaccording to claim 1, wherein: (a) the shmiR comprises a sequence setforth in SEQ ID NO: 55; and/or (b) the DNA sequence which encodes theshmiR is set forth in SEQ ID NO:
 68. 6. A plurality of nucleic acids,comprising: (a) at least one nucleic acid according to claim 1; and (b)at least one further nucleic acid comprising a DNA sequence whichencodes a shmiR comprising: an effector sequence of at least 17nucleotides in length; an effector complement sequence; a stemloopsequence; and a pri-miRNA backbone; wherein the effector sequence issubstantially complementary to a region of corresponding length in anRNA transcript set forth in any one of SEQ ID NOs: 1-12.
 7. Anexpression vector comprising: (a) a nucleic acid according to claim 1;(b) a ddRNAi construct comprising the nucleic acid of (a); or (c) a DNAconstruct comprising a ddRNAi construct of (b) and a PABPN1 constructcomprising a DNA sequence encoding a functional PABPN1 protein having amRNA transcript which is not targeted by the shmiR(s) encoded by theddRNAi construct.
 8. The expression vector of claim 7, wherein theexpression vector is a viral vector selected from the group consistingof an adeno-associated viral (AAV) vector, a retroviral vector, anadenoviral (AdV) vector and a lentiviral (LV) vector.
 9. A compositioncomprising: (a) a nucleic acid according to claim 1; (b) a ddRNAiconstruct comprising the nucleic acid of (a); (c) a DNA constructcomprising the ddRNAi construct of (b) and a PABPN1 construct comprisinga DNA sequence encoding a functional PABPN1 protein having a mRNAtranscript which is not targeted by the shmiR(s) encoded by the ddRNAiconstruct; (d) an expression vector comprising (a), (b) or (c); or (e) aplurality of expression vectors comprising at least one expressionvector comprising the ddRNAi construct of (b) and at least oneexpression vector comprising a PABPN1 construct comprising a DNAsequence encoding a functional PABPN1 protein having a mRNA transcriptwhich is not targeted by the shmiR(s) encoded by the ddRNAi construct;optionally wherein the composition further comprises one or morepharmaceutically acceptable carriers.
 10. A method of inhibitingexpression of a PABPN1 protein which is causative of oculopharyngealmuscular dystrophy (OPMD) in a subject, said method comprisingadministering to the subject: (a) a nucleic acid according to claim 1;(b) a ddRNAi construct comprising the nucleic acid of (a); (c) a DNAconstruct comprising a ddRNAi construct of (b) and a PABPN1 constructcomprising a DNA sequence encoding a functional PABPN1 protein having amRNA transcript which is not targeted by the shmiR(s) encoded by theddRNAi construct; (d) an expression vector comprising (a), (b) or (c);(e) a plurality of expression vectors comprising at least one expressionvector comprising the ddRNAi construct of (b) and at least oneexpression vector comprising a PABPN1 construct comprising a DNAsequence encoding a functional PABPN1 protein having a mRNA transcriptwhich is not targeted by the shmiR(s) encoded by the ddRNAi construct;or a composition comprising any one of (a)-(e).
 11. A method of treatingoculopharyngeal muscular dystrophy (OPMD) in a subject sufferingtherefrom, said method comprising administering to the subject: (a) anucleic acid according to claim 1; (b) a ddRNAi construct comprising thenucleic acid of (a); (c) a DNA construct comprising a ddRNAi constructof (b) and a PABPN1 construct comprising a DNA sequence encoding afunctional PABPN1 protein having a mRNA transcript which is not targetedby the shmiR(s) encoded by the ddRNAi construct; (d) an expressionvector comprising (a), (b) or (c); (e) a plurality of expression vectorscomprising at least one expression vector comprising the ddRNAiconstruct of (b) and at least one expression vector comprising a PABPN1construct comprising a DNA sequence encoding a functional PABPN1 proteinhaving a mRNA transcript which is not targeted by the shmiR(s) encodedby the ddRNAi construct; or (f) a composition comprising any one of(a)-(e).
 12. A DNA-directed RNA interference (ddRNAi) constructcomprising a nucleic acid according to claim
 1. 13. The ddRNAi constructaccording to claim 12, comprising a further nucleic acid comprising aDNA sequence which encodes a shmiR comprising: an effector sequence ofat least 17 nucleotides in length; an effector complement sequence; astemloop sequence; and a pri-miRNA backbone; wherein the effectorsequence is substantially complementary to a region of correspondinglength in an RNA transcript set forth in any one of SEQ ID NOs: 1-12.14. The ddRNAi construct according to claim 13, wherein: (a) the furthernucleic acid encodes a shmiR comprising an effector sequence which issubstantially complementary to a region of corresponding length in anRNA transcript set forth in one of SEQ ID NOs: 1, 2, 4, 7, 9 and 10; (b)the ddRNAi construct comprises a nucleic acid comprising or consistingof a DNA sequence encoding a shmiR comprising an effector sequence setforth in SEQ ID NO: 39 and an effector complement sequence set forth inSEQ ID NO: 38 (shmiR17) and a further nucleic acid selected from thegroup consisting of: a nucleic acid comprising or consisting of a DNAsequence encoding a shmiR comprising an effector sequence set forth inSEQ ID NO: 15 and an effector complement sequence set forth in SEQ IDNO: 14 (shmiR2); a nucleic acid comprising or consisting of a DNAsequence encoding a shmiR comprising an effector sequence set forth inSEQ ID NO: 17 and an effector complement sequence set forth in SEQ IDNO: 16 (shmiR3); a nucleic acid comprising or consisting of a DNAsequence encoding a shmiR comprising an effector sequence set forth inSEQ ID NO: 21 and an effector complement sequence set forth in SEQ IDNO: 20 (shmiR5); a nucleic acid comprising or consisting of a DNAsequence encoding a shmiR comprising an effector sequence set forth inSEQ ID NO: 27 and an effector complement sequence set forth in SEQ IDNO: 26 (shmiR9); a nucleic acid comprising or consisting of a DNAsequence encoding a shmiR comprising an effector sequence set forth inSEQ ID NO: 31 and an effector complement sequence set forth in SEQ IDNO: 30 (shmiR13); and a nucleic acid comprising or consisting of a DNAsequence encoding a shmiR comprising an effector sequence set forth inSEQ ID NO: 33 and an effector complement sequence set forth in SEQ IDNO: 32 (shmiR14); and/or (c) the ddRNAi construct comprises a nucleicacid comprising or consisting of a DNA sequence set forth in SEQ ID NO:68 (shmiR17) and a further nucleic acid selected from the groupconsisting of: a nucleic acid comprising or consisting of a DNA sequenceset forth in SEQ ID NO: 56 (shmiR2); a nucleic acid comprising orconsisting of a DNA sequence set forth in SEQ ID NO: 57 (shmiR3); anucleic acid comprising or consisting of a DNA sequence set forth in SEQID NO: 59 (shmiR5); a nucleic acid comprising or consisting of a DNAsequence set forth in SEQ ID NO: 62 (shmiR9); a nucleic acid comprisingor consisting of a DNA sequence set forth in SEQ ID NO: 64 (shmiR13);and a nucleic acid comprising or consisting of a DNA sequence set forthin SEQ ID NO: 65 (shmiR14).
 15. The ddRNAi construct according to claim13, said ddRNAi construct comprising: (a) a nucleic acid comprising orconsisting of a DNA sequence encoding a shmiR comprising an effectorsequence set forth in SEQ ID NO: 31 and an effector complement sequenceset forth in SEQ ID NO: 30 (shmiR13); and (b) a nucleic acid comprisingor consisting of a DNA sequence encoding a shmiR comprising an effectorsequence set forth in SEQ ID NO: 39 and an effector complement sequenceset forth in SEQ ID NO: 38 (shmiR17).
 16. The ddRNAi construct accordingto claim 15, said ddRNAi construct comprising: (a) a nucleic acidcomprising or consisting of the DNA sequence set forth in SEQ ID NO: 64(shmiR13); and (b) a nucleic acid comprising or consisting of the DNAsequence set forth in SEQ ID NO: 68 (shmiR17).
 17. The ddRNAi constructaccording to claim 12, comprising a RNA pol III promoter upstream of theor each nucleic acid encoding a shmiR, optionally wherein the or eachRNA pol III promoter is a U6 promoter selected from U6-9 promoter, aU6-1 promoter and U6-8 promoter, or a H1 promoter.
 18. A DNA constructcomprising: (a) a ddRNAi construct according to claim 12; and (b) aPABPN1 construct comprising a DNA sequence encoding a functional PABPN1protein having a mRNA transcript which is not targeted by the shmiR(s)encoded by the ddRNAi construct.
 19. The DNA construct according toclaim 18, wherein the DNA sequence encoding the functional PABPN1protein is codon optimised such that its mRNA transcript is not targetedby the shmiRs of the ddRNAi construct, optionally wherein the codonoptimised DNA sequence encoding the functional PABPN1 protein is setforth in SEQ ID NO:
 73. 20. The DNA construct according to claim 18,wherein the DNA sequence encoding the functional PABPN1 protein isoperably-linked to a promoter comprised within the PABPN1 construct andpositioned upstream of the DNA sequence encoding the functional PABPN1protein, optionally wherein the promoter comprised within the PABPN1construct is a muscle-specific promoter.
 21. The DNA construct accordingto claim 18, wherein: (a) the DNA construct comprises, in a 5′ to 3′direction, the ddRNAi construct and the PABPN1 construct; or (b) the DNAconstruct comprises, in a 5′ to 3′ direction, the PABPN1 construct andthe ddRNAi construct.
 22. A plurality of expression vectors comprising:(a) an expression vector comprising the ddRNAi construct of claim 12;and (b) an expression vector comprising a PABPN1 construct comprising aDNA sequence encoding a functional PABPN1 protein having a mRNAtranscript which is not targeted by the shmiR(s) encoded by the ddRNAiconstruct.
 23. The plurality of expression vectors according to claim22, wherein the DNA sequence encoding the functional PABPN1 protein iscodon optimised such that its mRNA transcript is not targeted by theshmiRs of the ddRNAi construct, optionally wherein the codon optimisedDNA sequence encoding the functional PABPN1 protein is set forth in SEQID NO:
 73. 24. The plurality of expression vectors according to claim22, wherein the DNA sequence encoding the functional PABPN1 protein isoperably-linked to a promoter comprised within the PABPN1 construct andpositioned upstream of the DNA sequence encoding the functional PABPN1protein, optionally wherein the promoter comprised within the PABPN1construct is a muscle-specific promoter.
 25. An adeno-associated virus(AAV) comprising a DNA construct comprising: (a) a muscle-specificpromoter; (b) a ddRNAi construct comprising: a nucleic acid comprising aDNA sequence encoding a shmiR comprising an effector sequence set forthin SEQ ID NO: 39 and an effector complement sequence set forth in SEQ IDNO: 38; and a nucleic acid comprising a DNA sequence encoding a shmiRcomprising an effector sequence set forth in SEQ ID NO: 31 and aneffector complement sequence set forth in SEQ ID NO: 30; and (c) aPABPN1 construct comprising a DNA sequence encoding a functional PABPN1protein having a mRNA transcript which is not targeted by the shmiRsencoded by the ddRNAi construct.
 26. The AAV of claim 25, wherein theDNA construct comprises, in a 5′ to 3′ direction, the muscle-specificpromoter, the PABPN1 construct, and the ddRNAi construct.
 27. The AAV ofclaim 26, wherein: the muscle-specific promoter is a Spc512 promoter;the ddRNAi construct comprises a nucleic acid comprising or consistingof the DNA sequence set forth in SEQ ID NO: 68 and a nucleic acidcomprising or consisting of the DNA sequence set forth in SEQ ID NO: 64;and wherein the DNA sequence encoding the functional PABPN1 protein iscodon optimised and its mRNA transcript is not targeted by the shmiRs ofthe ddRNAi construct, optionally wherein the codon optimised DNAsequence encoding the functional PABPN1 protein is set forth in SEQ IDNO: 73.